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1. GENERAL INTRODUCTION 
1.1. SINGLET OXYGEN 
1.1.1. Photophysical Properties 
 
The lowest lying excited electronic state of dioxygen (see below) is O2(a
1
∆g) [1, 2]. 
Historically O2(a
1
∆g) has simply been called “singlet oxygen”, thus distinguishing it from the 
triplet ground state that is 94.2 kJ/mol lower in energy (Fig. 1.1.) Reactions of singlet oxygen 
are associated with significant applications in several fields, including organic synthesis, 
bleaching processes, and, most importantly, the photodynamic therapy. 
 
Molecular oxygen has a remarkable electronic structure, as its highest occupied 
electronic level is constituted of two degenerate pi* orbitals. In the ground state each of two 
unpaired electrons lies in one pi* orbital and their spins are parallel, thus molecular oxygen is 
a triplet biradical, O2(X
3
Σg
-
) [1] or short 
3
O2, in the ground state. The lowest electronically 
excited state is a singlet state, O2(a
1
∆g), with 2 electrons in the same pi* orbital with anti-
parallel spin and energy of 94.2 kJ/mol or 0.977 eV, which shows a NIR phophorescence at 
1269 nm (see Fig. 1.1.) However, the second electronically excited state is also a singlet state, 
O2(b
1
Σg
+
), in which both anti-parallel spins aren’t paired. The energy difference to the ground 
state is 156.9 kJ/mol or 1.627 eV and the emission occurs at 762 nm. Although it has been 
speculated that the singlet sigma state, O2(b
1
Σg
+
), could play a role in solution-phase systems, 
it has only recently become possible to address this issue using direct spectroscopic 
measurements, see review article [1]. Because the relaxation to the triplet ground state from 
both of these excited states is spin forbidden, the 1269 nm and 762 nm emission are very 
weak. [3] For more details see review article [4]. In further text, the descriptor singlet oxygen 
(
1
O2) will be used for the lowest excited singlet state. 
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Figure 1.1. Simplified energy diagram of dioxygen (1pig)-orbital electron states: ground state and first 
two excited states.  
 
1.1.2. Biophysical Properties 
 
In Table 1.1. lifetimes of 
1
O2 in various solvents are given. The 
1
O2 lifetime in water is 
about 5 µs and the diffusion radius over a period t of twice its lifetime can then be estimated 
using a diffusion coefficient, D, for oxygen in water of 2 • 10
-5
 cm
2
 s
-1
 [5], according to 
equation 1 [6]: 
r = (6tD)
1/2
  (1) 
 to be about 350 nm. However, this is rather controversial, because the same research group 
in a recent report [7] measured the singlet oxygen lifetime in cytoplasm and nucleus of HeLa 
cells using the time-resolved singlet oxygen phosphorescence signals and found it to be in 30-
40 µs range. But, despite a relatively long intracellular lifetime, singlet oxygen did not diffuse 
a great distance from its site of production by irradiation of a sensitizer. This is a 
consequence of an apparent intracellular viscosity that is comparatively large [7]. 
 
1269 
762 
Emission  
λ/nm 
E [kJ/mol] 
94.2 
0
1
O2 0.97 (7872 cm
-1
) 
0
156.9 1.62 (13 112 cm
-1
) 
E [eV] 
3
O2 
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Table 1.1.
 1
O2 lifetimes in various solvents. [3] 
 
solvent  t/µs  solvent  t/µs  biological 
environment 
t/µs  
acetone  34-65  diethylether  26-35  water 3.3-7.4  
acetonitrile  54-69  ethanol  10-15  blood plasma 1.0  
chloroform  160-265  THF  20-30  leukemia 
cells 
0.17-0.32  
 
Thus, due to its high reactivity, singlet oxygen has a short lifespan in a cellular environment 
and limited diffusivity in tissue, which will be further discussed in Chapter 6.1. 
 
1.1.3. 1O2 Generation and Photochemical Properties  
 
Through interaction with photosensitizers (PS) 
3
O2 can be converted into other 
reactive oxygen species (ROS). Various possible interactions of excited PS in the triplet state 
3
PS*, with molecular oxygen are usually divided into three kinds of reactions [3].  
Type I processes lead to the production of free radicals or radical ions, via hydrogen 
or electron transfer:  
•• +−→−+ MHPSMHPS*3,1    (2)   
which can then react with 
3
O2 to form peroxides, peroxyl radicals etc. Type II reactions 
generate 
1
O2 via energy transfer from 
3
PS* (see equation 3). Type II reactions, in contrast, 
require an energy transfer mechanism from the triplet-state sensitizer to the ground state 
molecular oxygen, [8]:  
2
1
2
3*3 OPSOPS +→+       (3) 
General Introduction 
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Type III reactions involve reductive quenching of an excited photosensitizer and electron 
transfer from a donor, D, with subsequent reduction of 
3
O2, in case of suitable redox 
potentials:  
         
      
22
3
*3,1
−•−•
+•−•
+→+
+→+
OPSOPS
DPSDPS
        (4) 
Another possibility which belongs to Type III reactions is photoinduced electron transfer 
from excited photosensitizer to ground-state oxygen and superoxide-anion generation with 
subsequent regeneration of PS with electron transfer from a donor molecule, D: 
+•+•
−•+•
+→+
+→+
DPSDPS
OPSOPS 22
3*3,1
  (5) 
It is difficult to differentiate which of the three reaction types is occurring upon irradiation of 
a photosensitizer. When a PS absorbs light in the visible region, usually fast energy transfer 
(Type II) dominates and Type III reactions occur in the background. If a PS has a relatively 
high triplet-state energy (UV absorption), Type III reactions are more pronounced because a 
larger range of potential donors may be oxidized. Type I reactions dominate in the case of PS 
with n-pi* configurations, such as ketones and anthrachinones. [3] 
 To determine the singlet oxygen quantum yields of various photosensitizers several 
methods are used:  
• 1O2  phosphorescence measurements at 1269 nm [9] 
• stationary and time-dependent photothermal and photoacoustic methods [10] 
• chemical quenching of 1O2 using selective probes, such as 1,3-diphenylisobenzofuran 
(DPBF) [11] 
Apart from interactions with photosensitizers, the mentioned reactive oxygen species 
(ROS) including 
1
O2 can also be generated from various other reactions. For example, 
1
O2 is 
known to be formed in almost quantitative yields by oxidation of hypochlorite with hydrogen 
peroxide, by disproportionation of H2O2 catalyzed with MoO4
2-
 or WO4
2-
, by reduction of 
ozone with triphenylphosphite, by reactions in biological systems catalyzed with peroxidases 
or oxygenases, or by the thermolysis of polycyclic aromatic endoperoxides [12]. 
Unfortunately, these chemical sources of 
1
O2 are not compatible with conditions required by 
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biological systems (aqueous environment, neutral pH). Therefore, efforts have been devoted 
to develop suitable 
1
O2 generators based on endoperoxide thermolysis.  
1.2. AROMATIC ENDOPEROXIDES AS A SINGLET OXYGEN SOURCE 
1.2.1. Endoperoxide Formation 
 
Many polycyclic aromatic hydrocarbons are able to trap singlet oxygen. Some of the 
endoperoxides (EPOs), thus obtained, exhibit the exceptional feature of releasing oxygen, 
frequently in the excited singlet state, under heating or UV irradiation. [13] More than 400 
EPOs derived from polycyclic aromatic hydrocarbons have been described in the literature. 
[14] Most of them were prepared by photosensitized oxygenation involving a 
[4+2]cycloaddition of 
1
O2 on the electron-rich carbons of the aromatic substrate (Fig. 1.2.)  
 
 
 
Figure 1.2. Mechanism of [4+2] cycloaddition of 1O2 on aromatic hydrocarbons.  
 
The reactivity of aromatic hydrocarbons toward 
1
O2 increases with the electron 
density of the aromatic substrate, reflecting the electrophilic nature of 
1
O2. [15] A first 
structural effect is the number of fused rings of the substrate. The comparison of anthracene, 
tetracene, and pentacene shows that the reactivity increases by about 2 orders of magnitude 
for each supplementary fused ring. [13] The grafting of electron-releasing groups on the site 
of 
1
O2 addition increases the rate constants in the order H < C6H5 < CH3 ≤ OCH3. For 
example, 1-methylnaphthalene reacts slowly with 
1
O2, whereas naphthalene itself is 
completely unreactive. In the same way, neither benzene, toluene, xylene, nor tri- and 
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tetramethyl benzene react with 
1
O2, whereas penta- and hexamethyl-benzene provide the 
corresponding EPOs as primary oxidation products. [13] Steric strain is also an important 
parameter which can modify both the reactivity of the substrate and the regioselectivity of the 
cycloaddition of 
1
O2. Peri-interactions between two neighboring methyl groups bound to a 
polycyclic aromatic hydrocarbon enhance its reactivity toward 
1
O2 because the steric strain is 
somewhat relieved in the transition state. This phenomenon explains why, for example, 1,8-
dimethylnaphthalene is 4 times more reactive than the 1,5-isomer. [13] 
The cycloaddition of 
1
O2 to 1,4-dimethylnaphthalene (DMN) and derivatives has been 
studied in many solvents. It was found that the rate constant of 
1
O2 addition increases by 
more than 2 orders of magnitude from cyclohexane to formamide and it was even much 
higher in water when using water-soluble derivatives of DMN. This strong solvent effect on 
kinetics is thought to be caused by several solvent parameters, including dipolarity, 
polarizability, and solubility. [16] 
The mechanism of [4+2] cycloaddition of 
1
O2 to conjugated systems [16 - 18] is 
assumed to be very similar to the concerted mechanism of the Diels-Alder reaction. A 
theoretical study suggests that 
1
O2 addition occurs through a single-step concerted 
mechanism with a symmetric transition structure exhibiting significant charge transfer from 
the organic donor to oxygen. [17]. The first step of the reaction involves the reversible 
formation of an exciplex in the singlet state. This exciplex exhibits a charge-transfer character 
due to the strong electron attraction by 
1
O2. Subsequently, the solvated exciplex either 
collapses through a concerted mechanism into EPO (chemical quenching of 
1
O2) or goes 
through a spin-forbidden intersystem crossing (ISC), giving a triplet state complex which 
dissociates into 
3
O2 and the starting substrate (physical quenching of 
1
O2). [18]  
Under suitable conditions, appropriate aromatic substrates can trap most of the 
1
O2 
available, even when the rate of 
1
O2 generation is very low because the concentration of EPO 
formed is proportional to the cumulative amount of 
1
O2 generated. Water-soluble derivatives 
of rubrene, anthracene and methylnaphthalene are typical examples of this type of traps. [19] 
Chemical trapping by water-soluble aromatic hydrocarbons is also specific for 
1
O2 and can be 
much more sensitive than monitoring the 
1
O2  luminescence at 1275 nm for quantification of 
1
O2 in aqueous media. 
The reversibility of oxygen binding to polycyclic aromatic compounds was discovered by 
Dufraisse. [20, 12] The state of released oxygen by thermolysis of aromatic EPOs was 
determined by Wasserman and Larsen using EPO of 9,10-diphenylanthracene (DPA). [21, 
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12] When warmed to 80 °C, this EPO decays to the parent molecule and oxygen, with 32 % 
being 
1
O2. [12] In general, two primary pathways of transformation compete during 
thermolysis or photolysis of aromatic EPOs (Fig. 1.3.): cycloreversion, leading to the parent 
aromatic molecule and to oxygen, in a singlet or a triplet state; and homolytic cleavage of the 
peroxide bond, followed by rearrangement to more or less stable diepoxides or 
decomposition, leading to hydroxy-ketones or quinones. Endoperoxide thermolysis proceeds 
with AC, the yield of thermal cycloreversion, and AD, the yield of thermal decomposition:  
AD = 1 - AC. During photolysis QC, quantum yield of cycloreversion, and QD, quantum yield 
of decomposition apply. The relative amount of both processes depends on endoperoxide 
structures and experimental conditions. 
 
1.2.2. Endoperoxide Thermolysis 
 
The ratio between cycloreversion and cleavage may depend on the relative activation 
energies, as stated by Turro et al. [22] The activation enthalpy ∆H≠ for cycloreversion 
increases from benzenic [23] to naphthalenic [24] and 1,4-anthracenic EPOs, and then to the 
meso-substituted ones. Consequently, the cleavage starts to compete with cycloreversion in 
meso-substituted anthracenic EPOs, as well as in even more condensed analogues. However, 
the cycloreversion is greatly favored over cleavage by the presence of aromatic substituents 
at the peroxide bridgehead meso positions (for example, EPOs of DMN or DPA). 
 
 
Figure 1.3. Mechanism of endoperoxide transformation during thermolysis or photolysis. 
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A mechanistic hypothesis for thermal cycloreversion has also been suggested by 
Turro et al., [22] where they found that the yields of generated 
1
O2 were much higher for 
EPOs of parent molecules with endoperoxide bridge on 1,4 positions of the aromatic cyclic 
core (e.g. 1,4-dimethyl-9,10-diphenylanthracene-1,4-endoperoxide), than for the 9,10-
position of endoperoxide bridge, (e.g. 1,4-dimethyl-9,10-diphenylanthracene-9,10-
endoperoxide). This hypothesis was based on the observation that activation enthropies, ∆S≠ 
for EPOs of 1,4-type were 0 or slightly negative, while substantially positive values (+30 to 
+40 JK
-1
mol
-1
) were found for EPOs of 9,10-type.  
This Turro hypothesis invokes the two basic and potentially competing pathways for 
EPO thermolysis, as shown in Fig. 1.4.: a) a concerted mechanism, producing 
1
O2 
quantitatively, which would take place with 1,4-endoperoxide type, and b) a sequence leading 
successively to diradicals, at first singlet diradical, 
1
D, and then triplet, 
3
D, which are able to 
fragment to 
1
O2 and 
3
O2, respectively. The latter would take place with 9,10-endoperoxide 
type. Thus, a quantitative prediction of the yield of evolved 
1
O2 would not be possible. When 
homolysis of the peroxidic bond competes with cycloreversion, rearrangement and 
decomposition occur (Fig. 1.3.). For more detail, see references [13, 22].  
 
1O2+ 3O2
O
O
O O
+
O
O
concerted
cycloreversion
homolytic
cleavage
3D
ISC
O
O
1D
 
 
Figure 1.4. Scheme of competing pathways during endoperoxide thermolysis. 
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1.2.3. Endoperoxide Photolysis 
 
The same primary reactions as during thermolysis (Fig. 1.4.) compete during 
photolysis of EPOs. Irradiation of the 9,10-endoperoxide of 9,10-diphenylanthracene with 
wavelengths λ > 250 nm initiates cycloreversion, yielding the parent molecule and O2, 
whereas λ > 400 nm excitation initiates O-O bond cleavage and rearrangement producing a 
diepoxide, which undergoes irreversible subsequent reactions. [25] The detailed study of 
many EPOs showed that decomposition occurs from the lowest excited singlet state 
S1(pi*OOσ*OO), corresponding to the locally excited peroxide chromophore, with quantum 
yield QD
S1
. [26, 27] Nonsubstituted aromatic EPOs have maximum values of AD and QD
S1
. 
These values are smaller if the atoms next to the O-O bridge are bound to methyl or phenyl 
groups and even smaller if the phenyl substituents are additionally bound to the anthracene 
frame. [13] 
It was shown that cycloreversion of EPOs originates from an upper excited pipi* 
singlet state, and that O2 is produced in its excited singlet state. [28] Further investigations 
revealed that cycloreversion of EPOs generally leads to formation of 
1
O2 and ground-state 
parent aromatic molecule in 1:1 ratio and occurs from upper excited Sn(pipi *) (n ≥ 2), but not 
from S1 (pi*OOσ*OO) state. Moreover, cycloreversion quantum yield QC increases for many 
nonsymmetrical EPOs stepwise with decreasing λ, indicating that cycloreversion occurs from 
several excited Sn(pipi *) (n = 2, 3...) states. [29, 30] 
 
1.2.4. Aromatic Endoperoxides as Singlet Oxygen Carriers 
 
In general, EPOs are metastable and endoperoxide formation is a reversible reaction, 
see equation 6. When induced by thermolysis or photolysis EPOs are able to revert to the 
parent aromatic molecule releasing a mixture of 
1
O2 and 
3
O2. The rate of EPO decay via 
cycloreversion pathway and
 1
O2 yield both depend on the same structural, steric and solvent 
effects stated above for the endoperoxide formation. Whereas electron density is the main 
determinant of EPO formation, steric factors are most important in influencing the stability of 
EPOs [31]. It could be argued that even aromatic hydrocarbons with low electron density, 
such as benzene, toluene, naphthalene do form EPOs with a too short of lifetimes to be 
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detectable. On the other hand, there are EPOs too stable for 
1
O2-release by thermolysis, in 
which case photolysis is the only option. For example, up to four oxygen molecules are 
bound in the self-sensitized photoreaction of octaphenyltetraanthraporphyrazinato palladium 
complex, Fig. 1.5. [32] This fascinating complex with four endoperoxide bridges releases 
step-by-step all O2 when excited by consecutive two-photon absorption at 662 nm. 
 
 
Figure 1.5. Example of a thermally stable self-sensitized complex with four endoperoxide bridges on 
anthracene substituents. [32] 
 However, the focus of this work is on the endoperoxide thermolysis, not on 
photolysis. In order to achieve a chemical source of 
1
O2 in biological media, many efforts to 
develop suitable 
1
O2 generators based on the thermolysis of water-soluble naphthalene 
endoperoxides (equation 6) have been made. [12]  
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R1
R2
R3
R4
+ 1O2
R1
R2
R3
R4
O
O
0-5 °C
  (6) 
 
 The first prepared water-soluble 
1
O2 carriers were 4-methyl-1-naphthalenepropanoate 
(MNP), [33, 12] and anionic disodium 1,4-naphthalenedipropanoate (NDP), [34] bearing one 
or two sodium propanoate substituents grafted onto the 1,4 positions of the naphthalene core. 
However, these anionic compounds release 
1
O2 in the aqueous phase, far from potential 
biological targets in medical applications. Subsequently, a second generation of 
1
O2 carriers 
with specific groups, such as quaternary ammonium group in 4-methyl-N,N,N-trimethyl-1-
naphthaleneethanaminium chloride (MNEA), or nonionic hydrophilic groups in 1,4-
naphthalenedimethanol (NDMOL) or N,N’-di(2,3-dihydroxypropyl)-1,4-
naphthalenedipropanamide (DHPN), has been synthesized. 
 All the mentioned water-soluble naphthalenic carriers of 
1
O2 can be prepared from the 
cheap 1-methylnaphthalene compound as a starting material [12], as presented in Fig. 1.6. 
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Cl
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OH
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NDP
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CONH-CH2-CHOH-CH2OH
CONH-CH2-CHOH-CH2OH
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Figure 1.6. Reaction pathways for synthesis of water-soluble naphthalenic carriers of 1O2. 
 
The interaction of 
1
O2 with a naphthalene derivative N can be described by reactions 7 
and 8. Singlet oxygen produced by a chemical or photochemical source (see Chapter 1.1.3.) is 
either quenched by N with rate constant kq (reaction 7) or it reacts with forming an 
endoperoxide, NE, with rate constant kr (reaction 8). The overall reactivity of N toward 
1
O2 
can be expressed by the sum (kr + kq), which is readily determined by flash photolysis.  
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   (7) 
   (8) 
 
To explain the difference in reactivity of 1,4-substituted carriers toward 
1
O2, two phenomena 
have to be considered: the electron density of the naphthalene core and the steric hindrance 
induced by the substituents. Electronic effects are of primary importance when a short spacer 
separates the hydrophilic group from the naphthalene core. Thus, the electron-attractive effect 
by the quaternary ammonium group of MNEA or by the –OH groups of NDMOL cause 5 and 
17 times, respectively, lower 
1
O2 reactivity than for the MNP compound. [12] Longer alkyl 
spacers increase the electron density of the aromatic ring, but the resulting steric hindrance 
lowers the rate of reaction with 
1
O2 significantly. For instance, the overall rate constant (kr + 
kq), of NDP (2.8 • 10
6
 M
-1
 s
-1
) and of the more crowded DHPN (1.0 • 10
6
 M
-1
 s
-1
) are much 
lower than the value for MNP (7.0 • 10
6
 M
-1
 s
-1
). [12] For very crowded and poorly reactive 
compounds, 5,8-cycloaddition of 
1
O2 competes with the usual 
1
O2 addition on the 1,4-
positions. [35] The reactivity of naphthalene compounds can be considerably increased by 
grafting supplementary methyl groups on the same ring. [19, 36] However, the half-life time 
of such EPOs becomes > 50h at 37 °C in water, converting these compounds into 
1
O2 traps. 
 
1.2.5. Aromatic Endoperoxides‘ Decay Kinetics 
 
Thermolysis of naphthalenic EPOs (equation 9) gives back oxygen quantitatively 
according to first-order kinetics with a rate constant k.  
 
   (9) 
 
From rate constant k value, typically the half-life time of a specific endoperoxide is 
calculated: t1/2 = ln 2 / k. In Table 1.2. half-life times of EPOs of water-soluble naphthalene 
derivatives at 37 °C in water and cumulative yields of produced 
1
O2 by EPO thermolysis are 
given. [12] 
General Introduction 
14 
 
Table 1.2. Half-life times of endoperoxides in water at 37 °C and 1O2 yields by endoperoxide 
thermolysis. [12] 
EndoPerOxide of MNP NDP MNEA NDMOL DHPN 
t1/2 (min) 23 23 22 70 23 
1
O2 yield (%) 45 50 65 51 59 
 
The only systematic study concerning the stability of EPOs of various naphthalene 
derivatives has concentrated on the influence of steric factors connected with the pattern of 
alkyl substitution on naphthalene core using experimental as well as theoretical calculation 
data [31]. Half-life times of EPOs of various methylnaphthalene derivatives at 25 °C in 
CDCl3 from this reference are given in Table 1.3. 
 
Table 1.3. Stability of methylnaphthalene endoperoxides in CDCl3 at 25 °C, determined by 
1H NMR. [31] 
EndoPerOxide  t1/2 (h) 
1,4-dimethylnaphthalene-1,4-endoperoxide 5 
1,8-dimethylnaphthalene-1,4-endoperoxide 30 
1,2,4-trimethylnaphthalene-1,4-endoperoxide 70 
1,4,5-trimethylnaphthalene-1,4-endoperoxide 290 
1,2,3,4-tetramethylnaphthalene-1,4-endoperoxide indefinite 
 
1.2.6. Polymeric Carriers of Singlet Oxygen  
 
Polymer-immobilized naphthalenes have been obtained by grafting the sodium salt of 
MNP on a chloromethylated styrenedivinyl benzene beads or by polymerization of 
methylsubstituted vinylnaphthalene [37, 38, 39]. After photosensitized oxygenation, both 
systems give EPOs storable at low temperature. Half-life times of EPOs of polymer-
immobilized methylnaphthalene derivatives at 30 °C in dichloromethane [38] are given in 
Table 1.4. The t1/2 values at 37 °C were calculated using the t1/2 values at 30 °C and values of 
Arrhenius activation parameters Ea and ln A [38]. 
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Table 1.4. Half-life time values for thermolysis of polymer-immobilized naphthalene EPOs in 
dichloromethane.  
EndoPerOxide  t1/2 (min) at 30 °C t1/2 (min) at 37 °C 
Poly(1,4-dimethyl-6-vinylnaphthalene-1,4-endoperoxide) 80 31 
Poly(1,2,4-trimethyl-6-vinylnaphthalene-1,4-endoperoxide) 419 153 
 
Unfortunately, these hydrophobic polymers are unsuitable for aqueous media because 
the corresponding EPOs, prepared by photooxygenation, do not release a significant amount 
of 
1
O2 in water. Despite considerable efforts devoted to this problem, the design of polymeric 
carriers of 
1
O2 suitable for aqueous media remains an open challenge. 
 
1.2.7. Endoperoxide Characterization 
 
The naphthalene endoperoxides are characterized by their spectroscopic properties. In 
the IR, the aromatic band at 1580-1600 cm
-1
 disappears on photooxidation and a strong band 
appears at 1200-1250 cm
-1
. The UV absorption spectrum, endoperoxide formation is 
indicated by the disappearance of the naphthalene band at about 290 nm [31]. Hence, the 
EPOs thermolysis reaction rate can be conveniently determined by using UV absorption 
spectrometry to follow the rise of naphthalene concentration (corresponding to the absorption 
peak) with time [12, 31, 38]. 
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1.3. SINGLET OXYGEN APPLICATION IN THE PHOTODYNAMIC 
THERAPY 
 
Photodynamic therapy (PDT) is a strategy for treatment of cancer and other diseases 
with a combination of a photosensitizer and oxygen molecules which are present at the site of 
the treatment. Over the past decades, there was a period of intense PDT investigation, both in 
the laboratory and in the clinic. Although still widely considered to be an academic 
technique, its status and value within modern clinical practice gradually continues to grow. 
The PDT has to date been dominated by a small number of pharmaceutical companies and is 
used mostly by the scientists and clinicians involved in fundamental research. Pharmaceutical 
formulation development has been limited. 
PDT is based on the singlet oxygen generation after the irradiation of an intracellular 
photosensitising drug (which possesses no dark toxicity) with subsequent biochemical events 
to cause selective cell destruction [40]. When the photosensitizer is introduced into the body, 
it accumulates in tumour cells and a light source of appropriate wavelength (visible or near-
infrared) and intensity is then used to irradiate the target tissue [41, 42]. Light irradiation 
activates the drug through electronic excitation and triggers a series of cytotoxic reactions, 
which can be dependent on, or independent of, the generation of reactive oxygen species 
[43]. Typical photosensitizers (PS) used, such as tetrapyrrole derivatives, have a closed-shell 
electronic configuration, which leads to a singlet state in their lowest energy or ground state 
level, with no unpaired electron spins (Fig. 1.7.) [44, 45]. Following the absorption of a 
photon of a specific wavelength, the photosensitizer molecule is promoted to an excited state, 
1
PS*, which is also a singlet state and is usually short-lived with a half life between 10
-6 
and 
10
-9
 seconds [45, 46]. The photosensitizer can return to the ground state by emitting light 
energy as photons (fluorescence) or by internal conversion with energy loss as heat. 
Alternatively, the molecule may convert to the triplet state, 
3
PS*. This conversion occurs via 
intersystem crossing which involves a change in the spin multiplicity [47].  
*3*1 PSPSPS
ISChv
→→   (10) 
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Figure 1.7. Mechanism of PDT cytototoxicity: a simplified scheme of relevant photophysical processes 
and reactions represented in a modified Jablonski diagram. 
 
The triplet state photosensitizer has lower energy than the singlet state but has a 
longer lifetime, typically in the µs to ms range. PS in both singlet and triplet state can interact 
with surrounding oxygen molecules to form reactive oxygen species (see Chapter 1.1.3., 
reactions Type I-III). These reactive species, such as singlet oxygen and superoxide and 
peroxide anions, then attack cellular targets [48]. However, Type I reactions (equation 2) do 
not necessarily require oxygen and can cause cellular damage directly, through electron 
transfer processes and the action of free radicals, which may include sensitizer radicals.  
Moreover, via Type II reactions (equation 3) a sufficient concentration of highly 
cytotoxic singlet oxygen, 
1
O2, is produced to induce irreversible cell damage [45, 46]. In 
addition, the photosensitizer is not necessarily destroyed, but can return to its ground state by 
phosphorescence without chemical alteration and may be able to repeat the process of energy 
transfer many times [47]. Alternatively, the sensitizer may return to the ground state by 
transferring its energy to molecular oxygen, and may even be destroyed by photobleaching 
due to oxidation [49]. Evidently, many effects of PDT are oxygen-dependent and rely on the 
oxygen tension within the target tissue. Type I and Type II reactions can occur 
simultaneously and the ratio between the two depends on many factors, such as the 
photosensitizer, substrate, oxygen concentration and sensitizer to substrate binding [48].  
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Singlet oxygen, formed in Type II mechanism, is widely believed to be the major 
damaging species in PDT [40, 41, 45]. However, the Type I reactions are most efficient at 
low oxygen and high substrate concentrations. [50] 
The PDT efficiency crucially depends on the chemistry of the PS, the pharmaceutical 
formulations, the localization and the amount of PS in treated tissue, time of activation with 
light, the light doses and the amount of oxygen in irradiated region. 
 
1.3.1. Photosensitizers Used for Photodynamic Therapy 
 
The choice of a photosensitizer and its subsequent phototherapeutic effect depends on 
its physicochemical properties in the ground and excited states, pharmacokinetic and 
pharmacodynamic behavior, and photoactivity in vivo. Ideally, the photosensitizer should 
have the following properties: high selectivity, a high tumour to normal tissue accumulation 
ratio, rapid accumulation in tumour tissue, efficient body clearance, stability against 
molecular oxygen or other reactive oxygen species (ROS) generated in situ, no toxicity in 
dark state, have a high inter-system crossing yield, φISC from 
1
PS* to 
3
PS* with a long 
lifetime of 
3
PS* state, to allow efficient energy or electron transfer to the oxygen molecule 
(energy E[
3
PS*] > E[
1
O2] is a prerequisite for one photon excitation), thus having a high 
singlet oxygen yield, φ∆. Μoreover, a photosensitizer should show intensive absorption bands 
within the phototherapeutic window (ca. 620-850 nm), but its absorption in the range from 
400-600 nm should be as low as possible. This requirement is necessary to allow sufficient 
absorption inside the tissue and to avoid prolonged skin sensitivity toward solar irradiation 
following drug administration. Furthermore, PS should be sufficiently stable under 
physiological conditions. An amphiphilic character of the compound is advantageous, 
enabling its uptake and accumulation in membranes and cytoplasm. [51, 52] 
The first-generation photosensitizers in PDT are based on chemically modified natural 
hematoporphyrin. The most widely used first generation PS in clinical PDT is photofrin® 
[51], a purified “hematoporphyrin derivative” (HPD), porphyrin mixture containing several 
porphyrins, monomers as well as dimers and oligomers [46]. However, first-generation PS 
posses certain limitations such as weak absorption in the phototherapeutic window, ill-
defined chemical composition, as well as a relatively poor specificity of uptake and retention 
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with respect to malignant and healthy tissues. In addition, they cause prolonged skin 
photosensitivity (usually 2-3 months). [52] 
Subsequent extensive research helped to develop modern photosensitizers of the 
second and third generations. The second generation PDT sensitizers are mainly based on 
engineered, synthetic, and semisynthetic porphyrins with various substituents at the pyrrole 
rings and the methylene bridges [52] (see Fig. 1.8.) They are structurally homogeneous 
compounds with long-wavelength absorption bands of high intensity. So far many 
compounds have been tested as potential photosensitizers for application in PDT. [52, 53] 
They can be divided into the following groups: organic dyes (eosin, rose bengal, methylene 
blue), aromatic hydrocarbons (naphthalenes, anthracenes, biphenyls, quinines), tetrapyrrole 
and metallo-tetrapyrrole compounds (e.g. porphyrins, chlorins, bacteriochlorins, 
phthalocyanines, naphthalocyanines, texaphyrins, Fig. 1.8.) [52, 54]  
In Table 1.5. some examples of singlet oxygen yields of selected second-generation 
PS are given. [55] 
 
Table 1.5. Singlet oxygen yields, φ∆, of selected second-generation photosensitizers in 
various solvents. [55] 
PS Solvent φ∆ PS Solvent φ∆ 
Bacteriochlorophyll a C6H6 0.38 Chlorophyll b C6H5CH3 0.75 
Methylene blue EtOH 
H2O 
0.52 
0.60 
Porphyrin-Zn(II) C6H6 0.68 
Phthalocyanine-Zn(II) EtOH 
DMF 
0.53 
0.51 
Porphyrin, metal free C6H6 0.63 
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Figure 1.8. Structures of tetrapyrrolic photosensitizers: (a) porphyrin, (b) chlorin, (c) bacteriochlorin, 
(d) phthalocyanine, (e) naphthalocyanine, and (f) texaphyrin. 
 
The third-generation PS consist of the photosensitizer moiety linked to biomolecules 
such as monoclonal antibodies used for targeting, in order to allow selective delivery. [56] 
Other photosensitizers which have been already accepted for clinical applications are 
a precursor of protoporphyrin IX (PpIX), 5-aminolevulinic acid (ALA) and its methyl, hexyl 
and benzyl ester derivatives; and the synthetic m-tetrahydroxyphenylchlorin (mTHPC) as 
well as the luthetium texaphyrin complex. [46, 51, 57, 58] Aminolevulinic acid is a small, 
water-soluble, prodrug that is the naturally occurring precursor in the biosynthetic pathway of 
heme in mitochondria. Administration of excess of exogenous ALA avoids the negative 
feedback control that heme exerts over its biosynthetic pathway. Due to the limited capacity 
of ferrochelatase to convert PpIX into heme, the presence of an excess of exogenous ALA in 
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cells induces accumulation of PpIX [59, 60]. This effect is pronounced in sebaceous glands 
and also in neoplastic cells. [61] 
  
1.3.2. Light Sources Used in the PDT 
 
Typically, light fluxes of 50–500 J/cm
2
 of red light are needed in clinical PDT with 
photofrin®. [46] New sensitizers, e.g., mTHPC, are usually more efficient, mainly due to 
larger extinction coefficients in the red region. Consequently, a smaller light flux is required, 
typically 10 J/cm
2
. [62] If the surface irradiance exceeds 200 mW/cm
2
, local heating 
(hyperthermia) may also contribute to the PDT effect. [63, 64, 65, 66] For interstitial 
treatment with diffusing fibers inserted into the tumor, the hyperthermia limit is below 400 
mW/cm
2
 diffusing fiber [66]. Diode lasers giving a few watts of red light down to 630 nm are 
now commercially available and are probably the light sources of choice if only one 
sensitizer is to be used. [67] For surface irradiation LED arrays may be applied. However, for 
scientific purposes wavelength variation is necessary. Dye lasers, which can give up to a few 
watts of light in the red and near infrared region, have been the most widely used as light 
sources in PDT. For pumping the dye lasers either argon ion, copper vapors, or frequency-
doubled Nd-YAG lasers are being used. The sophisticated state-of-the-art light sources used 
are pulsed lasers based on nonlinear crystal oscillators, so-called optical parametric 
oscillators (OPOs), which can be tuned in a very wide wavelength region (220–2200 nm). 
[68]  
 
1.3.3. Medical Indications of the PDT  
 
To date, clinical applications of PDT have been limited to areas of the body easily 
amenable to irradiation from laser or incoherent light sources. Consequently, PDT has been 
primarily investigated as a treatment for tumours of the skin, bladder, mouth and female 
reproductive tract [40 - 43]. The first health agency approval for PDT (with photofrin®) was 
obtained in 1993 in Canada for the prophylactic treatment of bladder cancer [69]. 
Subsequently, approvals for photofrin® were obtained in the Netherlands and France for 
treatment of advanced esophageal and lung cancers; Germany for treatment of early stage 
lung cancer; Japan for early stage lung, esophageal, gastric, and cervical cancers as well as 
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cervical dysplasia; and in the United States for advanced esophageal cancer. In 1998 U.S. 
Food and Drug Administration (FDA) approved photofrin for use in PDT off early stage lung 
cancer. [46] 
In recent years, PDT has also been employed to treat other non-neoplastic diseases 
occurring at body sites accessible to irradiation, such as psoriasis, age-related macular 
degeneration of the eye and microbiological infections of skin wounds, burns and ulcers [70, 
71, 72].  
ALA, a photosensitiser prodrug with a relatively low molecular weight of 167.8 
daltons, is the most frequently employed agent in modern anti-cancer PDT [65]. ALA is 
typically applied to lesions in a topical cream, solution or patch-based formulation. PDT, 
based on topical application of ALA, has been successfully used in the treatment of basal cell 
carcinoma, actinic keratosis, Bowen’s disease, vulval intraepithelial neoplasia, vulval Paget’s 
disease and cervical intraepithelial neoplasia. [73] 
Results and patents based on formulations and clinical studies of ALA and derivatives 
thereof are described extensively in a review by Donelly et al. [61] Clinical status of PDT of 
advanced stage esophageal tumors, lung cancer, head and neck cancers, superficial bladder 
cancer and brain tumors using photofrin® and new sensitizers such as mTHPC is reviewed in 
detail by Dougherty et al. [46] 
 
1.3.4. Mechanism of Tumour Destruction by the PDT 
 
PDT in vivo acts through at least three principal modes: (i) direct cell killing by lethal 
oxidative damage of tumor cells (necrosis, apoptosis); (ii) indirect cell killing due to 
photodynamic damage or shutdown of the (neo)vasculature with loss of oxygen and nutrients 
supply to the tumor; and (iii) additional antitumor contributions from the inflammatory and 
immune responses. [74]  
The reactive oxygen species (and especially singlet oxygen) produced during the PDT 
are responsible for irreversible damage to various cell membranes including plasma, 
mitochondria, lysosomal and nuclear membranes and of protein modifications, depending on 
the PS localization site. Sensitizers that localize in mitochondria, like photofrin, or are 
produced in mitochondria, like 5-aminolevulinic acid (ALA)-induced protoporphyrin IX, are 
likely to induce apoptosis, while sensitizers localized in the plasma membrane are likely to 
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cause necrosis during light exposure [46]. There are reports that PDT can rapidly induce 
apoptosis, both in vitro [75, 76] and in vivo [77, 78]. Apoptosis is a mechanism whereby 
organisms initiate cellular death via a process that is normally part of the genetic apparatus 
[79]. The end result is fragmentation of nuclear DNA and dissociation of the cell into 
membrane-bound particles that are surrounded by adjoining cells, minimizing release of 
inflammatory products. A novel feature of PDT is the rapid apoptosis as the DNA ladders 
appear as early as 30 minutes after photodamage. 
Biological targets of 
1
O2 include unsaturated fatty acids, proteins, and DNA. [12] 
This, combined with the facts that normal tissue may not contain photosensitizer or may not 
be perfused by blood vessels damaged by PDT, means that healthy tissue is usually 
unaffected by exposure to light [41]. 
However, a parameter that can limit direct tumor cell death is the reduced availability 
of oxygen within the tissue undergoing PDT treatment. Two mechanisms can produce such 
limitations: The photochemical consumption of oxygen during the photodynamic process and 
the effects of PDT on the tissue microvasculature. The rate of oxygen consumption during 
photofrin–PDT can be enough to move a fraction of the tumor into very low levels of 
oxygenation, outpacing the rate of oxygen diffusion from the capillaries, and shrinking the 
radius of oxygenated tissue volume around them [80]. Preliminary clinical studies at the 
Roswell Park Cancer Institute showed oxygen depletion also occurring during PDT in 
patients. The kinetics for this depletion varied from very rapid (within seconds of light 
exposure) to slow (>10 minutes of light exposure) and to no effect at all in basal cell 
carcinoma lesions in patients undergoing photofrin (1 mg/kg)–PDT at a light dose rate of  
150 mW/cm
2
. [46] 
The oxygen supply in the tissue can also be diminished by the damaging effects of 
PDT on the microvasculature. With high doses of certain photosensitizers, e.g., photofrin, 
these effects can be sufficient to limit the oxygen supply to the tumor during PDT [81]. 
 
1.3.5. Limitations and Drawbacks of the PDT  
 
The main limitation of PDT is the depth of light penetration through human tissue, 
typically no more than 1 cm, depending on the light source energy. Thus, the application of 
PDT is restricted to the treatment of tumours on or under the skin, or on the lining of some 
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internal organs. PDT is less effective in treatment of large tumours and metastases and is 
mostly used as a complementary treatment with chemotherapy. Therefore, it is a local 
treatment, comparable to a surgery. Typically, the tumour surgery is preferred in comparison 
to PDT, except for cosmetically relevant cases (e.g. facial treatment). Moreover, after the 
treatment the patient has to avoid excessive exposure to sunlight if a photosensitizer has 
accumulated in healthy tissues.  
 
General Introduction 
25 
 
1.4. DRUG DELIVERY SYSTEMS USED IN THE PDT 
 
 As most photosensitizers are characterized by high lipophilicity, various 
encapsulation strategies have been studied to protect the hydrophobic photosensitizer from 
the aqueous environment. Ideally, the drug delivery system should be biodegradable, have 
minimum immunogenicity, incorporate the photosensitizer without loss or alteration of its 
activity and provide an environment where the photosensitizer can be administered in 
monomeric form (reducing aggregation which can decrease singlet oxygen quantum yields). 
Importantly, the delivery system should enable selective accumulation of the PS within the 
diseased tissue in therapeutic concentrations with little or no uptake by non-target cells.  
Delivery systems based on micellar oil-dispersions, liposomes, hydrophilic polymer-
photosensitizer conjugates or polymeric particles (nanoparticles and microparticles) have 
been developed, with varying degrees of success. Oil-based micellar drug formulations using 
polyoxyethylated castor oils (e.g., polysorbate-80, cremophor-EL etc.) enhance drug loading 
and improve tumour uptake over free drugs, presumably due to the interaction with plasma 
lipoproteins in blood. However, such emulsifying agents elicit acute hypersensibility 
(anaphylactic) reactions. Liposomal formulations can substantially improve efficacy and 
safety of photosensitizers, but are generally unable to establish elevated tumour-to-normal 
tissue ratios, because of short plasma lifetimes. [82] 
Nanoparticles (NPs) have a great potential as drug carriers because (a) they can 
transport hydrophobic drugs in blood, (b) their large surface area can be modified with 
functional groups for additional chemical/biochemical properties, (c) they have large volumes 
of distribution and are generally taken up efficiently by cells; (d) controlled release of drug is 
possible; and (e) numerous synthetic strategies exist. [82] Nanoparticle coating with 
poly(ethylene glycol) (PEG) increases the blood circulation time and subsequent 
accumulation in tumors. This is due to the “enhanced permeability and retention effect” 
observed in solid tumors whereby circulating nanoparticles are trapped in tumors by a 
combination of leaky vasculature, poor lymphatic drainage and increased vessel permeability. 
[83] 
An extensive review about carrier materials, especially nanoparticles, used in PDT 
with a functional classification of nanoparticles in PDT dividing them into passive carriers 
and active participants in photosensitizer excitation was written by Chatterjee et al. [82] 
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Passive carriers are then sub-classified by material composition into (a) biodegradable 
polymer-based nanoparticles and (b) non- biodegradable nanoparticles, e.g. ceramic (silica) 
and metallic (gold, iron oxide) nanoparticles. Biodegradable NPs are based mainly on 
polyesters poly(D,L-lactide-coglycolide (PLGA)) and poly(D,L-lactide (PLA)). For example, 
Alleman et al. [84] have studied the potential incorporation of phthalocyanine derivatives into 
PLA, which is approved by U. S. Food and Drug Administration. Active nanoparticles can be 
sub-classified by mechanism of activation into photosensitizer nanoparticles, [85, 86] self-
illuminating nanoparticles [87] and upconverting nanoparticles [88]. 
It should be pointed out that the effectiveness of photosensitizer drug delivery to the 
tumour cells using biodegradable PLGA nanoparticles depends on the particle size [89]. This 
could be due to the increased rate at which small-sized nanoparticles are internalised and 
released into the interior of the tumour cells (by endocytosis), thus allowing an increase of the 
drug concentration at its site of action. Moreover, smaller-sized PLGA particles also show 
higher drug release rates, possibly due to a corresponding increase in the total particle surface 
area, resulting in a larger fraction exposed to the leaching medium. The study [89] indicated 
that particle size was an important characteristic related to obtaining optimal in vitro efficacy. 
Specifically, a particle diameter of less than 200 nm is likely to be an optimal size, not only 
for the effective blood-tumour transfer of nanoparticles, but also for their long retention in 
tumour tissue. [82] 
Another example are surfactant-coated polymer NPs formulated using dioctyl sodium 
sulfosuccinate (aerosol OT) and sodium alginate used as a carrier to enhance the therapeutic 
efficacy of methylene blue as a photosensitizer resulting in higher cytotoxicity and necrosis 
of MCF-7 and 4T1 cancer cells. [90] 
Different strategies for PS drug delivery, including polymer–PS conjugation or 
encapsulation of the drug in colloidal carriers, such as oil-dispersions, liposomes and 
polymeric particles, have been reviewed in detail in [45]. Although these colloidal carriers 
tend to accumulate selectively in tumour tissues, they are rapidly taken up by the 
mononuclear phagocytic system. [91] In order to reduce this undesirable uptake by 
phagocytic cells, long-circulating carriers that consist of surface modified carriers, such as 
PEG-coated PLA NPs (see above) have been developed.  
However, systemic health effects and body distribution of mentioned carriers, 
especially nanoparticles, as comprehensively reviewed in [92, 93], have to be taken into 
account when they are used as a drug carrier. Irrespective of the uptake route, the body 
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distribution of NPs is mostly dependent on the surface characteristics and the size of the 
particles. For example, coating poly(methyl methacrylate) NPs with different types and 
concentrations of surfactants significantly changes their body distribution. Coating these NPs 
with ≥ 0.5 % polysorbate 80 surfactant reduces their liver concentration significantly after 
intravenous injection [94]. 
Interesting possibilities were opened by increasing the hydrophilicity of the PS 
through the conjugation with an appropriate polymer including N-(2-hydroxy- 
propyl)methacrylamide (HPMA) [95] to cationic, anionic or neutral poly-L-lysine [96], 
polyethylene glycol (pegylation) [97, 98, 99] or poly(vinyl alcohol) (PVAL) [100]. Another 
approach is to use quantum dots as photosensitizers or radiosensitizers for cancer therapy 
[101]. 
Moreover, considerable effort has been directed towards using other types of carriers 
to improve tumour targeting and to minimize the side effects. Lipoprotein-mediated delivery 
and monoclonal antibodies have been used to reach these goals. One approach is to entrap PS 
into the lipophilic core of low-density lipoproteins (LDL) without altering the physical or 
biological properties of LDL (no alteration of the LDL recognition by LDL receptor). The 
LDL receptor pathway is an important factor in the selective accumulation of PS in tumour 
tissue owing to the increased number of LDL receptors on the proliferating cell surface. [45, 
102, 103] 
Antibody (Ab)-based drug delivery is another approach to improve the specificity of 
PDT and to overcome side effects associated with this therapy. This strategy consists of 
linking PS with monoclonal antibodies against specific antigens of malignant cells. For 
detailed overview, see reference [45]. 
Finally, the most recent review of drug delivery systems for PDT [61] concentrates on 
patented advanced formulations (gels, creams, injections, etc.) for delivery of PS such as 
ALA already used in clinical studies. Love et al. [104] describe an innovative system for 
delivery of preformed porphyrin-type photosensitisers. The photosensitisers can be 
chemically-bound to the surface of biocompatible insoluble supports, or can be coated on the 
surface. The insoluble supports are polymeric materials, such as poly(acrylamide), 
poly(propylene) or silicon-based polymers. Such systems could be implanted directly into 
target tissue and release their drug payload to allow local photosensitisation without causing 
widespread photosensitivity of the rest of the body. Love et al. [105] also described 
formulations of various photosensitiser-loaded solution-, gel-, and powder-based systems for 
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use in PDT of bacterial infections. The formulations described could be injected, applied 
topically, sucked or inhaled. Taylor et al. [106] apply aqueous-based topical gel formulations 
containing zinc phthalocyanine for PDT of plaque psoriasis.  
In general, only a few patents exist on innovative formulations for photosensitiser 
delivery. There are several reasons for this. Firstly, despite the vast number of studies 
published in the area of topical PDT, a rational approach to formulation design has not taken 
place. This may be because this field is dominated by clinicians and basic scientists, rather 
than those involved in pharmaceutical formulation development. Secondly, the majority of 
clinical studies carried out to date have been sponsored by the pharmaceutical companies 
who own the patents on the small number of proprietary products approved [61]. 
Thus, the drug delivery is one of the main challenges in PDT to be overcomed. 
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2. SCOPE AND OBJECTIVES 
The lifetime, τ, of singlet oxygen (1O2) in a biological environment, e.g. intracellularly 
lifetime, is in µs range [6, 7]. Concerning medical applications, the distance between the 
location of 
1
O2 generation (by irradiation of a photosensitizer) and the effect of 
1
O2, is short, 
i. e. within the 
1
O2 diffusion radius, which is substantially less than 1 µm. [6] 
1
O2 can also be 
generated by the thermolysis of polycyclic aromatic endoperoxides [3]. Considerable efforts 
have been devoted to develop suitable 
1
O2 generators based on endoperoxide thermolysis in 
biological environment (see Chapter 1.2.4.).  
One of the polycyclic aromatic compounds capable of reacting with 
1
O2 in an organic 
solvent and subsequently releasing (thermally induced) of 
1
O2 is 1, 4-dimethylnaphthalene 
(N1). N1 is a commercially available material, typically used as a potato sprout inhibitor 
[107, 108] and is therefore approved for biological use. 1,4-dimethylnaphthalene-1,4-
endoperoxide (N1E) is chemically stable and able to release 
1
O2 with 76 % yield [22], with 
half-life time values of t1/2 = 1.5 h at 35 °C [22] and t1/2 = 5 h at 25 °C in organic solvents 
[109]. N1E is synthesized by reaction of N1 with 
1
O2 upon a photosensitzer irradiation at low 
temperature (0-5 °C) and is storable for months at -80 °C [22]. When gently warmed, it 
releases a definite amount of 
1
O2 free of other reactive oxygen species. However, until now 
N1E has not been generated in aqueous media. In order to use 
1
O2 generated by thermolysis 
of endoperoxides such as N1E in possible medical applications, it is necessary to load a 
biocompatible carrier with the endoperoxide and deliver it to the place of interest for the 
particular application (e.g. cancer cells). During the delivery time, the endoperoxide molecule 
should not thermally decay and release the 
1
O2. Therefore, the endoperoxide decay kinetics 
has to be adjusted to the demands of the particular application: in case of carrier delivery to 
the cancer cells, the endoperoxide half-life time, t1/2, should be significantly larger than the 
carrier cell-uptake time, tu, t1/2 > tu. 
The objectives of this work were the following:  
• synthesis of several derivatives of N1, capable of endoperoxide generation and 1O2-
release, in order to extend the range of 
1
O2-release time at 37 °C and to enable their 
incorporation in various carrier material types; 
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• preparation of various biocompatible carrier types (liposomes, polymer films, 
especially polymer nanoparticles), and examination of carrier uptake time in human 
breast cancer cells, line MDA-MB-231 [110] (used as a model for pharmaceutical 
applications) using confocal laser scanning microscopy; choice of appropriate carrier 
for delivery of 
1
O2-releasing endoperoxides 
• examination of endoperoxide decay kinetics in various biocompatible matrices with a 
systematical adjustment of the decay kinetics by means of various chemical and 
physical parameters in order to meet the condition that t1/2 is substantially longer than 
tu (e. g. for possible cancer treatment application), and the establishment of a 
microscopic model describing the chemical and physical modifications of the decay 
kinetics; 
• kinetic chemosensitivity assay [111] of various 1O2-releasing endoperoxides (with 
adjusted decay kinetics) in biocompatible carriers on MDA-MB-231 breast cancer 
cells in vitro; 
• synthesis and characterization of multichromophore molecules consisting of 
covalently linked, but electronically weakly coupled subunits: a red light absorbing 
photosensitizer core and up to four endoperoxide-forming aromatic units (derivatives 
of N1) on the periphery. These novel compounds with two chromophores combined 
in one molecule were studied with respect to their photophysical and photochemical 
properties. 
The motivation for the last issue was that such a system with an internal reactivity to 
generate and store 
1
O2 would combine the useful properties of tetrapyrrole derivatives as a 
sensitizer for photodynamic therapy with the ability of aromatic endoperoxides to release 
1
O2 
independently of the conditions in the tissue. Hence, after long-term irradiation such a system 
would react with 
1
O2 to form endoperoxides, which could later potentially serve as an internal 
source of 
1
O2. Contrary to the classical PDT where 
1
O2 is generated only upon irradiation, 
after the activation by light our system would conceivably also have a delayed 
1
O2 production 
by endoperoxide decay. 
The general concept of this thesis was to develop systems based on the controlled 
release of 
1
O2, consisting of an appropriate carrier containing endoperoxide-forming 
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molecules in order to adjust the decay kinetics. A photosensitizer is either also embedded in 
the carrier, or preferably dissolved in aqueous medium, where it can be extracted after the 
irradiation. If this concept would be realized, then a new type of 
1
O2 generation procedure 
would be developed [112]: in which the photosensitizer irradiation and subsequent 
endoperoxide formation could be performed outside of the patient body. Singlet oxygen 
would be temporarily “stored” in the endoperoxide-containing carrier, which should provide 
the adjustment of the 
1
O2 release in the human body. Finally, a long-term outlook would be 
the possiblity to use this procedure for the treatment of various diseases, including microbial 
infections and cancer. In contrast to conventional PDT, restrictions due to light penetration 
depth and post-treatment photosensibilization problems would not exist. 
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3. MATERIALS AND METHODS 
3.1. METHODS USED FOR SUBSTANCE CHARACTERIZATION  
 
Elemental analyses, as well as the NMR and MS spectroscopy and X-ray crystal 
structure determinations, were carried out by the Centre for Chemical Analysis of the Faculty 
of Chemistry and Pharmacy of the University of Regensburg. 
NMR spectroscopy 
NMR spectra were recorded with a Bruker Avance 300 Spectrometer (1H: 300.1 
MHz; T = 300 K). The chemical shifts are reported in ppm releative to external standards 
(solvent residual peak) and coupling constants are given in Hertz. 
EI-MS spectroscopy 
Mass spectra were recorded with a Varian CH-5 spectrometer. 
X-ray crystal structure determinations   
Diffraction data for synthesized compounds‘ crystals were collected with an Oxford 
Diffraction Gemini Ultra CCD diffractometer [113] with multilayer optics and Cu-
Kα  radiation (λ = 1.5418 Ǻ). 
UV-Vis Absorption 
Absorption spectra were recorded with a Varian Cary 300 Bio UV/Vis Spectrometer 
with a 1-cm quartz cell (Hellma GmbH & Co. KG, Müllheim, Germany) and Uvasol® 
quality solvents from Sigma-Aldrich (Munich, Germany). 
Emission spectroscopy 
Fluorescence spectra were recorded with an Aminco-Bowman Series 2 Spectrometer 
and a Perkin Elmer LS 50 B Spectrometer with a 1-cm quartz cell (Hellma GmbH & Co. KG, 
Müllheim, Germany) and Uvasol® quality solvents. 
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Dynamic light scattering 
Dynamic light scattering (DLS) experiments were performed on a Malvern Zetasizer 
3000 HR (Malvern, United Kingdom) using 633 nm laser scatter. Samples obtained from 
dialysis were diluted by a factor of ten, results shown are averages of ten independent 
measurement runs. Correlation curves and particle size distributions were calculated by 
Malvern software using the photon correlation spectroscopy (PCS) method. 
Transmission electron microscopy (TEM) 
TEM experiments were made at the Department of Pathology of the University 
Hospital Regensburg. 
The sample (drops of nanoparticles suspension in ddH2O) was placed on Formvar- 
and carbon-coated positively glow-discharge treated cupper grid (400 mesh) and 
subsequently blotted dry with filter paper.  
The sample was examined with a Zeiss LEO912AB electron microscope operating at 
100 kV, equipped with a side-mounted CCD-camera capable of recording images with 1k•1k 
pixels. The documentation was done with the iTEM –software, Ver. 5.0 (Olympus Soft 
Imaging Solutions GmbH, Muenster, Germany). 
 
3.2. CHEMICALS AND MATERIALS 
 
All chemicals used were of analytical grade or better. Methanol, 2-propanol, 
dichloromethane, chloroform, sodium chloride, potassium chloride, 
disodiumhydrogenphosphate dihydrate, potassium dihydrogenphosphate, sodium dodecyl 
sulfate (SDS), cetyltrimethylammonium bromide (CTAB) , sulphuric acid, sodium sulfite, 
sodium bisulfite, ammonium molybdate, glutardialdehyde, crystal violet and sulphuric acid 
were purchased from Merck KGaA (Darmstadt, Germany). 1-amino-2-naphthol-4-sulfonic 
acid was obtained from Serva Fine Chemicals (Heidelberg, Germany). 1-propanol, acetone, 
N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), and N,N,N',N'-
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tetramethylethane-1,2-diamine (TEMED), tween 20, polysorbate 80 and triton X-100 and 
were obtained from Sigma-Aldrich (Munich, Germany).  
1,4-dimethylnaphthalene (N1) in a form of 95% pure liquid was obtained from Merck 
KGaA (Darmstadt, Germany), and 1,4.5-trimethylnaphthalene (N2) in form of white crystals 
was obtained from ABCR GmbH & Co. KG (Karlsruhe, Germany). 
1,2-dimyristoyl-L-α-phosphatidylcholine (DMPC) was obtained from Sigma-Aldrich 
(Munich, Germany). Polyvinyl butyral (PVB, Mowital LPB 16H, molar mass 16 kDa) was 
obtained from Kuraray Europe GmbH (Frankfurt, Germany). N,N’-bis(2,6 -dimethylphenyl)- 
perylene-3,4,9,10- tetracarboxylic diimide (PTC) was from BASF (Ludwigshafen, Germany). 
Cell Mask Deep Red plasma membrane stain (Deep Red) was purchased from Invitrogen 
GmbH (Darmstadt, Germany). DRAQ5 nuclear stain (DRAQ5) was obtained from Biostatus 
Limited (Shepshed, United Kingdom). Doubly distilled water (ddH2O) was produced in-
house. LabTek II chambered cover glasses with 8 chambers were supplied by Nunc GmbH 
(Langenselbold, Germany). 
Phosphate buffered saline (PBS) pH 7.4, was made by adding 8.0 g of NaCl, 200 mg 
of KCl, 1.0 g of Na2HPO4·2H2O, 200 mg of KH2PO4 and 150 mg of NaH2PO4 to 900 mL 
Millipore quality H2O, titrating to pH 7.4 at room temperature (RT) and adding Millipore 
quality H2O to a final volume of 1 L. Cellulose filter paper type 595 (4 – 7 µm pores) was 
from Whatman GmbH (Dassel, Germany). Cellulose dialysis tubes type Visking (molecular 
weight cut off 14,000) were obtained from Carl Roth (Karlsruhe, Germany). Amicon Ultra-4 
cellulose centrifugal filter membranes (molecular weight cut off 10,000) were from Millipore 
GmbH (Schwalbach, Germany).  
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3.3. SYNTHESIS OF ENDOPEROXIDE-FORMING MOLECULES: 
NAPHTHALENE DERIVATIVES 
3.3.1. 1-(1,4-Dimethyl-Naphthalen-2-yl)-Ethanone 1-(1,4-Dimethyl-Naphthalen-2-yl)-
Ethanone (N3)  
 
N3 was synthesized from N1 using the Friedel-Crafts benzolyation by the Perrier 
addition procedure [114]: to a stirred solution of anhydrous AlCl3, (13.17 g, 0.1 mol) in 
dichloroethane (150 mL) was added dropwise acetyl chloride (7.1 mL, 0.1 mol) and than also 
dropwise N1 (14 g, 0.09 mol). The mixture was stirred overnight at 0-5 ºC and afterwards 
poured into ice-water bath. Concentrated hydrochloric acid was added dropwise until the 
brown precipitate dissolved. The organic layer was separated and the water layer was 
extracted with chloroform. The combined organic layers were dried over MgS04, and 
concentrated. The brown precipitate appeared from cold methanol and was then purified by 
column chromatography on Al2O3 with hexane and successively ethyl acetate as eluents to 
yield 8.14 g of white N3 (46 %). During this reaction a mixture of ketone products, 1-(1,4-
dimethyl-naphthalen-2-yl)-ethanone and 1-(1,4-dimethyl-naphthalen-6-yl)-ethanone, is 
formed, but only 1-(1,4-dimethyl-naphthalen-2-yl)-ethanone crystallizes from methanol. It is 
possible to isolate 1-(1,4-dimethyl-naphthalen-6-yl)-ethanone by treating the ketone mixture 
with an excess of hydroxylamine to give the a mixure of oxymes, treating the mixture with 
concentrated HCl and then crystallizing 1-(1,4-dimethyl-naphthalen-6-yl)-ethanone [38, 114]. 
Product characterization was done with elemental analysis, mass spectrum and 
1
H NMR: 
Elemental analysis: 
N3 molecule requires: 84.80% C, 7.07% H, and it was found: 84.55 % C, 7.22 % H. 
EI-MS: 
Detected were ions of the following mass/ion- charge (m/z) ratios: 198.1 (N3
+
); 183.1 (N3
+
 - 
CH3); 155.1 (N3
+
 - CH3 - CO). 
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1
H NMR: 
1
H (300 MHz, CDCl3): δ 2.60 (s, 3H), 2.65 (s, 3H), 2.71 (s, 3H), 7.35 (s, 1H) 7.55 (m, 2H), 
7.97 (m, 1H), 8.14 (m, 1H). 
 
3.3.2. 1-(1,4-Dimethyl-Naphthalen-2-yl)-Ethanol (N4)  
 
To a stirred solution of N3 (7.2 g, 36 mmol) in anhydrous ether (100 mL) was added 
slowly a suspension of LiAlH4, (1.05 g, 28 mmol) in anhydrous ether (100 mL) at room 
temperature. The mixture was stirred for 3h and poured into an ice-water bath. Hydrochloric 
acid was added to the contents until the white solid was dissolved. The organic layer was 
separated and the aqueous layer was extracted with ether. The combined organic layers were 
dried over MgSO4, and concentrated. The crude product was purified from N3 remains and 
from N5 product (see later) by column chromatography on Al2O3 with hexane and 
successively ethyl acetate as eluents. Subsequently from n-hexane 1.15 g of white crystals of 
N4 (16 %) were obtained.  
Product characterization was done with elemental analysis, mass spectrum, 
1
H NMR and  
x-ray crystal structure analysis: 
Elemental analysis: 
N4 molecule requires: 84.00% C, 8.00% H, and it was found: 83.88 % C, 8,20 % H. 
EI-MS: 
Detected were ions of the following m/z ratios: 200.1 (N4
+
); 185.1 (N4
+
 - CH3); 182.1 (N4
+
 - 
H2O). 
1
H NMR (300 MHz, CDCl3): δ 1.42 (d, 3H, 
3
JHH 6.8 Hz) 1.56 (s, 1H) 2.29 (s, 3H), 2.74 (s, 
3H) 4.74 (q, 1H, 
3
JHH 6.8 Hz) 7.54 (m, 3H), (m, 2H). 
X-ray crystal structure determination: 
Suitable X-ray single crystal (colourless) of compound N4 was obtained as described 
above and was mounted on top of glass fiber in a random orientation. Crystal data, data 
collection, and refinement parameters are given in Table 3.1. 
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Table 3.1. Crystal data, data collection, and structure refinement parameters for N4 
compound. 
 
 parameter N4 
empirical formula C14H16O 
formula mass, g mol
-1
 200.27 
collection T, K 123 
crystal system monoclinic 
space group P 21/n 
a (Ǻ) 8.1442(3) 
b (Ǻ) 4.8533(2) 
c (Ǻ) 27.8100(11) 
β (deg) 94.010(4) 
V (Ǻ 
3
) 1096.53(7) 
Z 4 
Dcalcd (g cm
-3
) 1.213 
crystal size (mm) 0.210 x 0.042 x 0.008 
F(000) 432 
abs coeff (mm
-1
) 0.574 
θ range (deg) 3.19 to 66.33 
range h, k, l -9/7, -5/5, -29/32 
no. total refl. 4568 
no. unique refl. 1897 
data/restraints/parameters 1897 / 0 / 143 
final R R1 = 0.0392 
[I > 2σ(I)] wR2 = 0.1094 
R indices (all data) R1 = 0.0464, wR2 = 0.1136 
goodness of fit/F
2
 1.051 
largest diff. Peak and hole (e Ǻ 
-
3
) 0.171 and -0.223 
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3.3.3. Di-1-(1,4-Dimethylnaphthene-2-yl)-Ethylether (N5) 
 
Synthesis procedure was the same as for N4. N5 was a novel, unexpected product of 
an in situ reaction: condensation of N4, H2O elimination and ether bound forming with an 
excess of LiAlH4 in anhydrous ether (see Scheme 1). The mixture of N5 and N4 and N3 was 
purified by column chromatography on Al2O3 with hexane and successively ethyl acetate as 
eluents. Subsequently from dichloromethane 2.1 g of white crystals of N5 (31 %) were 
obtained. 
Product characterization was done with elemental analysis, mass spectrum, 
1
H NMR and  
x-ray crystal structure analysis: 
Elemental analysis: 
N5 molecule requires: 87.96% C, 7.85% H, and it was found: 87.85 % C, 7.58 % H. 
EI-MS: 
Detected were ions of the following m/z ratios: 382.3 (N5
+
); 184.2 (N5
 +
 - C14H14O).  
1
H NMR: 
1
H NMR (300 MHz, acetone): δ 1.38 (d, 6H, 
3
JHH 6.6 Hz), 2.29 (s, 6H), 2.73 (s, 6H), 4.76 (q, 
2H, 
3
JHH 6.6 Hz) 7.56 (m, 6H), 8.06 (m, 4H). 
X-ray crystal structure determination: 
Suitable X-ray single crystal (translucent, colourless) of compound N5 was obtained 
as described above and was mounted on top of glass fiber in a random orientation. Crystal 
data, data collection, and refinement parameters are given in Table 3.2. 
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Table 3.2. Crystal data, data collection, and structure refinement parameters for N5 
compound. 
 
parameter N5 
empirical formula C28H30O 
formula mass, g mol
-1
 382.52 
collection T, K 123 
crystal system orthorhombic 
space group P b c n 
a (Ǻ) 7.6851(3) 
b (Ǻ) 16.8705(5) 
c (Ǻ) 16.3611(5) 
β (deg) 90 
V (Ǻ 
3
) 2121.24(12) 
Z 4 
Dcalcd (g cm
-3
) 1.198 
crystal size (mm) 0.210 x 0.042 x 0.008 
F(000) 824 
abs coeff (mm
-1
) 0.536 
θ range (deg) 5.24 to 65.05 
range h, k, l -8/6, -17/19, -9/18 
no. total refl. 6017 
no. unique refl. 1772 
data/restraints/parameters 1772 / 0 / 133 
final R R1 = 0.0444 
[I > 2σ(I)] wR2 = 0.1234 
R indices (all data) R1 = 0.0510, wR2 = 0.1282 
goodness of fit/F
2
 1.059 
largest diff. Peak and hole (e Ǻ 
-
3
) 0.263 and -0.225 
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3.3.4. 1,4-Dimethyl-2-Vinylnaphthalene (N6)  
 
To a stirred solution of N4 (300 mg, 1.5 mmol) in 5 ml CH2Cl2 was dropwise added 
SOCl2, (0.22mL, 3.0 mmol) at 0 °C. The reaction mixture was stirred for 4 h and excess of 
SOCl2 and the solvent were removed in vacuo. The residue (brown oil) was dissolved in 
DMF (6 mL). To the solution was added t-BuOK (0.26 g, 2.4 mmol) in small portions at ice-
water bath temperature with stirring. The mixture was stirred for 3 h, afterwards poured into 
ice-water bath, and extracted three times with ether. The combined ether layers were dried 
over MgSO4; the solvent was later evaporated. The yellow residue was purified by column 
chromatography on silica gel with hexane as eluent to give 150 mg of N6 (55%) white 
crystals.  
Product characterization was done with mass spectroscopy, and 
1
H NMR.  
EI-MS:  
Detected were ions of the following m/z ratios: 182.1 (N6
+
) and 167.1 (N6
+
 - CH3).  
1
H NMR (300 MHz, DMSO): δ 2.60 (s, 3H), and 2.62 (s, 3H), 5.41 (dd, 1H, 
5
JHH 1.6 Hz, 
3
JHH 17.5 Hz), 5.82 (dd, 1H, 
5
JHH 1.6 Hz, 
3
JHH 11.1 Hz) 7.26 (m, 1H) 7.55 (m, 3H), 7.97 (m, 
1H), 8.11 (m, 1H). 
 
3.3.5. Poly(1,4-Dimethyl-2-Vinylnaphthalene), (N7)  
 
N7 was synthesized in a form of nanoparticles as suggested by Dr. S. Nagl, similar to 
his polystyrene-based nanobeads synthesis procedure [115] directly from the monomer N6. 
410 mg N6 was mixed with 2 g sodium dodecyl sulfate (SDS) in 10 ml ddH2O in a 100 mL 
round flask equipped with reflux condenser and temperature control. 25 mg (NH4)2S2O8 was 
dissolved in 1 ml ddH2O and immediately added to the N6/water mixture. It was then heated 
to 90 °C under reflux for 2 h. After cooling down to the room temperature, the synthesized 
particles were dialyzed for several days against ddH2O using cellulose membranes to remove 
traces of monomers, side products and impurities. 
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 After irradiation and prior to the kinetic chemosensitivity assay on cancer cells, (see 
Chapter 3.6.2.), polysorbate 80™ surfactant was added to the larger (95 ±24 nm diameter, 
Figure 4.4. and 58 ± 9 nm diameter) N7 nanoparticle aqueous suspension (1% v/v 
polysorbate 80™ in dd H2O) in order to enable faster nanoparticle uptake by the breast 
cancer cells. Smaller N7 nanoparticles (diameter 12 ±3 nm) were not coated with polysorbate 
80™ surfactant. 
 
3.4. PHOTOSENSITIZERS AND LIGHT SOURCES 
 
Several light-harvesting photosensitizers were used for the generation of 
1
O2, which 
then reacted with naphthalene derivatives to form endoperoxides.  
In addition to the standard photosensitizer properties (see Chapter 1.3.1.) for the 
sample preparation several other conditions had to be fulfilled, such as a good solubility of 
the photosensitizer in the used solvent (H2O, ethanol, CHCl3) and/or high enough embedding 
of the photosensitizer in the carrier matrix, which was critical with polymer nanoparticles 
preparation procedure. Depending on the carrier material and sample preparation procedure, 
one of the following photosensitizers was chosen: 
 
3.4.1. Protoporphyrin-IX-Dimethylester (PpIX-DME)  
 
PpIX-DME was obtained from Sigma-Aldrich (Munich, Germany). On Figure 3.1. its 
structure and absorption spectrum are shown. 
This photosensitizer was preferably used in systems with liposome carrier because of 
good solubility in CHCl3 (solvent used for liposomes preparation), and subsequently good 
embedding in liposomes. 
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Figure 3.1. Structure and absorption spectrum of PpIX-DME photosensitizer in CHCl3 and a PVB polymer film.  
 
3.4.2. 5,10,15,20-Tetrakis-(2,3,4,5,6-Pentafluorophenyl)-Porphyrin-Pd(Ii), TPFPP-
Pd(II)  
 
TPFPP- Pd(II) was obtained from Porphyrin Systems GbR (Lübeck, Germany). On 
Figure 3.2. its structure and absorption spectrum are shown. This photosensitizer was 
preferred in PVB films and in PVB nanoparticles because of good solubility in ethanol 
(solvent used for PVB films and PVB nanoparticles preparation). 
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Figure 3.2. Structure and absorption spectrum of 10-6 M TPFPP-Pd(II) photosensitizer in EtOH. 
Materials and Methods 
43 
 
S
N
N N
Cl
 
3.4.3. Methylene Blue (MB)  
 
MB photosensitizer was obtained from Sigma-Aldrich (Munich, Germany). On Fig. 
3.3. its structure and absorption spectrum are shown. Because of its excellent water solubility, 
3,7-bis(Dimethylamino)phenazathionium chloride or commonly known as methylene blue 
was used in systems with nanoparticles suspension in H2O as a photosensitizer, dissolved in 
H2O, separately from endoperoxide-forming molecules embedded in polymer nanoparticles. 
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Figure 3.3. Structure and absorption spectrum of 2 •10-5 M methylene blue photosensitizer in H2O. 
In Table 3.3. molar extinction coefficient values of used photosensitizers at available light 
sources’ wavelengths are given. 
Table 3.3. Molar extinction coefficient values (ε / cm-1 M-1) of used photosensitizers at 
wavelengths of (in this work used) light sources. 
λ/nm PpIX-DME in CHCl3 TPFPP-Pd(II) in EtOH MB in H2O [116] 
420 150 000 120 000 598 
514 17 200 37 000 2 900 
658 5 300 / 70 280 
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3.4.4. Light Sources 
  
Depending on the photosensitizer molecule present in the system, different light 
sources were used throughout this work. 
For porphyrin-based photosensitizers (PpIX-DME, TPFPP-Pd(II) and P2) a blue 
(λ=420 ± 10 nm) high-power LED from R&D laboratory of Osram GmbH, (Regensburg, 
Germany) or an argon-ion laser (λ=514 nm, Model 2025 by Newport Spectra-Physics GmbH, 
(Darmstadt, Germany) was used. 
When MB photosensitizer was present in the system, a red (λ=658 nm) hand-made 
laser (by Mr. Putzcka, Faculty of Physics, University of Regensburg) or a red (λ=660 ± 15 
nm) high-power LED array of 16 power LED chips (type LED660-66-16100 from Roithner 
Lasertechnik, Vienna, Austria) was used. 
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3.5. CARRIER MATERIALS 
3.5.1. Liposomes, Preparation and Characterization 
 In this work conventional, uncoated liposomes in an aqueous suspension were 
prepared from 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC) with an extrusion 
technique (extrusion includes pressing liposomes through a membrane with well-defined 
pores in order to get liposomes of a homogenous size-distribution). DMPC was commercially 
available from Sigma-Aldrich (Munich, Germany). DMPC structure with its polar, 
hydrophilic “head” and an apolar, hydrophobic “tail” is shown in Fig. 3.4., as well as a 
scheme of a formed liposome bilayer sphere. Hydrophylic layers enable homogenous 
dispersion of liposome particles in water suspension, whereas hydrophobic compounds such 
as endoperoxide-forming naphthalene derivatives and photosensitizers (porphyrine 
derivatives), are stored and transported in alkyl centre of the lipid bilayer.  
 
 
Figure 3.4. DMPC lipid structure and a scheme of a unilammelar liposome. 
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3.5.1.1. Liposome Preparation Procedure 
  
10 mg/ml DMPC were dissolved in chloroform. To the solution were added 
endoperoxide-forming naphthalene derivative (e.g. N1/DMPC = 1/50) and PpIX-DME 
(PpIX-DME/DMPC = 1/5000) in chloroform. Then, solvent was totally evaporated using 
rotary evaporator at 35 °C, leaving a lipid film on flask wall. To the dry lipid film dd H2O 
was added, and the film was let to swell from the flask wall for 30 minutes forming a 
suspension of multilamillar liposomes of varying sizes. This suspension was shaken 3 times 
during these 30 minutes in order to detach the entire lipid from flask wall. Subsequently the 
liposome suspension was pressed 30 times through a 100 nm polycarbonate membrane using 
a Liposofast™ (from Avestin Europe GmbH, Mannheim, Germany) device to form a 
unilamellar liposome suspension. 
 Average hydrodynamic diameter of so formed liposomes was determined with DLS 
technique to be 116 ±32 nm. 
 
3.5.1.2. Determination of Lipid Concentration  
 
The lipid concentration in aqueous suspensions of liposomes was determined 
indirectly, measuring the phosphate content of the sample using a modification of the Bartlett 
assay [117]. In brief, organic phospholipids of an aqueous liposome suspension (0.4 ml 
aliquot) were transformed to inorganic phosphate by adding 0.1 ml of concentrated H2SO4 to. 
The liquid was evaporated on flame leaving a film on the flask wall. The cooled film was 
dissolved in 1 ml of H2O and heated up to the boiling point for 15 min. Afterwards, an excess 
of 2.5 % (w/w) ammonium molybdate and a drop of p-nitrophenol indicator were added to 
the cooled sample to transform phosphates to phosphato-molybdenum acid. This was finally 
reduced with 1-amino-2-naphthol-4-sulfonic acid in combination with sodium sulfite and 
sodium metabisulfite to molybdenum blue [118], an unstoichiometrical mixture of 
molybdates (Mo
4+
 to Mo
6+
), to give a blue solution. From the absorbance values of this 
solution at 720 nm exactly 10 minutes after reduction to molybdenum blue, the phosphate 
concentration, and subsequently the DMPC lipid concentration, in the sample were 
calculated. Calibration curve was made with solutions of KH2PO4 at known concentration 
using the same procedure. 
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3.5.1.3. Endoperoxide Formation in Liposomes 
 
 Formulation of a naphthalene derivative and PpIX-DME embedded in liposome 
suspension was irradiated with a blue (λ = 420 ± 10 nm) high-power LED or an argon-ion 
laser (λ = 514 nm) for 30 minutes at 15 °C to from endoperoxides embedded in liposome 
suspension. In this manner prepared sample of endoperoxides embedded in liposomes (an 
aqueous suspension) was tested for endoperoxide thermolysis or kinetic chemosensitivity 
assay (see Chapter 3.6.2.) on the human breast cancer cells. Prior to the chemosensitivity 
assay the liposome aqueous suspension was diluted in McCoy’s 5A or RPMI 1640 cell 
medium containing 5% fetal calf serum (see Chapter 3.6.) For chemosensitivity assay on 
human breast cancer cells a formulation of undoped liposome suspension with the same 
extrusion method was prepared, as well.  
For the absorption and emission measurements during endoperoxide thermolysis, 
liposome suspension was dissolved in methanol prior to the measurement in order to prevent 
light scattering skewing the UV spectra of naphthalene derivatives.  
Concentration of embedded naphthalene-derivative (N1, N2, N4, N5) in aqueous 
suspension of the liposome carrier was determined spectroscopically with a standard addition 
method according to Lambert-Beer’s law. For each naphthalene-derivative (N1, N2, N4, N5) 
a set of absorbance measurements in UV region at N1, N2, N4, N5 compound’s peak 
wavelength, respectively, was done. Prior to the measurement liposomes were dissolved in 
methanol in order to prevent light scattering on liposome spheres. From each sample three 
various aliquots were diluted in methanol and measured to check the fulfilling of Lambert-
Beer’s law linear dependence of absorbance on sample concentration. A calibration curve 
was made with a standard solution of known concentration of a particular naphthalene-
derivative (N1, N2, N4, N5) in methanol. 
Materials and Methods 
48 
 
3.5.2. Polyvinyl Butyral Film, Characteristics and Preparation 
 
Polyvinyl butyral (PVB) was received as ®Mowital LP B 16H powder product from 
Kuraray Specialities Europe GmbH (Frankfurt, Germany) with an average molar weight of 
16 kDa [119]. PVB is made by acetalisation of polyvinyl alcohol (PVAl) with butyraldehyde. 
PVAl itself is produced from the precursor polyvinyl acetate (PVAc) via transesterification. 
Because of this sequential production PVB is never obtained in a pure acetal form, but rather 
a copolymer consisting of (sequences) of polyvinyl alcohol, polyvinyl acetate and polyvinyl 
butyral with up to 30 % hydroxyl and around 1 - 5 % acetyl groups present (see Fig. 3.5. 
where the indexes m, n, o, represent the weight percentage of a particular group in the PVB 
polymer product) depending on the synthetic procedure.  
 
Figure 3.5. PVB polymer structure. Indexes m, n, o, represent the w/w percentage of a particular 
group in the final PVB product. 
In Table 3.4. the weight percentages of a each group in the polyvinyl butyral ®Mowital LP B 
16H are given [120]. 
Table 3.4. Polyvinyl butyral ®Mowital LP B 16H group weight percentages. 
PVB grade m (w/w %) n (w/w %) o (w/w %) non-volatile content 
(DIN 53216) (w/w %) 
Mowital LP B 16 H 75-81 1-4 18-21 > 97.5 
 
Materials and Methods 
49 
 
3.5.2.1. PVB Film Sample Preparation 
 
PVB was dissolved (0.20 % w/w) in ethanol, spectroscopic quality, and stirred 
overnight. To the PVB solution any of the endoperoxide-forming naphthalene derivative and 
the TPFPP-Pd(II) photosensitizer were added and stirred for 2 more hours. Such a mixture 
was then left to stand until air bubbles disappeared. A drop of the solution was put on a glass 
substrate and left in ethanol atmosphere for 1-2 days in order to let the ethanol slowly 
evaporate from the sample and to form a fairly evenly spread, highly concentrated thick 
polymer film. PVB film on a glass substrate was then mounted onto a special in-house hand-
made holder and was ready for optical investigations. 
Such a PVB film sample was then irradiated with Ar+ laser light (514 nm, P = 250 
mW,  Φ = 600 mWcm
-2
) for 1 h at various temperatures to form endoperoxides embedded in 
the PVB matrix. Thereby prepared samples of endoperoxides in PVB matrix were examined 
for thermolytic decay of the endoperoxides. 
 
3.5.3. Polyvinyl Butyral Nanoparticles, Preparation and Characterization 
 
The nanoparticle synthesis devised here is a modification of previously described 
syntheses of polyacrylonitrile beads and derivatives thereof [115, 121]. It can be classified in 
the group of precipitation methods. A polymer in solution is brought to precipitation via 
addition of a non-solvent (here: double distilled H2O). Controlling the experimental 
conditions during addition of water leads to precipitation of polymer chains forming particles 
in the nanometer scale. The solvent was then fully removed via evaporation or dialysis.  
PVB nanoparticle syntheses were varied with respect to polymer concentration, 
solvent, temperature, additives, addition speed, pH and ionic composition of the non-solvent 
water. In general, PVB was taken in appropriate amounts from stock solutions of PVB in the 
respective solvent. Stock solutions were magnetically stirred for at least two days at room 
temperature prior to use to ensure complete dissolution. The polymer solution was diluted to 
a volume of 50 mL with solvent (e.g. 2-propanol), and a total of 100 mL of non-solvent was 
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added via a peristaltic pump (Watson Marlow 505 Du) through a 400 µm (diameter) syringe. 
When the synthesis was carried out at different temperatures (see later in Chapter 4.4.1), the 
suspension of PVB nanoparticles in a solvent mixture (e.g. 2-propanol/ddH2O) was allowed 
to warm or cool down to room temperature (RT), and was filtrated using cellulose filter 
paper. Finally, the suspension was dialyzed in cellulose membranes against ddH2O for two 
days and used for characterization or further steps. 
The PVB nanoparticle concentration in aqueous suspension (w/w %) was determined 
gravimetrically: by measuring the mass of the PVB aqueous suspension and the mass of the 
PVB left after careful water evaporation using a rotary evaporator at 55 °C. 
 
3.5.3.1. Doping of PVB Nanoparticles  
The preparation method of the beads was based on aggregation allowing incorporation 
of dopant molecules in comparatively high concentration (up to several percent w/w) if the 
dopant and the polymer PVB possess comparable solubilites in the solvent and the non-
solvent, respectively.  
For confocal microscopy the PVB nanoparticles were doped with N,N’-bis(2,6 -
dimethylphenyl)-perylene-3,4,9,10-tetracarboxylic diimide (PTC): PTC and PVB were 
dissolved in 20 mL 2-propanol, and 40 mL of dd H2O was added via a peristaltic pump 
(Watson Marlow 505 Du) through a 400 µm (diameter) syringe. The rest of particles 
production procedure (filtration, dialysis) was the same as described above.  
The synthetic protocol that yielded the smallest (141 nm average diameter) PTC-
doped PVB nanobeads used in confocal microscopy (see Chapter 4.4.3.) was as follows: 8.0 
mg of PVB in 2-propanol and 160 µg of PTC in 2-propanol were combined and diluted with 
2-propanol to a total volume of 20 mL. 1.0 mL of CH2Cl2 were added, and the solution was 
stirred for 1 hour at 4 °C. 40 mL dd H2O (T = 4 °C) were added at a rate of 9 mL/min at 4 °C. 
Concentration of nanospheres was performed several times successively using Amicon Ultra-
4 centrifugal filter membranes in a laboratory centrifuge at 3000 g for several minutes. 
The same preparation procedure was used to synthesize PVB nanobeads doped with 
endoperoxide-forming naphthalene derivatives. Typically, 80 µg of the respective 
naphthalene derivative were added to 8.0 mg of PVB in 2-propanol with all the other 
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preparation parameters being constant. Concentration of embedded naphthalene-derivative 
(N1, N2, N4, N5) in aqueous suspension of PVB nanoparticles was determined 
spectroscopically with a standard addition method according to Lambert-Beer’s law. For each 
naphthalene-derivative (N1, N2, N4, N5) a set of absorbance measurements in UV region at 
N1, N2, N4, N5 compound’s peak wavelength, respectively, was done. Prior to the 
measurement PVB nanoparticles were dissolved in methanol in order to prevent light 
scattering on nanoparticles. From each sample three various aliquots were diluted in 
methanol and measured to check the fulfilling of Lambert-Beer’s law linear dependence of 
absorbance on sample concentration. A calibration curve was made with a standard solution 
of known concentration of a particular naphthalene-derivative (N1, N2, N4, N5) in methanol.  
 
3.5.3.2. Endoperoxide Formation in PVB Nanoparticles 
 
Methylene blue in H2O was added to the prepared and purified (after dialysis) 
aqueous suspension of naphthalene-derivative embedded in PVB nanoparticles. Afterwards 
this suspension was irradiated with red laser light (658 nm, P = 70 mW,  Φ = 140 mWcm
-2
) 
for 1 h at 15 °C to form endoperoxides in PVB nanoparticles. In this manner prepared 
samples of endoperoxides in PVB nanoparticles (aqueous suspension) were tested for the 
endoperoxide thermolysis and 
1
O2-release or kinetic chemosensitivity assay (see Chapter 
3.6.2.) on the human breast cancer cells. Prior to the chemosensitivity assay the samples were 
diluted in McCoy’s 5A or RPMI 1640 cell medium containing 5% fetal calf serum (see 
Chapter 3.6.) 
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3.5.4. Ethylcellulose Nanoparticles, Preparation and Characterization 
 
Ethylcellulose (EC) was commercially available from Sigma-Aldrich, (Munich, 
Germany). EC nanoparticles were also prepared via a precipitation procedure from a mixture 
of solvents. The ethylcellulose nanoparticles preparation procedure was described elsewhere 
[122]. In short, to 20 mL of 0.2 % (w/w) of ethylcellulose in acetone/tetrahydrofuran = 1/1, 
40 mL of ddH2O (non-solvent) were poured fast to form ethylcellulose nanoparticles. 
Acetone and THF were subsequently evaporated from such a suspension of ethylcellulose 
particles in ddH2O /acetone/THF on a rotary evaporator, resulting in EC nanoparticles 
suspended in ddH2O (cca. 0.1 % w/w) with a diameter of 62 ± 18 nm (measured with DLS).  
The EC nanoparticle concentration in aqueous suspension (w/w) was determined 
gravimetrically: by measuring the mass of the EC aqueous suspension and the mass of the EC 
left after careful water evaporation using a rotary evaporator at 55 °C.  
 
3.5.4.1. Doping of EC Nanoparticles 
 
In order to load EC particles with N4 derivative, 10.0 mg of N4 in acetone were added 
to 20 mL of 0.2 % (w/w) solution of EC in acetone/tetrahydrofuran = 1/1 and stirred for 10 
minutes at room temperature. Then 40 mL of dd H2O were poured fast into this „cocktail“ to 
get ethylcellulose nanoparticles. Acetone and THF were subsequently evaporated with a 
rotary evaporator, resulting in EC nanoparticles doped with N4 (diameter of 98 ± 25 nm, 
measured with DLS) and N4 concentration of 8.2·•10-4 M in aqueous suspension of EC 
nanoparticle carrier. A very similar procedure was done to prepare an aqueous suspension of 
N5 embedded in EC nanoparticles. A slightly different outcome was in the average diameter 
of the particles (136 ± 38 nm) and in the end concentration of N5 in dd H2O suspension 
(4.2•10
-4
 M).  
The concentration of doped naphthalene derivatives (N4, N5) aqueous suspension of 
EC nanoparticles was determined spectroscopically with a standard addition method 
according to Lambert-Beer’s law. For each naphthalene-derivative (N4, N5) a set of 
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absorbance measurements in UV region at N4, N5 compound’s peak wavelength, 
respectively, was done. Prior to the measurement EC nanoparticles were dissolved in 
methanol in order to prevent light scattering on nanoparticles. From each sample three 
various aliquots were diluted in methanol and measured to check the fulfilling of Lambert-
Beer’s law linear dependence of absorbance on sample concentration. A calibration curve 
was made with a standard solution of known concentration of a particular naphthalene-
derivative (N4, N5) in methanol. 
For confocal laser microscopy experiments (see Chapter 3.6.1.) EC nanoparticles 
were doped with PTC: EC and PTC (1% w/w to EC weight) were dissolved in 20 mL 
acetone/THF=1/1 and 40 mL of dd H2O were poured fast into this „cocktail“ to get EC 
nanoparticles. Acetone and THF were subsequently evaporated with a rotary evaporator, 
resulting in EC nanoparticles doped with PTC. 
 
3.5.4.2. Endoperoxide Formation in EC Nanoparticles 
 
Methylene blue photosensitizer dissolved in H2O was added to the prepared aqueous 
suspension of naphthalene-derivative embedded in EC nanoparticles, to make the end 
concentration 1.0•10
-5
 M of MB in dd H2O. Afterwards this suspension was irradiated with a 
red laser light (658 nm, P = 70 mW,  Φ = 140 mWcm
-2
) for various periods of time at 
different temperatures (e.g. 15 h at 4 °C) to form N4E and N5E in EC nanoparticles.  
In this manner prepared sample of endoperoxides embedded in EC nanoparticles 
(aqueous suspension) was tested for endoperoxide thermolysis and 
1
O2-release or kinetic 
chemosensitivity assay (see Chapter 3.6.2.) on the human breast cancer cells. Furthermore, 
after the irradiation and just prior to the chemosensitivity assay, polysorbate 80™ surfactant 
(by Sigma-Aldrich, Munich, Germany) was added to the EC nanoparticles suspension (1% 
w/w end concentration of polysorbate 80™ in dd H2O) in order to enable faster uptake of the 
EC nanoparticles by the breast cancer cells. The samples were left for 5 minutes in an 
ultrasonic bath to promote the adsorption of polysorbate 80™ on the EC nanoparticle surface.  
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3.6. CELL LINE AND CULTURE CONDITIONS 
 
The human estrogen receptor negative MDA-MB-231 (HTB 26) breast cancer cells 
were obtained from the American Type Culture Collection (ATCC), Rockville, USA. Cell 
banking and quality control were performed according to the "seed stock concept”. Cells 
were cultured in RPMI 1640 or McCoy´s 5A medium (Sigma Aldrich, Munich, Germany) 
containing L-glutamine, 2.2 g/l NaHCO3 and 5 % fetal calf serum, FCS (Biochrom, Berlin, 
Germany). Cells were maintained in a water saturated atmosphere (95 % air / 5 % carbon 
dioxide) at 37°C in 75-cm² culture flasks (Greiner, Frickenhausen, Germany), and were 
serially passaged following trypsinization using 0.05% trypsin/0.02% EDTA (Roche 
Diagnostics, Mannheim, Germany). Mycoplasma contamination was routinely monitored, 
and only Mycoplasma free cultures were used. 
 
3.6.1. Confocal Laser Scanning Microscopy Procedure  
 
Two days prior to the experiment the MDA-MB-231 cells (100 % confluency) were 
trypsinized and seeded in Nunc LabTek
TM
 II chambered cover glasses with 8 chambers in 
RPMI 1640 or McCoy´s 5A medium (250 µl) that contained 5 % FCS. On the day of the 
experiment the confluency of the cells was 40-50 %. After the culture medium was removed, 
the cells were washed once with Leibowitz’s L-15 culture medium (Invitrogen GmbH, 
Darmstadt, Germany). Subsequently, the cells were stained in L-15 medium containing 2.5 
µg/ml CellMask
TM
 Deep Red plasma membrane stain for 5 minutes at 37 °C. This staining 
solution was removed and the cells were washed 3 times with L-15 medium. Finally, the cells 
were covered with 250 µl of L-15 medium containing a 5 µM DRAQ5
TM
 nuclear stain and 
suspension of polymer (PVB or EC) nanoparticles doped with N,N’-bis(2,6 -dimethylphenyl)- 
perylene-3,4,9,10- tetracarboxylic diimide (PTC, see Figure 3.6.) The polymer nanoparticle 
suspension was diluted 1:50 with L-15 medium. 
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Figure 3.6. Structure and absorption spectrum of PTC. 
This photosensitizer was chosen to label the polymer nanoparticles because of a high 
molar absorption coefficient at available CLSM Ar+-laser wavelengths (488 nm, 514 nm): 
ε(488 nm) = 4.55 •104 cm-1M-1, ε(514 nm) = 3.05 •104 cm-1M-1 [123], which is critical for 
fluorescence microscopy recording of small polymer nanoparticles (diameter < 200nm).  
Confocal laser scanning microscopy experiments were performed with a Carl Zeiss 
Axiovert 200M microscope (Carl Zeiss AG, Oberkochen, Germany), equipped with a LSM 
510 laser scanner. PVB and EC nanoparticles (stained with PTC) were detected through the 
530-600 nm band-pass filter, after excitation with the 488 nm laser (4.8 % laser 
transmission). The nuclei stained with DRAQ5
TM 
and the plasma membranes stained with 
CellMask
TM
 Deep Red were detected with the 650 nm long-pass filter after excitation with 
the 633 nm laser (3.1 % laser transmission), as schematically depicted on Figure 3.7. 
Therefore, PTC fluorescence in particles was separated from the membrane stain 
fluorescence by both the excitation wavelength and emission filters and separated from the 
nuclear fluorescence (DRAQ5
TM
) with emission filters. The objective used was a Plan-
Apochromat 63R/1.4 with Immersol™ 518 F immersion oil for fluorescence microscopy 
(Carl Zeiss AG, Oberkochen, Germany). 
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Figure 3.7. Normalized fluorescence excitation and emission spectra of PTC and CellMaskTM Deep 
Red [124] dyes used in CLSM experiments. Solid lines are excitation spectra (blue: PTC, orange: 
CellMaskTM Deep Red) and dotted lines emission spectra (green: PTC, red: CellMaskTM Deep Red). 
Vertical lines are 488 nm and 633 nm laser excitation wavelengths, respectively. 
 
3.6.2. Chemosensitivity Assay 
 
The crystal violet chemosensitivity assays were performed with MDA-MB-231 
human breast cancer cells [110] according to the procedure by Bernhardt et al. [111] In brief: 
tumor cell suspensions (100 µl/well) were seeded into 96-well flat bottomed microtitration 
plates (Greiner, Frickenhausen, Germany) at a density of 10-15 cells/microscopic field 
(magnification 32x). After 1-2 days the McCoy´s 5A or RPMI 1640 culture medium 
(containing 5 % FCS) was removed by suction and replaced with fresh medium (200 µl/well) 
containing varying drug concentrations or different carrier (liposomes or polymer, EC or 
PVB nanoparticles) formulations, respectively.  
On every plate 16 wells served as controls and 16 wells were used per drug 
concentration. After various times of incubation the cells were fixed with glutardialdehyde 
and stored in a refrigerator. At the end of the experiment all plates were stained with crystal 
violet simultaneously. Absorbance, which corresponds to the living cells mass at each time-
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point, was measured at 578 nm using a Biotek 309 Autoreader (Tecnomara, Fernwald, 
Germany). The absorbance values were transformed into corrected T/C values, expressing the 
net growth of the treated cells, relative to the growth of the untreated control cells [111]. 
Corrected T/C values were calculated according to equation 
 
( ) 100[%]/
0,
0,
⋅
−
−
=
cc
cT
corr
AA
AA
CT    (11) 
where AT is the mean absorbance of the treated cells, AC the mean absorbance of the controls 
and Ac,o the mean absorbance at the time (t = 0) when drug was added [111].  
In this context drug fomulations used were endoperoxides of various naphthalene 
derivatives (N1, N2, N4, N5, N7) embedded in various carrier materials (coated with 
Polysorbate-80™ or non-coated), which were suspended in double distilled water. In order to 
differentiate the effect of endoperoxides from the possible effect of their “parent molecules” 
(naphthalene derivatives) and/or carrier materials on the proliferation of MDA-MB-231 cells, 
for each aromatic endoperoxides drug formulation, two sets of control formulations were 
used:  
1. non-irradiated undoped carrier material suspension of the same concentration (in ddH2O) 
as in the drug formulation to determine the carrier effect on the cell proliferation and  
2. non-irradiated naphthalene “parent molecule” of the same concentration as the 
endoperoxide and the same photosensitizer concentration (as in the drug formulation) 
embedded in the same carrier material suspension, also of the same concentration as in the 
drug formulation to determine the photosensitizer and “parent molecule” effect on the cell 
proliferation. 
Prior to the cell incubation, each of these formulations was sterilised for 15 min by irradiation 
with a UV-A lamp. 
As a positive control of the proliferation drug effect on the MDA-MB-231 cells, the 
clinically established cytostatics cisplatin (Sigma-Aldrich, Deisenhofen, Germany) or 
vinblastine (Sigma-Aldrich, Deisenhofen, Germany) were used. 
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4. RESULTS 
4.1. NAPHTHALENE DERIVATIVES AS ENDOPEROXIDE 
PRECURSORS 
 
As already stated in Chapter 1.2, naphthalene derivatives are adequate to 
intramolecularly “store” 
1
O2 in form of endoperoxides. 1,4-dimethylnaphthalene (N1) and 
1,4,5-trimethylnaphthalene (N2) were chosen, because they are both commercially available 
and because decay times of their endoperoxides were already experimentally measured in 
different solvents [22, 31] and found to be in range suitable for our purposes: in 1,4-dioxane 
at body temperature (37 ºC) calculated decay times of 1,4-dimethylnaphthalene-1,4-
endoperoxide (N1E) amount to 1.5 h and of 1,4,5-trimethylnaphthalene-1,4-endoperoxide 
(N2E) 16.1 h, respectively. Moreover, energy changes for decay process of N1E and N2E 
were also calculated [31]. 
Also, it can be presumed that both N1 and N2 are non-toxic, according to MSDS data 
by Sigma-Aldrich N1 “present at levels greater than or equal to 0.1 % N1 is not identified as 
probable, possible or confirmed human carcinogen by IARC [125]. Moreover, For N2 there is 
unfortunately no toxicological information available.  
 
4.1.1. Synthesis of Novel Naphthalene Derivatives 
 
In order to extend the range of decay-time (and thus 
1
O2  release-time) and also to 
adjust the solubility of the endoperoxide in media of different polarity, to enable 
incorporation into various biocompatible carrier materials such as liposomes or nanoparticles, 
and to introduce the possibility of synergistic interactions between multiple dioxygen 
activation sites in one molecule, a synthesis of several novel naphthalene derivatives was 
performed (see Scheme 1). 
Results 
59 
 
O
LiAlH4
OH
CH3COCl, AlCl3
in situ
N3
O
N5
-H2O
N4
N1
 
Scheme 1. Synthesis of various endoperoxide-forming naphthalene derivatives from starting N1 derivative. 
 
Figure 4.1 shows the structure of the 1-(1,4-Dimethyl-naphthalen-2-yl)-ethanol (N4) 
derivative, with selected bond distances and angles given in the Table 4.1. Compound N4 
crystallizes in the monoclinic space group P21/n, with four molecules present in the 
asymmetric unit. Each N4 molecule forms H-bonds over O(1)-H(1o) side-group with 2 other 
neighbouring N4 molecules, which is important for the discussion of 1-(1,4-dimethyl-
naphthalen-2-yl)-ethanol-1,4-endoperoxide (N4E) decay-times in different matrices (see 
Chapter 6.1.) 
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Figure 4.1. ORTEP diagram of N4 X-ray crystal structure with an arbitrary atom numbering scheme. 
Displacement ellipsoids are at the 50 % probability level.  
 
Table 4.1. Selected bond lengths (Ǻ) and angles (deg) and torsion angles (deg) of N4. 
Bond length (Ǻ)  
C1-O1 1.4330(16) 
O1-H1o 0.89(2) 
C1-C3 1.5247(18) 
C1-C2 1.5180(19) 
Binding angles (deg)  
C1-O1-H1o 109.2(13) 
O1-C1-C2 110.60(11) 
O1-C1-C3 112.18(10) 
C2-C1-C3 111.11(11) 
Torsion angles (deg)  
O1-C1-C3-C4 -28.09(15) 
O1-C1-C3-C12 154.20(11) 
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Figure 4.2. shows the structure of the di-1-(1,4-dimethylnaphthene-2-yl)-ethylether (N5) 
derivative, with selected bond distances and angles given in the Table 4.2. Compound N5 
crystallizes in the monoclinic space group P b c n, with four molecules present in the 
asymmetric unit.  
 
Figure 4.2. ORTEP diagram of N5 X-ray crystal structure with an arbitrary atom numbering scheme. 
Hydrogen atoms are left out for a better overview. Displacement ellipsoids are at the 50 % probability 
level. 
Table 4.2. Selected bond lengths (Ǻ) and angles (deg) and torsion angles (deg) of N5. 
Bond length (Ǻ)  
C11-O1/C11
i
-O1 1.4416(18) 
C1-C11/C1
i
-C11
i
 1.523(2) 
C11-C12/ C11
i
-C12
i
 1.518(2) 
Binding angles (deg)  
C11-O1-C11
i
 114.02(14) 
O1-C11-C1/ O1- C11
i
 - C1
i
 111.12(12) 
O1-C11-C12/ O1- C11
i
 - C12
i
 106.22(13) 
C1-C11-C12/ C1
i
 - C11
i
 - C12
i
 112.07(13) 
Torsion angles (deg)  
C11
i
-O1-C11-C1  61.47(14) 
C11
i
-O1-C11-C12 -176.39(11) 
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Scheme 2. Synthesis of poly(1,4-dimethyl-2-vinylnaphthalene), N7, from N4 derivative. 
 
4.1.2. Size Variation of N7 Polymer Nanoparticles 
Polymer poly(1,4-dimethyl-2-vinylnaphthalene), N7, in which each side group is an 
endoperoxide forming group, was synthesized in form of nanoparticles from N4 derivative as 
shown in Scheme 2. 
 
Figure 4.3. TEM image of smaller poly(1,4-dimethyl-2-vinylnaphthalene) nanoparticles (average diameter: 12 ± 
3 nm). 
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Using DLS and TEM techniques, the N7 nanoparticles average diameter was 
determined: 12 ± 3 nm, with the latter parameter being standard deviation (see Figure 4.3 
when synthesized according to the procedure described in Chapter 3.3.5. For CLSM and 
chemosensitivity assay purposes (see Chapters 3.6.1. and 3.6.2. respectively) the N7 
synthesis procedure was varied in order to get nanoparticles of different average diameters. 
The most significant procedure parameters were the polymerization time and the relative 
amount of (NH4)2S2O8 added, compared to the amount of N6 monomer in the reaction 
mixture. The average particles diameter increased with longer polymerization time and larger 
amounts of (NH4)2S2O8, whereas amount of SDS didn’t have such a significant influence on 
the N7 nanoparticles size.  For example on a smaller scale, a mixture of 8 mg N6, 23 mg 
SDS, 6 mg (NH4)2S2O8 in 10 ml dd H2O after 5h of polymerization produced N7 
nanoparticles of 95 ±24 nm, as measured with dynamic light scattering technique (see Figure 
4.4.) whereas a mixture of 13 mg N6, 56 mg SDS, 16 mg (NH4)2S2O8 in 10 ml dd H2O after 
3h of polymerization produced N7 nanoparticles of 58 ± 9 nm. 
 
Figure 4.4. Size distribution of larger (average diameter: 95 ±24 nm) poly(1,4-dimethyl-2-
vinylnaphthalene) particles measured with DLS method. 
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Note: It was not possible to freeze-dry the nanoparticles: the freeze-drying procedure 
caused particles aggregation. N7 nanoparticles tend to slowly aggregate in H2O suspension as 
well: the average diameter increases approximately 2-3 times after 1-2 months. 
 
4.1.3. Optical Properties of Endoperoxide-Forming Naphthalene Derivatives 
 
The electronic spectra of the endoperoxide-forming naphthalene derivatives were 
recorded in ethanol or chloroform solution. On Figure 4.5. the normalized absorption and 
emission spectra of N5 in CHCl3 are given as a typical example. The UV-spectra of other 
endoperoxide-forming naphthalene derivatives (N1-N6) are all very similar with strong 
absorption bands around 230 nm and weaker bands around 290 nm. This indicates that only a 
negligible perturbation of the electronic properties of the individual naphthalene 
chromophores occurs in the novel ether-bridged system (N5). Band maxima and calculated 
molar absorption coefficients for the naphthalene derivatives in methanol are given in Table 
4.3. 
Table 4.3 Band maxima of the electronic spectra of various endoperoxide forming 
naphthalene derivatives at room temperature in methanol solution.  
compound λmax/ nm ε / M
-1
cm
-1
) λem  / nm 
N1 287 (7 700) 329, 339, 355 
N2 293 (10 100) 332, 343, 355 
N4 289 (17 200) 332, 342, 355 
N5 287 (14 600) 331, 341, 355 
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 Figure 4.5. Absorption and emission spectra of N5 derivative in CHCl3. 
The emission spectra of the compounds investigated in this study display a main peak 
at around 340 nm and two shoulders at about 330 nm and 355 nm, respectively (Figure 4.5.) 
These data are in agreement with the well-known features of regular fluorescence spectra of 
condensed aromatic hydrocarbons, which in the case of naphthalene derivatives usually 
consist of a principal series of three to four vibronic bands equally spaced at approximately 
1000 cm-1 intervals [126]. In the concentration range applied for the present study, no 
conspicuous band splittings or other excited state interactions of the two equivalent 
fluorophore entities was detected in the bifunctional compound N5. 
O
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4.1.4.  Endoperoxide Formation and Decay Kinetics in Solvents 
 
N1E and N2E formation and decay, usually at 25 °C, in various solvents is described 
in the literature [22, 31, 12]. Average endoperoxide decay-times, t1/2, of these two derivatives 
in various solvents at human body temperature of 37 °C, were calculated from the literature 
t1/2 values at other temperatures and activation energy, Ea, values [22, 31] and are given in 
Table 4.4.  
R1 hν, O2
   ∆T
R1
O
O
 N, 
 fluorescent
NE, 
non luminescent
R2 R2
 
N1:  R1 = R2 = H 
N2:  R1 = H, R2 = CH3 
N3:  R1 = COCH3, R2 = H 
N4:  R1 = CHOHCH3, R2 = H 
N6:  R1 = CH=CH2, R2 = H 
N7 = poly (N6) 
Scheme 3. Endoperoxide formation and thermally induced decay on various naphthalene derivatives 
used in this work. 
 
Scheme 4. Endoperoxide formation on the N5 derivative, witch possesses double endoperoxide-
forming (and 1O2-releasing) function in comparison to derivatives in Scheme 3. 
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Endoperoxide formation and decay of novel naphthalene derivatives, N4 and N5 (see 
Schemes 3. and 4. respectively) were measured at 37 °C in ethanol with time-dependent 
fluorescence typical for each particular derivative. Fluorescence spectrum of 5 µM 
naphthalene derivative in ethanol was recorded prior to the light irradiation and photoreaction 
of endoperoxide formation. After the high power LED light irradiation (P = 120 mW/cm
2
) of 
sensitizer (1 µM MB) for 2-3 hours at 20 °C, formed 
1
O2 reacted with N5 or N4 to form 
endoperoxides causing the reduction of particular naphthalene derivative fluorescence 
intensity, from which the yield of this photoreaction was calculated. Such a simple 
endoperoxide formation procedure with a commercial light source at room temperature in an 
air atmosphere without O2 saturation is unprecedented and enables endoperoxide formation in 
a relatively high yield (about 50 % after 2 h irradiation) without any high-tech equipment. 
Afterwards, the endoperoxide solution in ethanol was kept at a constant temperature (37 °C) 
causing a thermal decay of endoperoxides to form the “parent molecule” and therefore, the 
reappearance of its fluorescence signal. This process and the time-dependency of the 
fluorescence values of a particular naphthalene derivative (N1, N2, N4, N5) were used to 
calculate the relative quantity of endoperoxide molecules at each time-point in order to 
determine endoperoxide decay and 
1
O2-release kinetics in ethanol.  
Table 4.4. Endoperoxide-decay kinetic constants, k, and decay-times, t1/2, of different 
endoperoxide-forming naphthalene derivatives in various organic solvents at 37 °C. 
 N1
a
 N2
a
 N4
b
 N5
b
 
k / s
-1
  1.618 •10
-4
 1.19•10
-5
 (4.408±0.014) • 10
-5
 (8.532±0.031) • 10
-5
 
t1/2 / h 1.19 16.2 4.37 2.26 
a
 average value in 1,4-dioxane, dichloromethane 
b
 in ethanol 
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4.2. ENDOPEROXIDE DECAY AND CYTOTOXICITY IN LIPOSOME 
CARRIER 
 
First carrier choice was liposomes, as a widely-used, biocompatible material [127, 128 
, 129, 130, 131]. Liposomes are often used as a drug-delivery system [132, 133]. Liposomes 
are artificially prepared vesicles made of lipid bilayer, which are stable in an aqueous 
environment. A liposome encapsulates a region of aqueous solution inside the liposome 
hydrophobic membrane where the dissolved hydrophilic solutes cannot pass through the lipid 
bilayer. Hydrophobic solutes can be dissolved into the membrane, and in this way liposome 
can carry both hydrophilic and hydrophobic substances, such as porphyrin-derived 
photosensitizers [46]. In several reports [134, 135] regarding classical photodynamic therapy, 
photosensitizers embedded in dimiristoyl-phosphatidylcholine vesicles exhibited greater 
efficiency of targeting cancer, compared with the same photosensitizers administered in a 
homogeneous aqueous solution. Namely, liposomes are long-circulating carriers in the blood 
stream and can rapidly enter tumour vessels (which lack the endothelial wall) from the blood, 
but are kept in the bloodstream by the endothelial wall in healthy tissue vasculature. This is 
known as the “enhanced permeability and retention (EPR)” effect [136]. Thus liposomes 
smaller than 400 nm typically accumulate much more in tumor tissue than in normal 
(healthy) tissues [133].  
 
4.2.1. Liposomes Size and Loading Efficiency 
 
On Figure 4.6. the size distribution of liposomes formed by extrusion, as described in 
Chapter 3.5.1.1., is shown. 
Loading of endoperoxide-forming naphthalene derivatives in liposomes during 
liposome preparation was possible with various efficiencies. As the determination of 
naphthalene derivatives concentration in prepared liposome carrier (see Chapter 3.5.1.3.) 
showed, 60 - 90 % of N1, N2 or N4 molecules present in the solution in CHCl3 with 1,2-
dimyristoyl-L-α-phosphatidylcholine (DMPC) lipid were successfully embedded in 
liposomes. Hence, the dopant losses during the liposome preparation by extrusion were  
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10-40 %. The percentage of embedded molecules severely dropped in case of the N5 
derivative: only 10 - 20 % of N5 molecules were embedded in prepared liposomes.  
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Figure 4.6. Size distribution of DMPC liposomes made with extrusion method, as measured with DLS. 
Average hydrodynamic diameter was 116 ± 32 nm. 
 
4.2.2. Endoperoxide Formation and Decay Kinetics in Liposome Carrier 
 
Formation of naphthalene-endoperoxides, NE (see Schemes 3. and 4.) in liposomes 
was very efficient: in general, after 15 min of light irradiation of the PS present in liposome 
matrix at 15 °C, about 90 % of a particular naphthalene derivative, N, reacted with 
1
O2 to 
form endoperoxides, NE. All of the naphthalene endoperoxides studied here share the 
property of thermal instability regenerating singlet oxygen and the parent naphthalene 
molecule. Since the reversible formation of naphthalene-derived endoperoxides, their meta-
stability and thermal singlet oxygen release is a known phenomenon with extensive literature 
[12, 13, 16, 22, 31, 137], formed endoperoxides of hereby examined naphthalene-derivatives 
Results 
70 
 
and subsequently released singlet oxygen were not detected, but rather taken as a given 
phenomena. Thus, the endoperoxide formation and thermal decay kinetics were verified only 
indirectly via the reversible changes of absorption/fluorescence intensity of the each 
naphthalene-derivative „parent molecule“ electronic spectra. Fluorescence intensity 
measurements data are shown in further text because of their better reproducibility and lower 
measurement error than of the absorbance measurements data of the same samples. 
Endoperoxide formation and decay were recorded at different temperatures, mainly at 
the human body temperature of 37 °C, which is most important for possible medical 
applications, with time-dependence of fluorescence typical for the particular naphthalene 
derivative, as shown in Figure 4.7. on the example of N1. Fluorescence spectrum of N1 
embedded in liposomes was recorded prior to the light irradiation and photoreaction of N1E 
formation (pink curve on Figure 4.7.) After the light irradiation (LED, λ = 420nm, P = 35 
mW, Φ = 140 mW/cm
2
, T = 14 °C, for t = 0.5h) of embedded sensitizer (PPIX-DME, c= 
2•10
-7
M), generated 
1
O2 reacted with N1 in liposomes to form N1E causing the reduction of 
N1 fluorescence intensity, from which the yield (87 %) of this photoreaction was calculated. 
Afterwards the liposome suspension with embedded endoperoxides was kept at a constant 
temperature (e. g. 37 °C) causing a thermal decay of N1E to form N1 “parent molecule” and 
therefore the reappearance of N1 fluorescence signal. This process and time-dependence of 
N1 fluorescence values were used to calculate the relative quantity of N1E molecules at each 
time-point in a particular carrier in order to determine endoperoxide decay and 
1
O2-release 
kinetics. 
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Figure 4.7. Recovery of N1 fluorescence due to the decay of N1E with time. ∆F value and its time 
dependence is being calculated from the fluorenscence maxima, as demonstrated here on the 
example of N1 embedded in liposomes.  
The difference in fluorescence peak intensity measured before N1E formation, F, (pink curve 
in Figure 4.7.) and immediately after endoperoxide formation (black curve in Figure 4.7.) 
corresponds to the number of formed endoperoxide molecules in total, F0. The other curves 
(with the reappearance of N1 molecules) show the course of thermal N1E decay with time 
and hence provide information about the quantity of remaining endoperoxide molecules at 
each time-point, ∆F(t), which corresponds to the difference in peak intensity measured before 
endoperoxide formation and particular curve for a decay time-point.  
Described experiments and ∆F(t) calculations were done for other (N5, N4, N1, N2) 
endoperoxide-forming naphthalene derivatives in liposome carrier material, as well as in 
other carriers (see later), at different thermolysis temperatures with emphasis on the human 
body temperature of 37 °C. 
The calculated time-dependence of endoperoxide quantity in liposomes is exemplarily 
shown in Figure 4.8. for N4E at 37 °C. In this particular experiment PPIX-DME sensitizer,  
c = 0.9 µM, was irradiated with LED (λ = 420 nm, P = 35 mW, Φ = 140 mW/cm
2
, T = 14 °C, 
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OH
for t = 1.25 h) to generate 
1
O2 which reacted with N4 (c = 8 0 µM in suspension) to form 
N4E (yield 96 %). The slope on such a semi-logarithmic plot corresponds to the 
endoperoxide decay rate constant, k. The endoperoxide decay times, t1/2, are then easily 
calculated [3, 12]:  
t1/2 = log 2/ k   (12) 
0 2 4 6 8 10 12 14
3
4
5
6
t1/2 = 11.5 h∆∆ ∆∆
F
 [
a
.u
.]
t [h]
T = 37 °C
  
Figure 4.8. Semi-logarithmic plot showing the decay of N4E in liposome aqueous suspension  
(c = 0.9 mM, liposomes diameter 109 ± 12 nm) at 37 °C measured with N4 fluorescence time-trace. 
On y-axis is the relative ∆F value, representing N4 molecules which are in endoperoxide form. 
 In Table 4.5. endoperoxide decay times, t1/2, of all naphthalene derivatives embedded 
in liposomes (average diameter 110 nm) at 37 °C are given. The sensitizer used was PPIX-
DME in all cases, c = 0.9
 
M. Irradiation was done with LED (λ = 420nm, P = 35 mW, Φ = 
140 mW/cm
2
, at T =1 4 °C). In all cases monoexponential endoperoxide decay in liposomes 
was observed. 
The stability factor, SF, which shows the increase of endoperoxide t1/2 in liposome 
matrix (or other matrices, see later) in comparison to the average t1/2 in various organic 
solvents (see values in Table 4.4.), was calculated according to the equation 13 and is also 
given in Table 4.5. 
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SF = t1/2 (liposomes) / t1/2 (solvent)  (13) 
 
Table 4.5. Monoexponential decay times of endoperoxides of different naphthalene 
derivatives embedded in liposomes (average diameter 110 nm) at 37 °C and calculated 
endoperoxide stability factors, SF, in comparison to the decay in organic solvents.  
Molecule in liposomes t1/2 /h SF 
                    N1 
 
1.1 
 
0.95 
O
    N5 
 
1.5 
 
0.66 
        N4 
 
11.5 
 
2.63 
                    N2 
 
17.1 
 
1.06 
 
 Endoperoxide decay was also observed at 46 °C, the temperature used to model 
extreme hyperthermia in cancer treatment [138, 139]. On Figure 4.9. decay time of N2E in 
liposomes at 46 °C is given. PPIX-DME sensitizer, c = 0.18
 
µM, was irradiated with LED 
(λ = 420 nm, P = 35 mW, Φ = 140 mW/cm
2
, T = 14 °C, for t = 0.4 h) to form 
1
O2 which 
reacted with N2 (c = 16 µM in aqueous liposome suspension) to form N2E (yield 94 %). On 
y-axis is the calculated percentage value of all N2 molecules which are in endoperoxide form 
at each particular time-point. This endoperoxide % value was calculated by dividing the 
quantity of remaining endoperoxide molecules at each time-point, ∆F(t), with the quantity of 
total N2 molecules before endoperoxide formation, F, (fluorescence peak intensity measured 
before N2E formation):  
% endoperoxides = ∆F(t) / F • 100   (14) 
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Figure 4.9. Semi-logarithmic plot showing decay of N2E in liposomes, c(lipid) = 0.9 mM, diameter 
109±12nm, at 46°C measured with N2 fluorescence time-trace. On y-axis is the percentage of all N2 
molecules which are in endoperoxide form at each particular time-point. 
 
4.2.3. In Vitro Cytotoxicity of 1O2-Releasing Endoperoxides in Liposome Carrier: 
Kinetic Chemosensitivity Assay Results 
 
Based on the endoperoxide decay time and corresponding 
1
O2-release time, N2E and 
N4E embedded in liposomes were most suitable for chemosensitivity assay on cancer cells 
[111]. As a positive control during the chemosensitivity assay, cisplatin, a standard cytostatic 
drug, was used. Thus, it was possible to compare the cancer cells chemosensitivity to 
endoperoxides and to such a standard drug. The chemosensitivity of MDA-MB-231 cells to 
cisplatin was determined at concentrations ranging from 300 nM to 10 µM cisplatin dissolved 
in DMF (see Figure 4.10.) The lowest cisplatin concentration (0.3 µM) yielded a very weak 
cytotoxic effect from which the cells recovered completely. 1.0 µM concentration had a 
strong cytotoxic effect with a slow cell population recovery after 125 h. 3.0 µM cisplatin had 
a cytostatic effect on MDA-MB-231 human breast cancer cells proliferation, whereas 10 µM 
cisplatin showed a cytocidal effect (see Figure 4.10.) The solvent DMF had no effect on the 
cell proliferation and was used as a negative growth control (). 
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Figure 4.10. Chemosensitivity of MDA-MB-231 cells (182nd passage) against cisplatin, up to a 10 µM 
concentration in DMF solvent. DMF was used as a negative growth control (). 
  
According to the procedure described in Chapter 3.5.1.1., the feed aqueous liposome 
suspensions for the chemosensitivity assays were prepared. The concentration of N2 or N4 in 
liposome stock suspension was determined photometrically according to Lambert-Beer’s law 
as described in Chapter 3.5.1.3. To distinguish the effect of 
1
O2-release from endoperoxides 
from the effect of N2 (or N4) and from the effect of liposomes on the cell proliferation, 3 
types of suspension were prepared: 
1. Light-irradiated N2 embedded in liposomes forming 1O2-releasing N2E embedded in 
liposomes 
2. Non-irradiated N2 of the same N2 concentration as in suspension 1 
3. Non-irradiated liposome suspension of the same lipid concentration as in suspension 1 
and 2. 
The same 3 types of suspensions were prepared with N4 embedded in liposomes.  
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4.2.3.1. Cytotoxicity of N2E Embedded in Liposomes 
 
The chemosensitivity of MDA-MB-231 human breast cancer cells to 
1
O2-releasing 
N2E was determined at a highest achieved N2 concentration in the liposome suspension, 
which after dilution in the RPMI cell medium was 6.5 µM (Figure 4.11.) Photosensitizer 
concentration was c (PPIX-DME in cell medium) = 0.09 µM. PPIX-DME sensitizer was 
irradiated with LED (λ =4 20 nm, P = 35 mW, Φ = 140 mW/cm2, T = 14°C, for t = 0.5 h) 
to form 
1
O2 which reacted with N2 to form N2E (yield 97 %). The cell incubation with a 
mixture of 6.3 µM 
1
O2-releasing N2E and 0.2 µM N2 embedded in liposomes yielded a 
cytotoxic effect of about 30 % ( on Figure 4.11.) compared to the growth of untreated cells. 
But the cells recovered until the end of the incubation period (ca. 200 hours). Non-irradiated 
6.5 µM N2 embedded in the same liposome suspension ( on Figure 4.11.) produced 
approximately only 10 % inhibition of cell growth with a full cell recovery after ca. 150 
hours. The proliferation of MDA-MB-231 cells was not inhibited by non-irradiated liposomes 
not carrying N2 ( on Figure 4.11.) As a comparison a cytostatic effect of cisplatin, is 
visible on Figure 4.11. ( symbols): growth of cells is about 70 % inhibited and cell 
population doesn’t recover after treatment with 10 µM Cisplatin. This particular stock 
solution of cisplatin was prepared in DMSO and a slow exchange of ammine groups of 
cisplatin with sulphoxide groups of solvent occurred, which resulted in partial inactivation of 
the drug. Hence, a cytostatic, insead of a cytocidal effect of 10 µM cisplatin is visible on 
Figure 4.11. This phenomenon also appeared in other chemosensitivity assay experiments 
when cisplatin was dissolved in DMSO, see later Figs.  
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Figure 4.11. Demonstration of a cytotoxic drug effect of N2E embedded in liposomes (diameter 109 ± 
12 nm) on human MDA-MB-231 breast cancer cells, passage 64, as a function of incubation time 
determined by the crystal violet assay.  N2, 6.5 µM, in liposomes, c(lipid)= 24 µM,  N2E, 6.3 µM + 
N2, 0.2 µM in liposomes, c(lipid)= 24 µM,  liposomes, c(lipid)= 24 µM,  positive control: Cisplatin, 
10 µM,  negative control: H2O. 
  
Probably with a higher concentration of N2E in the liposome suspension, a stronger 
cytotoxic or a cytostatic effect on the proliferation of MDA-MB-231 cells would have been 
achieved. But, it was not possible to produce a liposome suspension with a higher ratio of 
embedded N2 molecules to DMPC lipid molecules forming liposome membrane than the 
suspension used in Figure 4.11. in which this ratio was N2 / DMPC = 1 : 5 in CHCl3 prior to 
preparation of liposome suspensions (described in Chapter 3.5.1.)  
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Figure 4.12. Cytocidal drug effect of N2E when embedded in a higher, cytotoxic liposomes 
concentration (c(lipid) = 4•10-5 M, diameter 109 ± 12 nm) on human MDA-MB-231 breast cancer cells, 
passage 49, as a function of incubation time determined by the crystal violet assay.  N2, 2.4 µM, in 
liposomes, c(lipid)= 40 µM,  N2E, 2.3 µM + N2, 0.1 µM in liposomes, c(lipid)= 40 µM,  liposomes, 
c(lipid)= 40 µM,  positive control: cisplatin, 5 µM,  negative control: H2O. 
However, when the liposome concentration in an aqueous suspension is increased 
(c(lipid) = 40 µM in cell medium, diameter 109 ± 12nm), a mixture of 2.3 µM 
1
O2-releasing 
N2E and 0.1 µM N2 embedded in liposomes of such a high concentration do have a cytocidal 
effect on the proliferation of MDA-MB-231 cells, ( onFigure 4.12.) Even though the N2 
concentration, c(N2) = 2.4 µM in cell medium (and therefore N2E concentration, as well) is 
lower than in the previous assay (Figure 4.11.), the inhibitory effect on the cells is much 
stronger because the empty liposomes alone inhibit the cells growth ( on Figure 4.12.) and 
on top of that 
1
O2 from decaying N2E impacts the cell population growth. MDA-MB-231 cell 
population does slowly recover 120 h after non-loaded liposomes or N2 in liposomes 
incubation ( and  symbols, respectively) but does not recover after incubation of N2E in 
liposomes (). Cytocidal effect of N2E in liposomes is even stronger than the cytostatic 
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effect of 5 µM cisplatin ( symbols). Photosensitizer concentration was c(PPIX-DME in cell 
medium) = 0.05 µM. PPIX-DME sensitizer was irradiated with LED (λ = 420 nm, P = 35 
mW, Φ = 140 mW/cm2, T = 14 °C, for t = 0.5h) to form 1O2 which reacted with N2 to form 
N2E (yield 95 %).  
 
4.2.3.2. Cytotoxicity of N4E Embedded in Liposomes 
 
The chemosensitivity of MDA-MB-231 human breast cancer cells to 
1
O2-releasing 
N4E was tested, as well. The highest achieved N4 concentration in liposome suspension 
(c(lipid) = 3±1•10
-5
M in cell medium) diluted in RPMI cell medium was 10 µM. The 
chemosensitivity assay results of N4E formed from this highest concentrated N4-liposome 
suspension (see Figure 4.13.) were very similar to the cytotoxycity of 6.3 µM N2E in 
liposome suspension, shown in Fig. 4.11. The cells incubated with a mixture of 9.2 µM 
1
O2-
releasing N4E and 0.8 µM N4 embedded in liposomes yielded a cytotoxic effect of about 30 
% of growth inhibition compared to the normal growth of untreated cells, but the cells 
recovered until the end of the incubation period (ca. 200 hours). The photosensitizer 
concentration was c(PPIX-DME in cell medium) = 0.5 µM. PPIX-DME sensitizer was 
irradiated with LED (λ = 420 nm, P = 35 mW, Φ = 140 mW/cm
2
, T = 14°C, for t = 0.6 h) to 
form 
1
O2 which reacted with N4 to form N4E (yield 92 %). Non-irradiated 10 µM N4 
embedded in the same liposome suspension ( symbols on Figure 4.13.) and non-irradiated 
empty liposomes ( symbols on Figure 4.13.) produced only a slight insignificant inhibition 
of cell growth which was within the experimental errors of the treated cells. Therefore, even 
with a concentration increase of 
1
O2-releasing endoperoxides for about 50% (N4 in 
comparison to N2 in liposomes), chemosensitivity assay results did not change, probably due 
to the shorter decay time of N4E than of N2E, see Table 4.5. Moreover, there can be a loss of 
the N4E because of the solubility equilibrium shift: N4E is more water soluble than N4 
because of polar hydroxyl group and polar endoperoxide bridge, and thus some of N4E can 
be dissolved in water (outside of liposomes) before the liposome cell uptake. 
As a positive control again the cytostatic drug effect of 10 µM Cisplatin dissolved in 
DMSO is shown on ( symbols on Figure 4.13.) 
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Figure 4.13. A weak cytotoxic drug effect of N4E (c = 9.2 µM) embedded in liposomes (diameter 109 
± 12 nm) on human MDA-MB-231 breast cancer cells, passage 77.  N4, 10 µM, in liposomes, 
c(lipid) = 30 ± 10 µM,  N4E, 9.2 µM + N4, 0.8 µM in liposomes, c(lipid)= 30 ± 10 µM,  liposomes, 
c(lipid)= 30 ± 10 µM, positive control: cisplatin, 10 µM in DMSO,  negative control: H2O. 
Remarkably, liposomes could not be loaded with N5 derivative in a high enough 
concentration for chemosensitivity assay (in µM range) using the extrusion method for 
liposome preparation. Namely, the highest reached N5 concentration was 22 µM in aqueous 
liposome suspension, what would amount to about 0.8 µM in cell medium. 
Finally, in order to decrease the 
1
O2 losses due to relaxation within the liposomes, a 
50 nm diameter liposome production was tried using a 50 nm pore membrane in 
Liposofast™. Although some liposomes of such size were formed, the concentration of both 
liposomes and endoperoxide-forming derivatives was unusable for the chemosensitivity 
assay. 
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4.3. ENDOPEROXIDE FORMATION AND DECAY KINETICS IN THE PVB 
FILM 
 
Polyvinyl butyral (PVB) is among the synthetic polymers that are produced annually 
on a very large scale.  The composition of PVB (for details see Chapter 3.5.2.) proved to be 
useful in various applications [119]. Among other uses, film forming abilities and 
transparency of PVB in the visual range are being widely used in areas such as safety glass 
with PVB interlayers, e.g. for cars or buildings. PVB is an excellent substrate for dye 
incorporation, and many PVB-based paints, inks and lacquers are available. PVB is 
completely non-toxic and due to its composition of only carbon, hydrogen and oxygen it 
combusts with almost no residue, which resulted in its widespread use in food packaging. 
PVB was used as a model polymer because of its completely amorphous structure and 
excellent optical properties (no light scattering) [140]. On top of that, PVB could possibly be 
considered as a carrier material in implants [141]. 
All the endoperoxide-forming naphthalene derivatives (N1, N2, N5 or N4) were 
embedded in PVB film in a very high concentration, up to c = 5 mM in PVB film. TPFPP-
Pd(II) sensitizer was also embedded in PVB films. Ratios of embedded TPFPP-Pd(II) : 
naphthalene derivative varied from 1:10 to 1:100. 
  
4.3.1. Endoperoxide Formation in the PVB Film Carrier 
 
Endoperoxide formation and decay were measured at different temperatures with 
time-dependence of fluorescence typical for the particular naphthalene derivative, as 
described in Chapter 4.2.2. As naphthalene fluorescence decreases, relative amount of 
naphthalene molecules in endoperoxide form increases. Efficiency of endoperoxide formation 
depends on the ethanol content in PVB film during light irradiation. Because the PVB film 
samples were kept in an ethanol atmosphere prior to the light-irradiation, endoperoxide 
formation process was remarkably fast, with 60-90 % of endoperoxides formed after 40-50 
minutes of irradiation at room temperature, depending on the sample thickness, uniformity 
and ethanol content. An example of N5E formation in PVB film at room temperature 
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depending on the light irradiation-time is given in Figure 4.14. In general, endoperoxide-
formation process in PVB film was approximately logarithmic, reaching saturation after ca. 
1h of LED irradiation for each naphthalene derivative.  
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Figure 4.14. N5E formation yield in PVB polymer film at room temperature (25 °C) depending on LED 
irradiation-time measured with N5 fluorescence time-trace. TPFPP-Pd(II) sensitizer, c = 15 µM in PVB 
film, was irradiated with LED (λ = 420nm, P = 35 mW, Φ = 140 mW/cm2, T = 24 °C) to form 1O2 which 
reacted with N5, c = 0.3 mM in PVB film, to form N5E. 
 
4.3.2. Endoperoxide Decay Kinetics in the PVB Film Carrier 
 
In order to determine endoperoxide decay and 
1
O2-release kinetics thermally-induced 
process of endoperoxide decay was measured at different temperatures with time-dependence 
of fluorescence typical for the particular naphthalene derivative, as described in detail in 
Chapter 4.2.2. The percentage of still existing endoperoxide molecules at each time-point was 
calculated according to equation 14. In Figure 4.15. an example of N4E decay in PVB film at 
37 °C is shown. TPFPP-Pd(II) sensitizer, c = 15 µM in PVB film, was irradiated with LED 
(λ = 420nm, P = 35 mW, Φ = 140 mW/cm
2
, T = 28 °C, for t = 0.75 h) to form 
1
O2 which 
reacted with N4, c = 3 mM in PVB film, to form N4E (yield 86 %). Remarkably, the 
endoperoxide decay of examined naphthalene derivatives (except N5) in PVB film was 
O
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biexponential and not monoexponential like in solvents (see Chapter 4.1.4.) or in liposomes 
(see Chapter 4.2.2.)  
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Figure 4.15. Semi-logarithmic plot showing decay of N4E in PVB polymer film at 37 °C measured with 
N4 fluorescence time-trace. On y-axis is the percentage of all N4 molecules which are in 
endoperoxide form at each particular time-point. 
During the biexponential decay in PVB film there is a certain percentage of fast-
decaying endoperoxides (FDE), with a decay-time shorter (N2E, N4E) or similar to the 
decay-time in liposome aqueous suspension. After the decay of FDE there is a sharp change 
in semi-logarithmic plots showing endoperoxide decay (e.g. see Figure 4.15.) of each 
examined naphthalene derivatives (N1, N2, N4, N5), marking the transition to another 
population  of endoperoxide molecules, slowly-decaying endoperoxides, SDE. SDE are more 
stable than endoperoxides of the same “parent molecule” in liposome matrix. In Table 4.6. 
endoperoxide decay times of all examined naphthalene derivatives in PVB film matrix at 37 
°C, as well as the correspondineg percentages of FDE and SDE are given. 
 
OH
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Table 4.6. Decay times of endoperoxides of different naphthalene derivatives in PVB film 
matrix at 37 °C. In parenthesis are the percentages of formed endoperoxides decaying with 
corresponding t1/2. For both FDE and SDE calculated endoperoxide stability factors, SF, in 
comparison to the average decay in various organic solvents are given. 
 
 
 
 
 
 
 The sensitizer used were TPFPP-Pd(II), c = 1.5•10
-5 
M in PVB film, and in case of N1 
derivative PPIX-DME, c = 6.0•10
-4 
M in PVB film. Light-irradiation was done with LED 
(λ = 420 nm, P = 35 mW, Φ = 140 mW/cm
2
, at room temperature), and in case of N1 with 
Ar
+
 laser (λ = 514 nm, P = 150 mW, Φ = 600 mW/cm
2
, at room temperature). N5E had no 
significant FDE part and showed a monoexponential decay. 
 
4.3.3. Systematical Adjustment of the Endoperoxide Decay Kinetics in the PVB Film 
 
Influence of different parameters during the endoperoxide formation procedure on the 
endoperoxide decay-time and relative percentages of FDE and SDE was tried out. First of all, 
changing the ethanol content in the PVB sample before or shortly after light irradiation was 
tried by putting the PVB film sample under vacuum before or after light irradiation, as well 
as leaving it on a temperature (ranging 37 °C - 56 °C) higher than the room temperature for 
up to 1 day before light irradiation. By varying these parameters no significant or systematic 
increase of endoperoxide stability could be achieved. However, by varying the temperature 
on sample during the light irradiation this goal was achieved. The optimal temperature on 
sample during the light irradiation was 32 °C, see Figure 4.16. and Figure 4.17. When the 
sample was held during irradiation at even higher temperatures, such as 37 °C, the yield of 
endoperoxide formation was poor. For example, after 50 minutes of LED irradiation with 33 
Molecule in PVB film t1/2 (% endoperoxides) 
N1 1.7 h (30%) SF = 1.42; 7.3 h (12%) SF = 6.08 
N4 4.4 h (8%) SF = 1.00; 26.6h (16%) SF = 6.09 
N2 6.4 h (8%) SF = 0.39; 19.4h (18%) SF = 1.20 
N5 6.0 h (50%) SF = 2.65 
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°C on N1 in PVB sample, N1E yield was 84 %, and when temperature on the sample was 37 
°C (with all the other parameters unchanged), the yield was only 40 %. 
 In Fig. 4.16. an example of endoperoxide decay-time prolongation is shown. N2E in 
PVB film were formed by light-irradiation with 32 °C on PVB sample during this process. 
The endoperoxide decay at 46 °C was examined. TPFPP-Pd(II) sensitizer, c= 15 µM in PVB 
film, was irradiated with Ar
+
 laser (λ=514nm, P = 180 mW, Φ = 720 mW/cm
2
, T = 32 °C, for 
t = 0.67 h) to form 
1
O2 which reacted with N2, c = 3 mM in PVB film, to form N2E (yield 93 
%). 
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Figure 4.16. Semi-logarithmic plot showing decay of N2E in PVB polymer film matrix at 46 °C 
(hyperthermia model temperature) measured with N2 fluorescence time-trace. On y-axis is the 
percentage of all N2 molecules which are in endoperoxide form at each particular time-point. 
A significant part is FDE, 32 % of formed N2E decay with t1/2  = 1.9h, faster than in 
liposomes t1/2  = 5.1 h, probably because this part of endoperoxide molecules have enough of 
free volume present in PVB matrix and are able to decay without any hindrance from PVB 
matrix wall. But, SDE part of formed N2E is stabilized presumably due to the physical 
processes of continuous forming and decay (thermal back-reaction) during irradiation at 
increased temperature. For more details, see Chapter 6.1. Decay-time of such stabilized SDE, 
t1/2 = 45.7 h, is even at 46 °C longer than t1/2 = 19.4 h at 37 °C (Table 4.6.) of SDE N2E 
formed at room temperature.  
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Figure 4.17. Demonstration of adjusting the decay-time of both FDE and SDE N1E, as well as their 
relative amount in PVB film at 56°C. The adjustment is done by the process of successive 
thermocycles of endoperoxide formation and decay. Semi-logarithmic plots showing decay of N1E in 
PVB polymer film after 3 sucessive thermocycles, measured with N1 fluorescence time-trace. 
Moreover, a possibility to adjust the decay-times (and therefore 
1
O2 release-time) and 
relative amount of both fast-decaying and slowly-decaying endoperoxides with a more 
complex method consisting of successive repetition of light-induced endoperoxide formation 
and subsequent thermal decay was found. As demonstrated in Figure 4.17. on the example of 
N1E formation at 32 °C and decay at 56 °C, by cyclic use of aforementioned physical 
processes, the percentage of FDE decreases with each formation-decay cycle, whereas the 
percentage of SDE increases accordingly. On top of that, the decay-time of SDE is 
significantly prolonged, up to the factor of 8 from 1
st
 to 3
rd
 formation-decay cycle. TPFPP-
Pd(II) sensitizer, c = 15 µM in PVB film, was irradiated with LED (λ = 420nm, P = 35 mW, 
Φ = 140 mW/cm
2
, T = 32 °C, for t = 0.5 h) to form 
1
O2 which reacted with N1, c = 0.6 mM in 
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PVB film, to form N1E. Only FDE and a small portion of SDE N1E was allowed to decay at 
56°C before LED irradiation at 32°C was repeated and endoperoxides were formed again. 
The same adjustment effect appeared for N1E decaying at 37 °C and is shown in 
Table 4.7. In parenthesis are the relative amounts of faster- and slowly-decaying N1E in PVB 
film at 37 °C, respectively. The LED irradiation of TPFPP Pd(II), c = 15 µM in PVB film and 
endoperoxide formation was performed at 32 °C, which turned out to be the optimal 
temperature for tuning the endoperoxide decay-time in PVB film.  
 
Table 4.7. Decay-times and relative amounts of FDE and SDE N1E molecules with corresponding 
decay-time at 37 °C in PVB film after 1 and 2 cycles of N1E formation at  
32 °C and decay at 37 °C. In parenthesis are the percentages of formed endoperoxides decaying with 
corresponding t1/2. For both FDE and SDE calculated endoperoxide stability factors, SF, in 
comparison to the average decay in various organic solvents are given as well. 
 
Cycle No. t1/2 (% endoperoxides) 
1
st 1.5h (36%) SF = 1.25; 7.6h (24%) SF = 6.33 
2
nd
 1.7h (35%) SF = 1.42; 38.2h (55%) SF = 31.83 
 
A model explaining all of these findings will be given in the Chapter 6.1. where the 
interaction between the embedded endoperoxide molecules and the matrix and influence 
modes on this interaction will be discussed in detail.  
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4.4. ENDOPEROXIDE DECAY AND CYTOTOXICITY IN PVB 
NANOPARTICLES CARRIER 
PVB nanoparticles were prepared as described in Chapter 3.5.3. The aim was to 
produce such PVB nanoparticles which could be used as an intracellular drug delivery 
material, i. e. which would be small enough to permeate into cancer cells and deliver 
1
O2-
releasing endoperoxides in a short enough time after light-irradiation of particle-loaded 
naphthalene derivatives. 
4.4.1. Systematical Adjustment of PVB Nanoparticles Size 
The size of the resulting particles is a function of various parameters. In general, in 
order to obtain small particles, it is preferable to use a polymer with small molecular weight 
and therefore size. Initial tests (results not shown) were carried out with Mowital B60T 
(average molecular weight 60 kDa). This polymer formed rather large particles in the 
micrometer regime. All following experiments were carried out with PVB Mowital LPB 16H 
(average molecular weight 16 kDa), which proved to be better suited for synthesis of 
nanometer-sized beads. 
Firstly, the results for variation of the solvent with constant PVB concentration of 1 
g/L, and 0.8 mL/min flow rate of ddH2O non-solvent drops addition at room temperature are 
summarized in Table 4.8. 
Table 4.8. Mean PVB nanoparticle diameters depending on solvent during synthesis. 
solvent particle diameter 
(nm) 
methanol 1058 
TEMED
 
902 
acetone 536 
ethanol 442 
1-propanol 448 
2-propanol 430 
DMF 362 
DMSO 262 
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It was found that the particle size depends strongly on the solvent used with no clear trend 
visible with respect to polarity or groups present in the solvent. The smallest particle sizes 
were obtained for DMSO, DMF and 2-propanol solvents. Another parameter of investigation 
was the speed of addition of the non-solvent. For precise control of addition speed a 
peristaltic pump was employed. Table 4.9. shows the obtained nanobead size with constant 
PVB concentration of 1 g/L, and ddH2O non-solvent drops addition at room temperature.  
Table 4.9. Mean PVB nanoparticle diameters depending on addition speed of non-solvent. 
solvent flow rate 
(mL/min) 
particle diameter 
(nm) 
DMSO 0.095 518 
DMSO 0.51 272 
DMSO 1.96 246 
DMSO 3.45 216 
DMSO 5.71 176 
DMSO 6.9 164 
2-propanol 0.05 585 
2-propanol 0.25 458 
2-propanol 5.0 242 
2-propanol 9.0 195 
 
Clearly, the size of PVB nanoparticles decreases with increasing flow rate indicating a rapid 
mixing of solvent and non-solvent to be advantageous with respect to small particle 
formation. Even higher mixing rates did not result in smaller beads. Simply pouring one 
liquid onto another resulted in large particles in micrometer range and wide particle size 
distributions. 
The dependence of particle diameter on reaction temperature was also examined. It 
would be expected that because of slower diffusion at lower temperatures (Einstein-Stokes 
equation) smaller particles are synthesized at lower T, whereas raising the temperature leads 
to larger particles. Table 4.10. summarizes syntheses with constant PVB concentration of 1 
g/L in 2-propanol solvent, and 2.0 mL/min flow rate of ddH2O non-solvent drops addition at 
different temperatures. 
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Table 4.10. Mean PVB nanoparticle diameters depending on temperature. 
temperature 
(° C) 
particle diameter 
(nm) 
65 516 
45 442 
25 342 
5 282 
 
The results confirm that at lower temperatures smaller spheres are formed, therefore, low 
temperatures are preferred for synthesis. A roughly linear relationship is obtained between 
temperature T and average particle size suggesting diffusive contributions to be dominant for 
particle formation although the number of experimental points is too low in these 
experiments to obtain quantitative conclusions. Since the nanoaggregation of polymer chains 
depends on the availability of polymer in the solution it appears reasonable that the 
concentration of polymer is also a major factor in determining particle size. Results of 
particle syntheses performed at different polymer concentrations in 2-propanol solvent with 
constant 2.0 mL/min flow rate of ddH2O non-solvent drops addition at 25 °C are displayed in 
Table 4. 11.  
 
Table 4.11. Mean PVB nanoparticle diameters depending on polymer concentration. 
concentration 
(g/L) 
particle diameter 
(nm) 
3 550 
1 360 
0.4 286 
0.1 262 
 
The dependence of particle size on PVB concentration is evident. Relating polymer 
concentration to particle diameter a roughly linear relationship is also obtained. Clearly, low 
polymer concentrations are favourable. However, in practice this parameter is not as useful as 
other parameters, since it is desirable to obtain the as-synthesized particles in as high of a 
concentration as possible. To sum up, systematic increase of ddH2O non-solvent dropping 
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rate, temperature decrease and polymer concentration decrease all cause the mean PVB 
nanoparticle diameter decrease.  
The effect of replacing the non-solvent ddH2O with aqueous buffers of various ionic 
conc. and pH was also investigated. However none of those led to the formation of smaller 
particles than the respective synthesis in ddH2O with other parameters unchanged. The 
addition of surfactants (SDS, tween 20, triton X-100, CTAB) to ddH2O neither led to smaller 
particles.  
 Finally, an addition of a small volume, 2.5 % (v/v), of a second solvent to the 0.4 g/L 
PVB solution in 2-propanol prior to the addition of 9 ml/min ddH2O non-solvent at 4 °C was 
tested, as shown in Table 4.12.  
 
Table 4.12. Mean PVB nanoparticle diameters depending on the second solvent addition 
during synthesis. 
solvent solvent 2 particle diameter 
(nm) 
2-propanol chloroform ≥350: aggregates 
2-propanol 1-octanol ≥350: aggregates 
2-propanol cyclopentanone 210  
2-propanol toluene 209  
2-propanol 
acetonitrile 155 (67%) 
232 (33%) 
2-propanol acetyl acetone 172  
2-propanol dodecane 162  
2-propanol diethylether 158  
2-propanol ethyl acetate 154 
2-propanol 1,4-dioxane 147  
2-propanol dichloromethane 135  
2-propanol DMSO 135  
2-propanol DMF 128  
2-propanol pentane 98  
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Again, no clear trend with respect to polarity or groups present in the second solvent 
on PVB particle size was established. Addition of some solvents caused strong particle 
aggregation to micrometer size, whereas some caused a formation of particles with 2 various 
average diameters, possibly due to various solvent miscibilities with H2O. For the purposes of 
high incorporation of PTC and endoperoxide-forming dopants (see later) a combination of 2-
propanol and dichloromethane solvents proved to be the best one.   
The optimal parameters regarding the nanoparticle size included pumping dd H2O 
dropwise through a syringe at a rate of 9 ml/min at 4 °C to produce nanoparticles of average 
141 nm diameter. However, it was not possible to reduce the average diameter of the particles 
to less than 100 nm using the obtained PVB polymer. On the contrary, when drops of 1 mM 
NaOH were slowly (4-5 drops/s) dropped to the PVB solution in 2-propanol at the room 
temperature larger particles of 420 nm average diameter were synthesized (see Figure 4.19). 
PVB nanoparticles show a very slow sedimentation over the course of several weeks 
to months in aqueous solution which may easily be reversed by stirring or shaking the 
suspension thoroughly. Apart from that the beads showed no significant aging effect in H2O 
suspension as well as in cell culture RPMI medium at RT. No aggregates were detectable via 
DLS even after several months. It was possible to concentrate the suspension of PVB 
nanoparticles up to 300 ppm = 0.30 g/L using Amicon® Ultra-4 centrifugal filter membranes 
(10 000 NMWL) and a 3000 g centrifuge before aggregates detectable with DLS formed. 
In order to determine the size uniformity, as well as the shape of the nanoparticles, 
transmission electron microscopy technique was used. Very good size uniformity and the 
particle’s spherical shape were all confirmed with TEM of dried PVB particles (Figure 4.18.) 
Size distribution from DLS of this representative sample was calculated as (141 ± 40) nm 
with the latter parameter being one standard deviation.  
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Figure 4.18. PVB nanoparticles average diameter measured with DLS (a) and TEM (b). 
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4.4.2. PVB Nanobeads Doping with PTC 
 
N,N’-bis(2,6 -dimethylphenyl)- perylene-3,4,9,10-tetracarboxylic diimide (PTC) was 
used as a PVB nanobeads dopant for CLSM purposes. PTC is soluble in alcohols and other 
solvents of intermediate polarity, but it is almost insoluble in water and nonpolar compounds. 
Therefore, PTC has similar solubility properties as PVB. 1 % (w/w) dopant concentration 
with respect to the PVB weight was chosen in order to obtain bright nanoparticles, but also to 
avoid excessive self-quenching of dye molecules. 
The influence of PTC addition to PVB with respect to particle preparation and particle 
size was investigated using the solvents DMSO and 2-propanol (Table 4.13.) while 6 mL/min 
ddH2O non-solvent was added at 5 °C.  
 
Table 4.13. Parameters of PVB nanoparticle preparation using dopant molecules. 
concentration 
(g/L) 
solvent particle diameter 
(nm) 
0.2 2-propanol 190 
0.2 (1 % PTC) 2-propanol 202 
0.2 DMSO 176 
0.2 (1 % PTC) DMSO 250 
  
It was found that using 2-propanol as solvent, bright fluorescent nanospheres are formed, 
where PTC is almost quantitatively incorporated. The influence of PTC addition on particle 
diameter was found to be negligible (within the standard deviation of particle diameter). On 
the other hand, PTC addition using DMSO as solvent system did not yield satisfactory 
results. Particles showed only weak fluorescence, as apparently most of the PTC precipitated 
before PVB particles formed, and particle diameter was also increased by about 40 %. 
Possibly, PTC is too poorly soluble in DMSO yielding rapid precipitation upon addition of 
non-solvent.  
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4.4.3. PVB Nanobeads Cell Uptake, Determined with CLSM 
 
To determine if the PVB nanoparticles are taken up by the MDA-MB-231 breast 
cancer cells confocal microscopy was used. Firstly, larger particles (420 nm in average 
diameter) were tested. As it is visible on Figure 4.19. a) and b), these particles doped with 
PTC dye (green colour) are not taken up by the breast cancer cells (stained with nuclear dye 5 
µM DRAQ5™, red colour), but stay adsorbed to the cell membrane, even 22 hours after 
incubation of the cells with the nanoparticles.  
   
a)      b) 
Figure 4.19. False color multifluorescence CLSM images of living MDA-MB-231 cells, passage 323 
(stained with nuclear counterstain DRAQ5™, (5 µM), red colour), incubated with uncoated PVB 
polymer nanoparticles (diameter: 420 ± 55 nm, doped with PTC, green colour). PVB nanoparticles 
remain at the cytoplasmic membrane a) 4 h and b) 22 h after incubation. Only a small part of the 
particles, even after 22 hours, is inside the cell. Plan-Apochromat 63x/1.4 oil, Ar 488, HFT 488, 
BP530-600; HeNe 633, HFT 488/543/633, LP650. 
This result is contrary to the work of J. Rejman et al [142], where the beads with 500 
nm diameter were taken up by the eukaryotic non-phagocytic B16 cells but remained on the 
cell periphery and were not to be found in the perinuclear region or lysosomes. In the same 
paper, it was stated that particles with diameter < 200 nm were internalized by the cells faster 
(than those with 500 nm diameter) and are accumulated in the perinuclear region and 
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subsequently ended in lysosomes. Due to this observations, the PVB nanoparticles with the 
average diameter smaller than 200 nm were prepared and the CLSM experiment repeated 
yielding a positive result, see Figure 4.20. 
 
a) 
    
   b)      c) 
Figure 4.20. CLSM images showing the time-scale of uncoated PVB nanoparticles (diameter :141 ± 
40 nm, doped with PTC, green colour) uptake by the living MDA-MB-231 cells, passage 180 (stained 
with 5µM nuclear counterstain DRAQ5™ and 5µg/mL CellMask Deep Red™ plasma membrane stain, 
red colour). The PVB particles appear in all of cells, some are close to the cell membrane, and some 
are dispersed in the cell cytoplasm after 2 h incubation (a). After 3.5 h (b) and c)) the particles appear 
in all of the cells dispersed in the cell cytoplasm. Plan-Apochromat 63x/1.4 oil, Ar 488, HFT 488, 
BP530-600, Pinhole 122; HeNe 633, HFT 488/543/633, LP650, Pinhole 1000. 
On Figure 4.20. CLSM images of living MBA-MB-231 human breast 
adenocarcinoma cells incubated with 141 ±4 0 nm average diameter PVB nanoparticles 
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loaded with PTC dye (green colour) can be seen. Cells were stained with nuclear counterstain 
DRAQ5™ (5 µM) and 5µg/mL CellMask
 
Deep Red™ plasma membrane stain (red colour on 
Figure 4.20.) 2 h after the incubation PVB nanoparticles are already inside the living MBA-
MB-231 cells: some nanoparticles remain at the cell membranel, and some are dispersed in 
the cytoplasm (Figure 4.20. a). After 3.5 h (Figure 4.20. b) and c) the particles appear in all of 
the cells dispersed in the cell cytoplasm. Therefore, it can be summed up that the average cell 
uptake time, tu, of uncoated PVB nanoparticles (size 141 nm) is in the region of 2-3 hours. 
Note: the CLSM microscope pinhole was opened to 122 µm (single layer scanned) in 
nuclei and plasma membrane channel (filter LP650), and to 1000 µm (all layers scanned, as 
with a fluorescence microscope) in PVB particles channel (filter BP 530-600). Therefore, the 
fluorescence of the particles is very strong and they appear to be much larger and the 
resolution is low. Prior to the recording of each figure, the cells were washed 3 times with 
Leibowitz’s L-15 medium in order to make sure that all the fluorescence of PVB particles 
comes from intracellular particles. 
Furthermore, PVB nanoparticles with the average diameter of 238 nm were 
synthesized as well. Using CLSM technique it was also found that these particles are taken up 
by the cells and dispersed in the cytoplasm, but after a longer time period than the particles 
with the average diameter of 141 nm. 
Therefore, the cell uptake of these PVB nanoparticles is strongly size-selective with a 
threshold value for particles diameter at around 300 nm. 
 
4.4.4. Cytotoxicity of Undoped PVB Nanobeads Determined with Kinetic 
Chemosensitivty Assay 
 
After finding out that PVB nanoparticles are indeed cell-penetrable, the cytotoxicity 
of 141 nm average diameter PVB particles was tested using the kinetic crystal violet 
chemosensitivity assay [111] and compared with the cytotoxicity of conventional, 
unmodified liposomes (Chapter 4.2.3.) Cells were treated (T values) with PVB nanoparticles 
and liposomes and compared to control growth curve of untreated cells (C values) to yield a 
T/C profile (Figure 4.21.) which compares the growth speed of treated cells to the growth 
speed of untreated cells. 
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Figure 4.21. Comparison of non-toxic effect of 300 ppm (w/w) aqueous suspension of PVB 
nanoparticles (141 nm average diameter) with a strong cytotoxic effect of 40 ppm (w/w) DMPC 
liposomes aqueous suspension on proliferation of MDA-MB-231 cancer cells determined using a 
crystal violet chemosensitivity assay. For the positive control, a cytostatic effect of 10 µM cisplatin is 
shown. 
As can be seen on Figure 4.21. a concentrated aqueous suspension (300 ppm w/w) of 
PVB nanoparticles (diameter 141 ± 40 nm) which contained no aggregates of nanoparticles, 
as measured with dynamic light scattering) showed no inhibitory effect on proliferation of 
human breast cancer cells MDA-MB-231 as a function of incubation time. On the contrary; 
an order of magnitude less concentrated aqueous suspension of conventional, unmodified 
liposomes, (40 ppm w/w, diameter 109 ± 8 nm) shows an initial inhibitory effect on the 
growth of MDA-MB-231 cells, after which the cell population slowly recovers after 125 h. 
PVB nanoparticles have no short-term cytotoxic effect whatsoever and regarding the 
achievable intracellular concentration are a favourable carrier comparatively to conventional 
liposomes. On Figure 4.21. a comparison with a cytostatic effect of cisplatin, is also shown. 
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Whereas the cells treated with 40 ppm (w/w) liposomes starts to multiply after 125 h, the 
growth of cells treated with cisplatin is fully inhibited and cell population doesn’t recover.  
300 ppm (w/w) PVB nanoparticles concentration in aqueous suspension was the 
highest achievable concentration with the preparation method described in Chapter 3.5.3. 
including the centrifuge procedure. At higher suspension concentrations PVB particles 
aggregated strongly forming aggregates of several micrometers.  
 
4.4.5. Adjustment of Endoperoxide Decay Kinetics in PVB Nanobeads Carrier 
 
It was found that naphthalene derivatives were not quantitavely incorporated into 
PVB nanobeads: it was reproducibally possible to incorporate about 10 % of added 
naphthalene derivatives into PVB nanobeads. 
When the possibility of PVB nanoparticle use as a carrier for intracellular drug 
delivery purposes in high concentrations was established, endoperoxide decay times in PVB 
nanoparticles were explored. In Table 4.14. endoperoxide decay times, t1/2, of all naphthalene 
derivatives embedded in PVB nanoparticles at 37 °C are given. The sensitizer used was MB 
in all cases, c = 10
 
µM. Irradiation to form endoperoxides was done with laser (λ = 658 nm,  
P = 70 mW, for t = 0.5 h at T = 14°C). In parenthesis the percentages of endoperoxides 
corresponding to the particular decay time are given. The stability factor, SF, showing the 
increase of t1/2 in PVB nanoparticles matrix in comparison to t1/2 in organic solvents 
(calculated according to equation 13), is also given in Table 4.14. 
Table 4.14. Decay times of endoperoxides of different naphthalene derivatives embedded in 
PVB nanoparticles at 37 °C and calculated endoperoxide stability factors, SF, for 
comparison to the decay in various organic solvents. In parenthesis are the percentages of 
formed endoperoxides decaying with corresponding t1/2,.. 
 
Molecule in PVB nanoparticles t1/2 (% endoperoxides) 
N1 0.8 h (75%), SF = 0.66; 1.6h (13%), SF = 1.33; 5.8h (5%), SF = 4.83 
N2 18.7 h (20%), SF = 1.15 
N4 7.5 h (28%), SF = 1.72; 17.5 h (19%), SF=4.01 
N5 2.0 h (45 %), SF = 0.88; 2.65 h (20%), SF = 1.17 
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Equally as in PVB film carrier, influence of different parameters during the 
endoperoxide formation procedure in PVB nanoparticles on the endoperoxide decay-time was 
researched. In general, the yield of endoperoxide formation was lower than in liposomes or 
PVB film. For example, after 0.5 hours of laser (λ = 658 nm, P = 70 mW) irradiation at room 
temperature the yield of N4E in PVB nanoparticles was only 59 %, compared to 85 % in 
PVB film and 98 % in liposomes under similar conditions. Even after longer irradiation (up 
to 2 h) and/or irradiation at lower temperature (e. g. 4 °C), the highest endoperoxide yield in 
PVB nanoparticles was 77 %. This was probably due to the necessary transport of 
1
O2 from 
dissolved MB sensitizer molecules (
1
O2 generation location) to the naphthalene molecules in 
PVB nanoparticles (
1
O2 local storage location in endoperoxide form). 
Moreover, a method of successive repetition of light-induced endoperoxide formation 
and subsequent thermal decay (which was very valuable in adjustment of 
1
O2 release time in 
PVB film, e. g. Figure 4.17.) was tested on endoperoxide-loaded PVB nanoparticles, as well. 
An example for decay of N4E in PVB nanoparticles (size: diameter 155 ± 41 nm) at 37 °C is 
given in Figure 4.22. By cyclic use of aforementioned physical processes it was possible to 
extend the decay time of FDE N4E in PVB nanoparticles for almost 50 % from 6.0 hours (in 
first formation-decay cycle decay of FDE only) to 8.8 hours in the second cycle. The FDE 
and SDE decay-times in the second cycle have rather similar values, but the approximation of 
biexponential decay is still acceptable, see Figure 4.22. b). MB sensitizer (c = 10 µM) was 
irradiated with laser (λ = 658 nm, P=70 mW, T = 32° C, for t = 0.5 h) to form 
1
O2 which 
reacted with N4 (c = 1.7 µM in aqueous suspension) to form N4E (yield 61 %), which 
subsequently decayed at 37 °C. 
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Figure 4.22. Semi-logarithmic plot showing the adjustment of N4E decay times due to the processes 
of successive thermocycles of endoperoxide formation in PVB nanoparticles (size: diameter 155 ± 
41nm) at 37 °C measured with N4 fluorescence time-trace. Decay after 1 thermocycle (a) and after 2 
successive thermocycles (b). On y-axis is the percentage of all N4 molecules which are in 
endoperoxide form at each particular time-point. 
 Finally, the set of parameters which enabled the most appropriate adjustment of decay 
times and FDE and SDE relative amounts in PVB film was applied on endoperoxides in PVB 
nanoparticles. This included endoperoxide formation at 32 °C combined with repetitions of 
formation-decay cycle. The results of such experiments are shortly presented in the Table 
4.15. on the example of N1E decay in PVB nanoparticles at 37 °C. The sensitizer used was 
methylene blue in all cases, c = 10 µM. Irradiation was done with laser (λ = 658 nm, P = 70 
mW, for t = 0.5 h). 
 From the data in the Table 4.15. it is visible that FDE N1E are stabilized when formed 
at 32 °C, in comparison to endoperoxides formed at 14 °C, presumably due to the physical 
processes of continuous formation and decay (thermal back-reaction) during irradiation at the 
increased temperature. Decay-time of such stabilized FDE, t1/2 = 5.3 h, is comparable to t1/2 = 
5.8 h of SDE N1E formed at 14 °C. On top of that, by cyclic use of endoperoxide formation-
decay physical processes, the percentage of FDE decreased with each formation-decay cycle, 
whereas the percentage of SDE increased accordingly. Moreover, the decay-times of FDE 
and SDE are both extended in the second cycle up to the factor of 4 compared to t1/2 values of 
FDE and SDE formed at 14 °C. Thus, t1/2 of both FDE and SDE was adjusted to be longer 
than the cell-uptake time, tu, of PVB nanoparticles (diameter 141±40 nm) by the MDA-MB-
231 human breast adenocarcinoma cells. 
OHOH
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Table 4.15. Decay times of N1E embedded in PVB nanoparticles at 37 °C depending on the 
endoperoxide-formation parameters: temperature during irradiation and number of 
successive cyclic repetitions of photoinduced endoperoxide formation and thermally 
activated decay. In parenthesis are the percentages of formed endoperoxides decaying with 
corresponding t1/2. Endoperoxide stability factors, SF, in comparison to the decay in organic 
solvents were calculated. 
Endoperoxide-formation parameters t1/2 (% endoperoxides) 
T = 14°C, 1 cycle 0.8 h (75%) SF = 0.66; 1.6h (13%) SF = 1.33; 5.8h (5%) SF = 4.83 
T= 32°C, 1 cycle 5.3 h (45%) SF = 4.42 
T= 32°C, 2 cycles 7.5 h (35%) SF = 6.25; 21.4 h (12%) SF = 17.83 
  
4.4.6. In Vitro Cytotoxicity of 1O2-Releasing Endoperoxides in PVB Nanobeads: 
Kinetic Chemosensitivity Assay Results  
 
Cytotoxicity of N4E, N5E and N2E embedded in non-coated PVB nanoparticles in 
aqueous suspension on MDA-MB-231 cancer cells using crystal violet chemosensitivity 
assay was tested. The highest reached concentrations for each endoperoxide-forming 
derivative in cell medium were: 0.3 µM N4 in 155±41 nm PVB (270 ppm w/w), 0.5 µM N2 
in 144 ± 43 nm PVB (290 ppm w/w) and 1.6 µM N5 in 177±39 nm PVB (320 ppm w/w). On 
Figure 4.23. an example of non-inhibitory influence of both 0.3 µM N4 in 155±41 nm PVB 
nanoparticles aqueous suspension (270 ppm w/w in cell medium) and a mixture of 0.25 µM 
N4E and 0.05 µM N4 in the same PVB nanoparticle suspension, on the proliferation of 
MDA-MB-231 cells is shown. MB sensitizer (c = 0.11 µM) was irradiated with laser (λ = 
658nm, P = 70 mW, T = 14 °C, for t = 1 h) to form 
1
O2 and subsequently N4E (yield 83 %). 
A cytotoxic effect of 10 µM cisplatin dissolved in DMSO on the growth of MDA-MB-231 
cells ( symbols on Figure 4.23.) is given for a comparison.  
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Figure 4.23. No cytotoxic effect of N4E in non-coated PVB nanoparticles (diameter 155 ± 41nm) on 
human breast adenocarcinoma cells MDA-MB-231, passage 331, as a function of incubation time 
determined by the crystal violet assay. Neither the non-coated PVB nanoparticles nor N4 embedded 
in non-coated PVB nanoparticles exhibit any toxicity on the MDA-MB-231 cells.  N4, 0.30 µM, in 
PVB nanobeads, 270 ppm (w/w),  N4E, 0.25 µM + N4, 0.05 µM in PVB nanobeads, 270 ppm (w/w), 
 PVB nanobeads, 300 ppm (w/w),  positive control: cisplatin, 10 µM in DMSO,  negative control: 
H2O. 
Necessary final endoperoxide concentrations in cell medium of 6 µM or higher (see 
Figure 4.11. and Figure 4.12.) were not reachable because of rather poor loading efficiency of 
PVB nanoparticles with naphthalene derivatives. The highest reached concentrations were 
insufficient for any of endoperoxide-forming derivatives in PVB nanoparticles to have any 
inhibitory effect on the growth of MDA-MB-231 cells. 
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4.5. ENDOPEROXIDE DECAY AND CYTOTOXICITY IN EC 
NANOPARTICLES CARRIER 
4.5.1. EC Nanoparticles Reproducibility and Size Dependence on Preparation 
Parameters 
 
Ethylcellulose nanoparticles were prepared as described in Chapter 3.5.4. Whereas the 
size of the EC nanoparticles was regularly < 150 nm in diameter as measured with DLS, 
using the TEM technique a considerable tendency of EC nanoparticles towards cluster 
formation was found out (see Figure 4.24.), which caused some problems with the 
reproducibility of naphthalene derivative doping concentration, as well as some precipitation 
of the EC nanoparticles from aqueous suspension after 1 - 2 weeks at RT conditions. The 
amount of EC clusters present in the aqueous suspension is difficult to quantify. It was not 
possible to destroy the EC clusters in an ultrasonic bath or by coating the EC with 
polysorbate 80™. This problem triggers reproducibility problems with chemosensitivity 
assays: EC concentration reproducibility, and doped endoperoxide-forming derivative 
concentration reproducibility in aqueous suspension. 
The EC particles size dependence on similar preparation procedure parameters 
variation as in case of PVB nanobeads was tested, as well. The temperature had no significant 
influence on the EC particle diameter. Controlled, slower ddH2O non-solvent addition using 
the peristaltic pump caused systematic increase in EC particles diameter in 200-400 nm 
range: the slower the ddH2O flow rate, the larger were EC particles. Finally, the EC polymer 
concentrations of 0.4 % (and above) EC in THF/acetone caused more pronounced cluster 
formation in aqueous suspension. 
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Figure 4.24. Average diameter of EC nanoparticles loaded with N4, measured with DLS (a) 
and TEM (b). 
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The size of formed EC nanoparticles varied somewhat depending on the nature of the 
derivative loaded, as stated above. Later, it was possible with the same procedure as 
described above to produce N4 loaded EC particles of 46±11 nm average diameter as 
measured with DLS. However, the main problem with EC particles production was cluster 
forming in aqueous suspension as seen on TEM picture on Figure 4.24. Moreover, EC 
nanoparticles underwent an aging effect in aqueous suspension: after 2 months approximately 
half of the EC nanoparticles with diameter under 150 nm formed clusters larger than 300 nm. 
 
4.5.2. EC Nanoparticles Cell Uptake, Determined with CLSM  
 
For confocal microscopy experiments the EC nanoparticles were doped PTC (1 % 
w/w to EC polymer), and particles production procedure (as described in Chapter 3.5.4.1.) 
gave particles of 90 ± 23 nm average diameter, as measured with DLS.  
  
a) after 4h, uncoated   b) after 9h, polysorbate 80™-coated 
 
Figure 4.25. False color multifluorescence CLSM images of living MDA-MB-231 cells, passage 75 
(stained with 5 µM nuclear counterstain DRAQ5™ and 5µg/mL CellMask Deep Red™ plasma 
membrane stain, red colour) incubated with EC nanoparticles (45 ppm w/w, diameter: 90 ± 23nm, 
doped with PTC, green colour). a) uncoated EC nanoparticles 4 h after incubation appear only in a 
few of living MDA-MB-231 cells and b) polysorbate 80™-coated (100 ppm w/w) EC nanoparticles 9 h 
after incubation appear in all of the cells, homogenously dispersed in the cell cytoplasm. Plan-
Apochromat 63x/1.4 oil, Ar 488, HFT 488, BP530-600; HeNe 633, HFT 488/543/633, LP650. 
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To determine the potential of the EC nanoparticles as a drug-delivery carrier, cell 
uptake of EC nanoparticles by the MDA-MB-231 breast cancer cells the CLSM technique 
was used. Firstly, uncoated EC nanoparticles (average diameter 90 ± 23 nm) doped with PTC 
dye were tested, Figure 4.25. a). Only a few of uncoated EC nanoparticles (green colour on 
Figure 4.25.) appear after 4 hours of incubation in MDA-MB-231 cells (red colour on Figure 
4.25.), which suggests a very slow cell penetration by the uncoated EC nanoparticles.  
 However, when the EC nanoparticles were coated with polysorbate 80™ surfactant, 
the cell uptake was much stronger, as can be seen on Figure 4.25. b): all of the polysorbate 
80™-coated EC nanoparticles are inside of MDA-MB-231 cells 9 h after incubation. 
polysorbate 80™-coated ethylcellulose particles appear in all of the cells, homogenously 
dispersed in the cell cytoplasm. Cell nucleus and plasma membrane were stained with 5 µM 
DRAQ5
TM 
and 5 µg/mL CellMask
TM
 Deep Red, respectively. Prior to the CLSM recording of 
pictures, the cells were washed 3 times with Leibowitz’s L-15™ medium in order to make 
sure that all the fluorescence of EC nanoparticles comes from intracellular particles.  
When it was established that only the polysorbate 80™-coated EC nanoparticles enter 
the MDA-MB-231 cells, time-scale of the EC particles uptake (see Figure 4.26.) was 
determined using the same CLSM procedure. The EC particles appear in most of cells and are 
close to the cell membrane after 1 h incubation (Figure 4.26. a and b). After 2 h (Figure 4.26. 
c) the particles appear in all of the cells, some still close to the cell membrane, some 
dispersed in the cell cytoplasm. After 3 h (Figure 4.26. d) the particles appear in all of the 
cells, fluorescing strongly, dispersed in the cell cytoplasm. This suggests that polysorbate 
80™-coated EC nanoparticles cell-uptake time, tu, is in the 1 - 2 h range. 
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   a)       b) 
      
   c)       d) 
Figure 4.26. CLSM images showing the time-scale of polysorbate 80™-coated EC nanoparticles 
(diameter :94 ± 19nm, doped with PTC, green colour) uptake by the living MDA-MB-231 cells, 
passage 180th (stained with 5µM nuclear counterstain DRAQ5™ and 5µg/mL CellMask Deep Red™ 
plasma membrane stain, red colour). The EC particles appear in most of cells and are close to the cell 
membrane after 1 h incubation, Fig. a) and b). After 2h (Fig. c) the particles appear in all of the cells, 
some still close to the cell membrane, some dispersed in the cell cytoplasm. After 3h (Fig. d) the 
particles appear in all of the cells, fluorescing strongly, dispersed in the cell cytoplasm. Plan-
Apochromat 63x/1.4 oil, Ar 488, HFT 488, BP530-600; HeNe 633, HFT 488/543/633, LP650. 
Thus, it was found that the polysorbate 80™-coated EC nanoparticles are suitable to 
be used as a carrier for intracellular drug delivery purposes. After that endoperoxide decay 
times in EC nanoparticles were explored.  
 
Results 
109 
 
4.5.3. Adjustment of Endoperoxide Decay Kinetics in EC Nanoparticles Carrier 
 
EC nanoparticles loaded with N4 and N5 were prepared. It was not possible to prepare 
EC nanoparticles loaded with N2 or N1. Having N1 or N2 in the EC “cocktail” (see Chapter 
3.5.4.1.) caused severe aggregation of EC polymer when dd H2O was poured into the 
„cocktail“ solution. The concentration of N4 and N5 in the aqueous EC suspension was 
determined with a standard addition method measuring UV-absorption, according to 
Lambert-Beer’s law. In both cases a high concentration of loaded naphthalene derivative in 
EC particle suspension was reached. In case of N4 EC particles with diameter of 98 ± 25 nm 
(measured with DLS) and N4 concentration of 0.82 mM in aqueous particle suspension were 
produced. In case of N5 EC particles with average diameter of 136 ± 38 nm (measured with 
DLS) and N5 concentration of 0.42 mM in aqueous particle suspension were produced. 
 Endoperoxide decay of both N4 and N5 in EC particle aqueous suspension at 37 °C 
was examined. In general, the yield of endoperoxide formation was lower than in other 
carriers, liposomes or PVB film or even than in PVB nanoparticles. After 1.5 hours of MB 
sensitzer irradiation at T = 15 °C with laser (λ = 658 nm, P = 70 mW) the yield of N4E in EC 
nanoparticles was only 34 % (Figure 4.27.), and after 16 hours of irradiation the yield was 73 
% (Figure 4.28.). Therefore the endoperoxide building was slower than in PVB nanoparticles, 
when after 0.5 hours of irradiation, the N4E yield was 59%. 
The sensitizer (MB) and irradiation conditions were the same for EC and PVB 
nanoparticles, the lower yield is probably due to much higher concentration of loaded 
naphthalene derivatives in the core of EC particles. Probably most of the embedded N5 or N4 
molecules are in the core of EC particles and not on the surface of particles, which hinders 
the transport of 
1
O2 from iraddiated MB sensitizer dissolved in water (
1
O2 generation 
location) to the naphthalene derivatives in the core of the EC particles (
1
O2 storage location in 
endoperoxide form).  
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Figure 4.27. Semi-logarithmic plot showing N4E decay after short irradiation time of 1.5 h in EC 
nanoparticles (diameter 98±25nm, concentration 130 ppm w/w) at 37 °C measured with N4 
fluorescence time-trace. On y-axis is the percentage of all N4 molecules which are in endoperoxide 
form at each particular time-point. 
Endoperoxides of both N4 and N5 in EC particles showed biexponential decay, with 
FDE and SDE part. Due to a low yield of endoperoxide formation, it was relatively difficult 
to influence on the relative amounts of formed FDE and SDE by varying the procedure 
parameters during the endoperoxide formation. However, by extending the irradiation time 
from 1.5 hours to 16 hours, it was possible to adjust the t1/2 of both FDE and SDE N4E in EC 
particles: t1/2 of FDE was extended from 0.7 h to 8.5 h and t1/2 of SDE from 9.6 h to 24.6 h 
(Figure 4.27. and Figure 4.28. respectively). Both FDE and SDE are stabilized in the carrier 
matrix during the longer irradiation time, due to the process of continuous forming and decay 
of endoperoxides. This will be further discussed in the Chapter 6.1. 
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Figure 4.28. N4E decay after long irradiation time of 16 h in EC nanoparticles (diameter 98 ± 25nm, 
concentration 130 ppm w/w) at 37 °C measured with N4 fluorescence time-trace. On y-axis is the 
percentage of all N4 molecules which are in endoperoxide form at each particular time-point. 
In order to be suitable for a chemosensitivity assay on MDA-MB-231 cancer cells, the 
endoperoxide decay time has to be longer than the cell-uptake time of polysorbate 80-coated 
EC nanoparticles, t1/2 >tu. After short irradiation (1.5 hours) time only SDE part of formed 
endoperoxides have long enough of decay time (Figure 4.27.) to be suitable for cancer cell 
chemosensitivity assay, whereas after long irradiation time (16 hours) both FDE and SDE are 
stable long enough (Figure 4.28.) to satisfy the condition t1/2 >tu. 
OH
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Figure 4.29. Decay of N5E after long irradiation time of 16 h in EC nanoparticles (size: diameter 136 ± 
38 nm, concentration 130 ppm w/w) at 37 °C measured with N5 fluorescence time-trace. On y-axis is 
the percentage of all N5 molecules which are in endoperoxide form at each particular time point. 
 On Figure 4.29. decay of N5E in EC nanoparticles (average diameter 136 ± 38nm) at 
37 °C is shown. Due to the long irradiation time of 16 hours, the N5E formation yield is a 
high 92 %. On top of that, t1/2 of both FDE and SDE, though shorter than those of N4E, are 
suitable for a chemosensitivity assay on MDA-MB-231 cancer cells, t1/2 >tu. Methylene blue 
sensitizer (c = 3 µM) was irradiated with laser (λ = 658nm, P = 70 mW, T =1 5 °C, for t = 16 
h) to form 
1
O2 which reacted with N5 (c = 40 µM) to form N5E (yield 92 %). 
 
4.5.4.  In Vitro Cytotoxicity of 1O2-Relasing Endoperoxides in EC Nanoparticles 
Carrier: Kinetic Chemosensitivity Assay Results   
 
Cytotoxicity of N4E (Figure 4.32.) and N5E (Figure 4.33.) embedded in polysorbate 
80™-coated EC nanoparticles in aqueous suspension on MDA-MB-231 cancer cells using 
crystal violet chemosensitivity assay [111] was tested. But firstly the cytotoxicity of 
polysorbate 80™ surfactant (Figure 4.30.) and of undoped EC nanoparticles (Figure 4.31.) on 
MDA-MB-231 breast cancer cells was tested. From the chemosensitivity assay results for 
polysorbate 80™ on Figure 4.30. it can be concluded that up to 0.005 % (v/v) Polysorbate 
80™ does not affect MDA-MB-231 cancer cell proliferation, whereas in the 0.010-0.020 % 
O
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(v/v) range polysorbate 80™ is cytotoxic with full cell population recovery after 150 h, and 
0.040 % (v/v) Polysorbate 80™ is cytocidal for MDA-MB-231 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30. Chemosensitivity of MDA-MB-231 cells (182nd passage) against surfactant polysorbate 
80™, up to 0.040 % (v/v) in cell medium. H2O was used as a negative growth control (). 
Chemosensitivity of MDA-MB-231 breast cancer cells on unloaded EC nanoparticles 
(diameter 62 ± 15 nm), both non-coated and polysorbate 80™-coated is shown on Figure 
4.31. At a low concentration of 20 ppm (w/w) polysorbate 80™-coated (0.0021 % v/v), 
unloaded EC nanoparticles are not cytotoxic ( symbols on Figure 4.31.) However, with the 
EC nanoparticles concentration increase, a cytotoxic effect of the non-coated unloaded EC 
particles appears: 90 ppm (w/w) non-coated unloaded EC nanoparticles inhibit the cell 
proliferation process up to 50 %, with a full cell population recovery occurring after 180 h 
( symbols on Figure 4.31.) 140 ppm (w/w) non-coated unloaded EC nanoparticles exhibit 
an even stronger cytotoxic effect ( symbols on Figure 4.31.), after which the cell population 
does not fully recover within the assay time-frame (190 h). Hence, the EC nanoparticles 
should not be used for drug-delivery at this or an even higher concentration. Furthermore, 
when the cytotoxic 90 ppm (w/w) EC particles were coated with a polysorbate 80™ cytotoxic 
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concentration of (0.0098 % v/v), a cytostatic effect on the MDA-MB-231 cell proliferation 
occurred ( symbols on Figure 4.31.) Therefore, in order to get a cytotoxic effect by 
1
O2-
releasing endoperoxides, and not by EC nanoparticles, the loading efficiency of such a 
complex carrier system is extremely important.  
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Figure 4.31. Chemosensitivity of MDA-MB-231 cells (181st passage) against non-coated and 
polysorbate 80™-coated unloaded EC nanoparticles (diameter 62±15nm).  EC particles, 20 ppm 
(w/w), polysorbate 80™-coated (0.0021 % v/v);  EC particles, 90 ppm (w/w), non-coated;  EC 
particles, 140 ppm (w/w), non-coated;  EC particles, 90 ppm (w/w), polysorbate 80™-coated 
(0.0098 % v/v); H2O was used as a negative growth control (). 
The cell incubation with a highly-concentrated mixture of 21.5 µM 
1
O2-releasing N4E 
and 5.5 µM N4 embedded in polysorbate 80™-coated EC nanoparticles (diameter 98 ± 25 
nm, concentration 120 ppm w/w) yielded a strong cytocidal effect on proliferation of MDA-
MB-231 cells ( symbols, Figure 4.32.) Methylene blue sensitizer (c = 0.33 µM) was 
irradiated with laser (λ = 658nm, P = 70 mW, T = 4°C, for long irradiation time t = 15 h) to 
form 
1
O2, which reacted with N4 to form N4E (yield 79%). After the irradiation EC particles 
were coated with polysorbate80™, 0.033 % (v/v end-concentration). Non-irradiated 27 µM 
N4 embedded in the same 120 ppm (w/w) EC nanoparticles produced approximately 40 % 
Results 
115 
 
inhibition of cell growth with a cell recovery starting after ca. 125 hours ( symbols, Figure 
4.32.) This effect was probably caused by polysorbate80™ surfactant cytotoxicity (compare 
Figure 4.30.) As a comparison a weak cytostatic effect of 10 µM cisplatin dissolved in 
DMSO is shown: growth of cells is about 70% inhibited and cell population doesn’t recover 
after treatment with 10 µM cisplatin. 
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Figure 4.32. Cytocidal drug effect of highly concentrated N4E (c = 21.5 µM) in Polysorbate 80™-
coated EC nanoparticles on human breast adenocarcinoma cells MDA-MB-231, passage 78, as a 
function of incubation time. On the contrary, non-irradiated N4, c = 27 µM, in the same 
polysorbate80™-coated EC nanoparticles suspension has only an initial inhibitory effect on the cell 
proliferation, after which the cell population recovers (after 125h). As a comparison, a cytostatic effect 
of cisplatin is shown.  N4, 27 µM, in EC nanoparticles, 120 ppm (w/w), coated with polysorbate80™, 
0.033 % (v/v)  N4E, 21.5 µM + N4, 5.5 µM in EC nanoparticles, 120 ppm (w/w), coated with 
polysorbate80™, 0.033 % (v/v),  positive control: Cisplatin, 10 µM in DMSO,  negative control: 
H2O. 
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Figure 4.33. Cytostatic drug effect of N5E in polysorbate 80™-coated EC nanoparticles on human breast cancer 
cells MDA-MB-231, passage 78, as a function of incubation time, comparable to the effect of 10 µM cisplatin 
dissolved in DMSO. Non-irradiated N5 in the same polysorbate 80™-coated EC nanoparticles has only an 
initial inhibitory effect on the cell proliferation, after which the cell population recovers (after ca. 150 h).  N5, 
3.5 µM, in EC nanoparticles, 70 ppm (w/w), coated with polysorbate80™, 0.020 % (v/v);  N5E, 3.0 µM + N5, 
0.5 µM in EC nanoparticles, 70 ppm (w/w), coated with polysorbate80™, 0.020 % (v/v);  N5, 8.4 µM, in EC 
nanoparticles, 50 ppm (w/w), coated with polysorbate80™, 0.020 % (v/v);  N5E, 7.2 µM + N5, 1.2 µM in EC 
nanoparticles, 50 ppm (w/w), coated with polysorbate80™, 0.020 % (v/v);  positive control: cisplatin, 10 µM 
in DMSO;  negative control: H2O. 
The MDA-MB-231 cell incubation with 
1
O2-releasing N5E embedded in polysorbate 
80™-coated EC nanoparticles (two various batches: batch 1: diameter 136±28 nm, 
concentration 50 ppm w/w; batch 2: diameter 122±26 nm, concentration 70 ppm w/w) 
yielded a strong cytostatic effect of about 80 % of growth inhibition compared to the normal 
growth of untreated MDA-MB-231 cells (7.2 µM N5E in batch 1 (50 ppm w/w) EC 
nanoparticles,  symbols, Figure 4.33. and 3.0 µM N5E in batch 2 (70 ppm w/w) EC 
nanoparticles,  symbols, Figure 4.33.) MB sensitizer (c = 0.2 µM) was irradiated with laser 
(λ = 658nm, P= 70 mW, T = 4°C, for long irradiation time t = 15 h) to form 
1
O2 and 
subsequently N5E (yield 86 %). After the irradiation EC particles were coated with 
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polysorbate80™, 0.020 % (v/v in cell medium). Cytostatic effect of N5E in polysorbate 
80™-coated EC nanoparticles is comparable to the effect of 10 µM cisplatin dissolved in 
DMSO on the growth of MDA-MB-231 cancer cells. On the contrary, non-irradiated 8.4 µM 
N5 embedded in the batch 1 (50 ppm w/w) EC nanoparticles produced approximately 60 % 
inhibition of cell growth with a cell recovery after ca. 150 hours ( symbols, Figure 4.33.). 
Similar effect had non-irradiated 3.5 µM N5 embedded in the batch 2 (70 ppm w/w) EC 
nanoparticles: inhibiting the cell growth for approximately 75 % with a cell recovery after ca. 
150 hours ( symbols, Figure 4.33.). This cytotoxic effect of non-irradiated N5 is rather 
caused by the cytotoxicity of 0.020 % (v/v) polysorbate80™ surfactant (compare results on 
Figure 4.30.) and for batch 2 by the cytotoxicity of 70 ppm (w/w) EC nanoparticles (compare 
results on Figure 4.30.) 
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4.6. ENDOPEROXIDE DECAY AND CYTOTOXICITY OF POLY(1,4-
DIMETHYL-2-VINYLNAPHTHALENE) NANOPARTICLES  
 
Poly(1,4-dimethyl-2-vinylnaphthalene) nanoparticles were prepared as described in 
Chapter 3.3.5. To determine the cell uptake of N7 nanoparticles by the MDA-MB-231 breast 
cancer cells the CLSM technique was used. In order to enable their detection with CLSM, 
coating of N7 nanoparticles (average diameter 12 ± 3 nm) with PTC fluorescencing dye was 
tried, but was rather unsuccessful. Thus, it was not possible to determine if N7 nanoparticles 
do permeate the MDA-MB-231 cells and what is their cell-uptake time. 
 
4.6.1. Endoperoxide Formation in Poly(1,4-Dimethyl-2-Vinylnaphthalene) 
Nanoparticles 
N7E formation and decay were traced with N6 absorption (294 nm) intensity change. 
In general, the yield of endoperoxide formation was relatively low, see Figure 4.34. After 7 
hours of MB sensitizer (c = 3 µM) irradiation with laser (λ=658nm, P=70 mW, T=4°C) a 
saturation value of endoperoxide yield of 45 % was reached. Such a low yield complies with 
the explanation of endoperoxide formation yields in PVB and EC nanoparticles. Namely, due 
to a high concentration of N6 in aqueous suspension and the necessary transport of 
1
O2 from 
iraddiated MB sensitizer dissolved in water (
1
O2 generation location) to the N7 in the core of 
its nanoparticles (
1
O2 storage location in endoperoxide form), the endoperoxide yield is low. 
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Figure 4.34. N7E formation yield in N7 nanoparticles at 4°C depending on laser irradiation-time 
measured with N6 absorbance change.  
*
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4.6.2. Endoperoxide Decay Kinetics in Poly(1,4-Dimethyl-2-Vinylnaphthalene) 
Nanoparticles 
 
0 2 4 6 8 10
32
34
36
38
40
42
 
 
t1/2(2)= 39.7 h
t1/2(1)=6.8 h
t [h]
%
 e
n
d
o
p
e
ro
x
id
e
s
T = 37 °C
 
Figure 4.35. Decay of N7E in form of nanoparticles (size: diameter 12 ± 3 nm,) at 37 °C measured 
with N6 absorbance change, after long (t = 9 h) laser irradiation of MB sensitizer (c= 3 µM). On y-axis 
is the percentage of all N6 molecules which are in endoperoxide form at each particular time-point.  
On Figure 4.35. the biexponential decay of N7E (in form of 12 ± 3 nm nanoparticles) 
is shown. Methylene blue sensitizer (c= 3 µM) was irradiated with laser (λ = 658 nm, P = 70 
mW, T = 4°C, for t = 9 h) to form 
1
O2 which reacted with N7 polymer (N6 concentration in 
aqueous suspension = 0.2 mM) to form N7E (yield 42 %). Both FDE with decay-time of 6.8 
hours and SDE with decay-time of 39.7 hours at the human body temperature of 37 °C are 
suitable for cancer cell chemosensitivity assay. 
 
4.6.3. In Vitro Cytotoxicity of 1O2-Releasing Endoperoxides in N7 Nanoparticles 
Carrier: Kinetic Chemosensitivity Assay Results  
 
Cytotoxicity of various sizes and concentrations (measured with absorption: 
corresponding to N6 monomer) of non-irradiated N7 nanoparticles in aqueous suspension on 
MDA-MB-231 cancer cells using crystal violet chemosensitivity assay was tested (see Figure 
4.36.) With the increase of non-coated N7 (diameter 12 ± 3 nm) particles concentration in 
aqueous suspension, their cytotoxicity increases: at low concentration of c(N6) = 0.4 µM, 
there is no influence on the growth of MDA-MB-231 cancer cells by the N7 particles ( 
*
*
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symbols on Figure 4.36.); whereas 1.9 µM N7 nanoparticles are cytotoxic and inhibit the 
MDA-MB-231 cell growth for about 50 % after 235 hours ( symbols on Figure 4.36.); and 
6.3 µM N7 nanoparticles (	 symbols on Figure 4.36.) show a cytostatic effect comparable to 
the effect of 100 nM vinblastine ( symbols on Figure 4.36.), a known potent cytostatic drug 
used as a positive chemosensitivity control. 
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Figure 4.36. The chemosensitivity of MDA-MB-231 cancer cells, passage 64, on various sizes and 
concentrations of N7 in form of nanoparticles.  N7, 0.4 µM, non-coated nanoparticles, diameter 12 ± 
3 nm;  N7, 1.9 µM, non-coated nanoparticles, diameter 12 ± 3 nm; 	 N7, 6.3 µM, non-coated 
nanoparticles, diameter 12 ± 3 nm;  N7, 12.5 µM, polysorbate80™-coated (0.005% v/v) 
nanoparticles, diameter 58 ± 9 nm;  N7, 50.0 µM, polysorbate80™-coated (0.020% v/v) 
nanoparticles, diameter 58 ± 9 nm  positive control: vinblastine, 100 nM,  negative control: H2O. 
On the other hand, larger N7 particles of 58 ± 9 nm average diameter were much less 
cytotoxic: 12.5 µM non-irradiated N7 polysorbate80™-coated (0.005 % v/v) nanoparticles 
showed no inhibitory effect on MDA-MB-231 cell growh ( symbols on Figure 4.36.) even 
though they were in a much higher concentration in comparison to non-coated N7 particles of 
12 ± 3 nm diameter. Only at very high N7 concentration of 50.0 µM, do polysorbate 80™-
coated (0.02 % v/v) non-irradiated N7 (58 ± 9 nm) nanoparticles inhibit the cell proliferation 
(
 symbols on Figure 4.36.), for about 50% after 100 hours with subsequent cell culture 
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recovery (full recovery reached after 220 h). Probably the majority of this cytotoxic effect is 
caused by 0.02 % v/v polysorbate 80™ toxicity: compare with Figure 4.30. 
The cytotoxicity of N7E in nanoparticle form on MDA-MB-231 human cancer cells 
was tested in the same concentration range and compared with the cytotoxicity of non-
irradiated N7 nanoparticles, see Figure 4.37. and Figure 4.38. Unfortunately, a mixture of 
N7E and N7 ( symbols on Figure 4.37.) showed no cytotoxicity increase in comparison to 
non-irradiated N7 nanoparticles (diameter 12 ± 3 nm,  symbols on Figure 4.37.), as seen on 
the example of 1.9 µM N7 nanoparticles and the mixture of 0.7 µM N7E, and 1.2 µM N7. 
Remarkably, the cytotoxicity of N7 nanoparticles (diameter 12 ± 3 nm) regularly decreased 
when endoperoxides were formed in the whole N7 concentration range shown on Figure 
4.36. N7E formation: 25 nM MB sensitizer was irradiated with laser (λ = 658nm, P = 70 
mW, T = 20 °C, for long time t = 15 h) to form 
1
O2 which reacted with N7 to form N7E 
(yield 36 %). 
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Figure 4.37. Chemosensitivity of MDA-MB-231 cells, passage 64, to N7E and N7 in form of non-
coated nanoparticles (diameter 12 ± 3nm).  N7, 1.9 µM, non-coated nanoparticles;  N7E, 0.7 µM, 
+ N7, 1.2 µM in non-coated nanoparticles;  positive control: vinblastine, 100 nM,  negative control: 
H2O. 
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The cell damage mechanism by N7 nanoparticles is unknown. Perhaps the very small 
N7 nanoparticles interact with cell DNA. Therefore, further chemosensitivity assay 
experiments with larger N7 nanoparticles (58 ± 9 nm average diameter) were performed. 12.5 
µM non-irradiated N7 polysorbate80™-coated (0.005% v/v) nanoparticles of this size 
showed no inhibitory effect on MDA-MB-231 cell growh ( symbols, Figure 4.38.) 
However, when 41 % of N7 reacted upon irradiation to form N7E in polysorbate80™-coated 
(0.005% v/v) nanoparticles, a weak inhibitory effect of about 30 % on cell proliferation ( 
symbols, Figure 4.38.) ocurred, with cell recovery after 150 h.  
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Figure 4.38. The cytotoxic effect of 1O2-releasing N7E in polysorbate80™-coated nanoparticles 
(diameter 58 ± 9nm) on MDA-MB-231 cell growth, passage 79, determined by the crystal violet assay. 
 N7, 12.5 µM, polysorbate 80 ™-coated (0.005% v/v) nanoparticles;  N7E, 5.1 µM, + N7, 7.4 µM 
polysorbate 80 ™-coated (0.005% v/v) nanoparticles;  N7, 50.0 µM, polysorbate 80™-coated 
(0.020% v/v) nanoparticles;  N7E, 20.5 µM, + N7, 29.5 µM polysorbate 80™-coated (0.020% v/v) 
nanoparticles;  positive control: cisplatin, 5 µM in DMSO,  negative control: H2O. 
When the N7 concentration was increased to 50.0 µM, both non-irradiated N7 
polysorbate80™-coated (0.020% v/v) nanoparticles ( symbols on Figure 4.38.), and a 
mixture of 41% formed N7E and 59 % N7 in polysorbate80™-coated (0.020% v/v) 
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nanoparticles ( symbols on Figure 4.38.) made a cytotoxic effect on the MDA-MB-231 cell 
proliferation. The inhibitory effect (rather by N7 nanoparticles than 
1
O2-releasing N7E) on 
the cell growth was 60 % after 100 hours with subsequent cell recovery: full recovery after 
220 h. N7E formation: 40 nM methylene blue sensitizer was irradiated with laser (λ = 
658nm, P = 70 mW, T = 20 °C, for t = 13 h) generating 
1
O2 which reacted with N7 to form 
N7E (yield 41 %). After irradiation nanoparticles were coated with polysorbate80™. 
N7 nanoparticles with 95 ±10 nm average diameter were prepared, as well, for details 
see Chapter 4.1.2. However, the concentration (corresponding to the monomer N6) of such 
particles in aqueous suspension was rather low. The highest reached concentration in cell 
medium was 1.4 µM (size 95 ± 10 nm). Due to such a low concentration neither 
polysorbate80™-coated (0.01% v/v) N7 nanoparticles, nor its polysorbate80™-coated 
(0.01% v/v) endoperoxides showed any inhibitory effect on the growth of MDA-MB-231 
cells. 
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5. NAPHTHYL-SUBSTITUTED PORPHYRIN 
MULTICHROMOPHORE MOLECULES FOR THE SELF-
PHOTOSENSITIZED FORMATION OF ENDOPEROXIDES  
5.1. INTRODUCTION 
 
In another project of this work it was desired to synthesize and characterize 
multichromophore molecules consisting of up to four endoperoxide-forming aromatic units 
(derivatives of N1) covalently linked to a red-light absorbing photosensitizer core (porphyrin 
derivatives). Such a system would combine the useful properties of tetrapyrrole derivatives as 
a sensitizer for photodynamic therapy with the ability of aromatic endoperoxides to release 
1
O2 and thus would have an internal reactivity to generate and “store” 
1
O2.  
5.2. EXPERIMENTAL 
5.2.1. Materials and Methods 
 
The starting compounds and 1,3-diphenylisobenzofurane (DPBF) were obtained 
commercially from Sigma–Aldrich and were used without further purification. All reactions 
were carried out under nitrogen atmosphere in degassed solvents, which were dried using 
conventional methods. 
NMR spectra were recorded with a Bruker Avance Spectrometer (
1
H: 200 MHz; T = 
308 K). Additionally, higher-resolved 
1
H and 
13
C HMBC spectra were recorded using a 
Bruker NMR spectrometer operating at 500 MHz for 
1
H and 125.725 MHz for 
13
C. The 
chemical shifts are reported in ppm releative to external standards (solvent residual peak) and 
coupling constants are given in Hertz.  
EI-MS spectra were obtained with a Varian CH-5 spectrometer. 
Electronic absorption spectra were recorded with a Varian Cary 300 Bio UV/Vis 
spectrophotometer and fluorescence spectra were obtained using a Horiba Jobin Yvon 
Fluorolog-3 spectrofluorometer equipped with two double-grating monochromators, a R928P 
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photomultiplier, and an FL-1040 phosphorimeter using Uvasol quality solvents and teflon 
stoppered 1-cm quartz cells under aerobic conditions. 
5.2.2. Synthesis of 5,10,15,20-Tetrakis-(4-Methyl-Naphthyl)Porphyrin (P1)  
 
To a refluxing mixture of 100 ml propionic acid, 850mg (5 mmol) 4-
methylnaphthaldehyde, and 0.34 ml (4.9 mmol) of freshly distilled pyrrole were added. This 
mixture was refluxed for 10 days. Then the mixture was poured on 750ml of water and the 
precipitate formed was filtered off and dried. The raw material was purified by extensive 
column chromatoghaphy (SiO2, pentane/toluene), and the first orange-red fraction was 
collected to obtain the pure free ligand P1. The compound was analysed with mass 
spectrometry and NMR. 
 
ESI-MS (dichloromethane/methanol 1:1, positive ion mode): m/z 871.5 ([P1+H]
+
);  
ESI-MS (dichloromethane/methanol 1:1, negative ion mode): m/z 743.8 ([P1-C10H6]
-
);  
 
1
H NMR (200 MHz, CD2Cl2): δ -2.21 (s, 2H, pyrrole-NH), 3.07 (s, 12H, 4 CH3), 5.9 & 6.6 
(CH=CH of endoperoxide form), 7.24 (m, 8H), 7. 57 (t, J =7.15 Hz, 4H), 7.78 (d, J =7.6 Hz, 
4H), 8.23 (m, 4H), 8.36 (d, J =8.7Hz, 4H), 8.52 (s, ß-pyrolle 8H) 
 
5.2.3. Metalation of P1 
 
200 mg of the ligand P1 (0,23mmol) were dissolved in CHCl3:CH3OH (1:1, v/v) and 
2g (ca. 9 mmol) of zinc-acetate tetrahydrate dissolved in 1ml of glacial acetic acid was added. 
The reaction mixture was refluxed on a water bath for 2 hours. Within this time the 
metallation was completed as could be seen by UV-Vis spectroscopy. The mixture was 
washed free of unreacted salts and the zinc complex P2 was purified by column 
chromatography (SiO2, chloroform). The first deeply coloured band was collected, yielding a 
purple-red product after slow evaporation of the solvent, which was analysed with mass 
spectrometry and NMR. 
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EI-MS (dichloromethane/methanol 1:1 + 10 mM NH4OAc, positive ion mode): m/z 548.3 
([M1+NH4]
+
); 932.2 (M
+
); 933.2 ([M+H]
+
); 966.9 ([M + H+ O2]
+
); 994.6 ([M +H+ 2 O2]
 +
); 
1030.7 [M +H + 3 O2]
 +
); 1058.9 ([M + H + 4 O2]
+
); 1079.0 ([M + H+4 O2 + OH]
 +
); 1111.3 
([M + H+4 O2 + 3 OH]
 +
) 
EI-MS (dichloromethane/methanol 1:1 + 10 mM NH4OAc, negative ion mode):  
m/z 529.4 ([M1 - H]
-
); 565.4 ([M1 + Cl]
 -
); 967.3 ([M + Cl]
 -
); 991.4 ([M + CH3COO]
-
);  
M= P2 = 932 Da, M1 = M+ 4 O2 = 1060/2=530 Da 
 
1
H NMR, (200 MHz, CD2Cl2) 
δ 3.01 (s, 12H, 4 –CH3), 6.7 (s, CH=CH of endoperoxide form), 7.20 (m, 8H), 7. 56 (t, J =7.5 
Hz, 4H), 7.76 (d, J =7.8 Hz, 4H), 8.20 (dd, J =3.2 Hz, 4H), 8.34 (d, J =8.7Hz, 4H), 8.62 (s, ß-
pyrolle 8H) 
1
H NMR, 
13
C NMR (500 MHz, CDCl3) 
δC/δH 133.05/8.56 (ß-pyrolle 8H), the assignment of methylnaphthyl substituent is given in 
the Table 5.1. 
 
Table 5.1. 
1
H-NMR, 
13
C-NMR, HMBC data for P2 compound. 
Atom number δC δH 
C1   
C1’ 133.0 / 
C2’ 126.2 7.67 
C3’ 125.0 8.25 
C4’ 135.9 / 
C4’a 126.7 / 
C5’ 130.7 7.25 
C6’ 126.7 7.09 
C7’ 126.3 7.50 
C8’ 130.7 7.25 
C8’a 139.4 / 
C9’ 21.0 3.01 
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5.2.4. Self-Sensitized Peroxidation of P2 Complex 
 
P2 was dissolved in dichloromethane and irradiated with the full light of a high-
pressure xenon lamp passing through a Schott GG 475 nm cut-off filter and a water-cooled 
infra-red filter. During the irradiation procedure solution of P2 was constantly saturated with 
O2. Light power in Q band region of P2 was 11.3 mW cm
-2
. The progress of peroxidation 
reaction was monitored by observing the appearance of endoperoxide peaks using 
1
H NMR 
spectroscopy.  
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5.2.5. Singlet Oxygen Assay 
 
Photosensitized singlet oxygen generation by novel 5,10,15,20-tetrakis-(4-methyl-
naphthyl)porphyrinato-zinc(II) (P2) and zinc(II)-meso-tetraphenylporphyrin (ZnTPP) as a 
reference was monitored in aerobic toluene solution at room temperature by following the 
time-dependence of DPBF absorption at 412 nm depending on sample irradiation time. DPBF 
was acting as a 
1
O2 scavenger [143]. The absorbencies of Q-band maxima of both P2 and 
ZnTPP were set to approximately identical values of ca. 0.05. DPBF in toluene was added to 
a final concentration of 3 ×10
-5
 M and 2.0 ml samples were irradiated with the 533-548 nm 
polychromatic light of Hanovia Xe/Hg 977 B-1 lamp at ambient air conditions. Sample area 
of 2.02 cm
2 
was irradiated with light power density of 1.8 mW cm
-2
, which was measured 
with a Luzchem Research spectroradiometer SPR-4001. After each irradiation cycle DPBF 
absorbance at 412 nm was measured and sample absorbance value at 412 nm was deducted 
from it. As a control, only 2% bleaching of DPBF occurred during irradiation at the same 
conditions in absence of a 
1
O2 producing porphyrin-derivative sample. 
The 
1
O2 quantum yields were determined using the following equation 
   (15) 
where C0 and Ct are the DPBF concentration prior to and after irradiation, respectively, V the 
reaction volume, S the irradiated area of the cell, t the irradiation time per cycle, NA the 
Avogadro’s number and Iabs the overlap integral of the irradiation light source intensity and 
the absorption of the particular sensitizer in the Q band region and is defined as 
 
   (16) 
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where Iλ is the intensity of light and Aλ the absorbance of the sensitizer at wavelength λ. 
Values of C0 and Ct  after irradiation were calculated using the extinction coefficient of DPBF 
in toluene, εtoluene = 21 000 l mol
-1
 cm
-1
 [144]. 
 
5.3. RESULTS AND DISCUSSION 
 
5.3.1. Characterization of Novel Multichromophore Molecules 
 
5,10,15,20-tetrakis-(4-methyl-naphthyl)porphyrin (P1) was synthesized using the 
Adler method [145] and used as a precursor for synthesis of 5,10,15,20-tetrakis-(4-methyl-
naphthyl)porphyrinato-zinc(II) (P2), according to the reaction sequence shown in Scheme 5. 
Both substances were obtained as dark red powder materials and characterized with mass 
spectroscopy, NMR, and electronic absorption and emission. 
 
Scheme 5. Synthesis pathway of P1 and P2 with Adler method. 
 
The electronic spectra of the functionalized porphyrin derivatives P1 and P2 were 
recorded in ethanol or chloroform solution. Fig. 5.1.a shows typical electronic absorption 
spectra of the free-base ligand P1 and the zinc complex P2 in chloroform and in Fig. 5.1.b 
extinction molar coefficient values of complex P2 in ethanol are given. The absorption 
maximum at 425 nm corresponds to the Soret, or B band of P1. The free-base porphyrin 
complex shows the typical pattern of four Q bands in the visible spectral region with a 
phyllo-type intensity distribution. A further, weak absorption feature in the 280-300 nm 
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region is present and attributed to the pi-electron system of the methylnaphthyl substituent. 
Metalation of P1 causes a small Soret maximum redshift in P2 spectrum (Fig. 5.1.a), and a 
change of Q band with only one maximum at 551 nm.  
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Figure 5.1. a) Absorption spectrum of P1 and P2 compounds in chloroform. b) Molar extinction 
coefficient of P2 in ethanol. 
 
A relatively strong electronic coupling of the porphyrin core with methylnaphthyl 
substituents occurs and causes an antenna effect by excitation of methylnaphthyl subsituents 
to porphyrin luminescence in multichromophore complexes P1 and P2, see Figs. 5.2. a) and 
5.3. a), respectively. When complex P1 is excited at 290 nm absorption of methylnaphthyl 
substituent, a weak emission around 380 nm, coming from methylnaphthyl side-groups and a 
strong energy transfer (the antenna effect) to the porphyrin emitting part of the P1 compound 
appears, with peaks at 650 nm and 716 nm, respectively (Fig. 5. 2. a). Excitation spectrum for 
650 nm emission (shown in Fig. 5.2. c) confirms the antenna effect. For comparison the 
porphyrin emission with Soret band excitation is given in Fig. 5.2. b). 
On Fig. 5. 2. a) there are several artifacts: solvent Raman spectrum peaks at 317 nm and re-
absorption by the porphyrin Soret-band at 425 nm.  
The excitation spectra for 650 nm emission (Fig. 5.2. c) and for 716 nm porphyrin 
emission bands of P1 multichromophore compound do match. Excitations of both the 
naphthyl substituent (UV region) and Soret- and Q-bands of the porphyrin core cause the red 
light emission by P1. 
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Figure 5.2. P1 luminescence (a and b) and excitation (c) spectra in CHCl3. Excitation of methylnaphthyl side-
group with 290 nm (a) and in the Soret band of the porphyrin core with 420 nm light (b), respectively.  
Naphthyl-Subst ituted Porphyrin Mult ichromophore Molecules for the 
Self-Photosensit ized Formation Of Endoperoxides 
132 
 
300 400 500 600 700 800
300 350 400 450 500
* solvent Raman spectrum
em
iss
ion
Wavelength /nm
*
e
m
is
s
io
n
wavelength [nm]
 excitation 284 nm
**
**  excitation  wavelength, 2nd ordera)
500 550 600 650 700 750 800
e
m
is
s
io
n
wavelength [nm]
 Soret band excitation
 Q band excitation
b)
 
Figure 5.3. Luminescence spectra of P2 in CHCl3. a) Excitation of methylnaphthyl side-group of P2 
with 290 nm. b) Soret band (427 nm) and Q band (551nm) excitation of the porphyrin core of P2 
complex.  
When complex P2 is excited at 284 nm absorption of methylnaphthyl substituent, a 
very weak methylnaphthyl substituents’ emission around 330 nm and a strong energy transfer 
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(antenna effect) to the S1 state of porphyrin emitting part of the P2 complex with peaks at 
605 nm and 652 nm appear, see Fig. 5.3. a). Moreover, a weaker emission from porphyrin S2 
state occurs with maximum at 440 nm. S2 porphyrin emission of compound P1 does not 
appear, compare Fig. 5.2. a). For comparison the porphyrin S1 state emission after Soret band 
excitation is given in Fig. 5.3. b). On Fig. 5.3. a) there is an artifact of solvent Raman 
spectrum at 310 nm.  
On Fig. 5.4. the excitation spectra, which confirm that emission around 440 nm is by 
the S2 state of the porphyrin core and the emission around 650 nm is by the porphyrin S1 
state, are shown. On top of that, the excitation spectrum of S1 state on Fig. 5.4. b) confirms 
the antenna effect from methylnaphthyl substituents to the S1 state of the porphyrin core. 
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Figure 5.4. a) Excitation spectrum for the 445 nm S2 emission band; and b) for the 652 nm S1 
emission band of the P2 compound’s porphyrin core. 
 
5.3.2. Photogeneration of Singlet Oxygen by P2 Complex 
 
A standard assay with 1,3-diphenylisobenzofurane (DPBF) as singlet oxygen (
1
O2) 
scavenger was used to track the well-known 
1
O2 generation by the commercial reference 
sensitizer zinc(II)-meso-tetraphenylporphyrin (ZnTPP) and by complex P2. As shown in  
Fig. 5.5. the formation rate of 
1
O2 by multichromophore complex P2, when its oxygen 
saturated solution is irradiated in the Q band region, is very similar to the 
1
O2 formation rate 
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by ZnTPP reference under the same conditions. The curve profiles on Fig. 5.5. suggest a 
rapid consumption of the dissolved dioxygen in the teflon-stoppered cuvettes used in the 
assay. 
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Figure 5.5. Photosensitized singlet oxygen generation by 4 µM P2 and 3 µM ZnTPP reference 
detected with 412 nm DPBF absorption assay in oxygen saturated toluene solution at room 
temperature.  
Both the ZnTPP reference and novel multichromophore P2 complex were irradiated 
in the Q band region because irradiation in the Soret band caused immediate photobleaching 
of the DPBF 
1
O2 trap. Moreover, using other light sources with stronger light intensity in the 
sensitizer Q band region caused even faster consumption of the dissolved dioxygen. 
Therefore, the 533-548 nm polychromatic light source with light intensity of about 10
14
 
photons s
-1
 cm
-2
, although not at the Q band maximum, showed to be best suitable for this 
assay.  
Singlet oxygen yields, Φ∆ , integrated over the overlap of the irradiation light source 
intensity and the absorption of each sensitizer were obtained from equations [146] and Stern-
Volmer plots described in detail in literature [147] and are given in Table 5.2. The deviation 
of values obtained by our measurement from published values [147] is presumably caused by 
our inability to precisely measure and tune the light intensity used for sample irradiation. 
Therefore, both values were corrected with the same factor to reach the published yield value 
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of 0.94 for ZnTPP reference in toluene [147]. Nevertheless, Φ∆ of complex P2 is very similar 
to the Φ∆ of ZnTPP reference sensitizer, as values in Table 5.2. show. 
Table 5.2. Singlet oxygen quantum yields, Φ∆, of ZnTPP and ZnTMNP obtained with 
chemical quenching of DPBF in comparison to published values. 
compound λ
a
(nm) solvent Φ∆, measured Φ∆, 
corrected 
ZnTPP 546 toluene 0.45 0.94 
P2 546 toluene 0.41 0.86 
a sample irradiation wavelength 
 
5.3.3. Endoperoxide Formation on Methylnaphthyl Substituents of P2 Complex 
 
When it was established that P2 reacts with dioxygen to generate 
1
O2 upon short 
irradiation times, reaction of singlet oxygen with methylnaphthyl substituents of complex P2 
to form endoperoxides [12, 31] after longer irradiation (reaction) times and possible 
subsequent release of reactive oxygen species [13, 148] was investigated. Using 
1
H-NMR and 
mass spectroscopy it was found that a very small, non-quantifiable portion of both P1 and P2 
in solid state reacted spontaneously with ambient oxygen under room light to form 
endoperoxides (
1
H-NMR weak peaks at 5.9 and 6.6 ppm, respectively), although the whole 
synthesis and purification procedure of both P1 and P2 complexes were performed under 
sunlight protection. 
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Scheme 6. P2 photooxidation to a mixture of endoperoxides on methylnaphthyl substituents (P2E) 
and photobleaching products (P3). 
Moreover, a constantly oxygen-saturated solution of multichromophore complex P2 
in dichloromethane was irradiated up to several hours, firstly in the Soret band region and 
later in the Q-band region. It was found that the Soret band irradiation causes a rather fast (in 
less than 1 hour) photobleaching process of compound P2. However, when the oxygen 
saturated solution of P2 was irradiated in the Q band region with less light intensity, a 
mixture of endoperoxides on naphthyl substituents (P2E) and undefined photobleaching 
products (P3) was formed, according to Scheme 6. The endoperoxide formation reaction was 
confirmed with 
1
H-NMR, electronic absorption and mass spectroscopy.  
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Figure 5.6. 1H NMR spectrum of the P2 complex in CD2Cl2 at 298 K. Below are numbers of protons 
corresponding to each peak. 
On Fig. 5.6. a 
1
H NMR spectrum of non-irradiated ZnTMNP (P2) in CD2Cl2 is 
shown. Below the spectrum numbers of protons corresponding to each peak are given. As can 
be seen on Fig. 5.7., upon longer irradiation of P2 in the Q band region under aerobic 
conditions, a significant change in both the aromatic region and the methyl region of 
1
H 
NMR occurs. Peaks assigned to complex 2 decrease and multiple new peaks appear: the 
multiplet around 2.7 ppm (Fig. 5.7. a) probably corresponds to methyl group protons [31, 34] 
of formed various number of methylnaphthyl-1,4-endoperoxide substituents and the multiplet 
in the aromatic region at about 6.55 ppm (Fig. 5.7. b) corresponds to 2 protons on HC=CH 
double-bond [31, 34] of methylnaphthyl-1,4-endoperoxide substituents. Due to formation of a 
mixture with various numbers (1-4) of endoperoxide substituents, P2E, a multiplet and not a 
singlet peak appears. Due to the undefined ptohobleaching products, several unassigned new 
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peaks appear in the aromatic region, which compromises the sensitizing potential of 
compound P2 after several hours of irradiation. 
a) 
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Figure 5.7. a) 1H NMR spectra in MeOD at 308 K of the –CH3 region showing the photooxidation 
reaction of P2 to a mixture of P2E and P3 after various irradiation times of P2 in the Q band region 
under aerobic conditions in CH2Cl2. b) 
1H NMR spectra of the aromatic region showing the 
photooxidation reaction of P2 to a mixture of P2E and P3 taken under same conditions as in Fig. a). 
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The photoproducts P2E and P3 were not isolated because a preparative amount of 
material after irradiation was not available. 
The reaction mixture of P2, P2E and P3 after various irradiation times was analysed 
using mass spectroscopy and 932.20 m/z peak of complex P2 was detected, as well as 965.20 
peak assigned to cation of P2E with one endoperoxide containing substituent.  
On Fig. 5.8. the change of electronic absorption spectra depending on the irradiation 
time in the Q band region of P2 under aerobic conditions is shown. The longer the irradiation 
time, the less is absorbance in both Soret and Q band, with a slight blueshift of both bands. 
After 13 h of irradiation the photobleaching of P2 is almost complete: the porphyrin core 
opens up and the absorption in the UV region rises probably due to the absorption of single 
pyrrole rings which were previously forming the porphyrin core. 
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Figure 5.8. Electronic absorption spectra of P2 and photoproducts showing the photooxidation 
reaction and the degradation of P2 upon irradiation in the Q band region under aerobic conditions in 
CH2Cl2. 
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5.3.4. In Vitro Cytotoxicity of Non-Irradiated P2 Complex 
 
In vitro cytotoxicity of non-irradiated (5,10,15,20-tetrakis-(4-methyl-
naphthyl)porphyrinato-zinc(II) (P2) sensitizer on MDA-MB-231 human breast cancer cells 
was also tested with the kinetic crystal violet chemosensitivity assay [111], see Fig. 5.9. The 
results were compared with cisplatin, a known cytostatic drug, which served as a positive 
control.  
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Figure 5.9. Non-inhibitory effect of non-irradiated 1-10 µM P2 multichromophore on the proliferation of 
human MDA-MB-231 breast cancer cells, passage 179th, as a function of incubation time.  
It was determined that non-irradiated complex P2 in a 1-10 µM concentration range 
has only a minor initial inhibitory effect of about 30 % on the MDA-MB-231 cells 
proliferation, after which the cell population quickly recovers. Comparable cisplatin 
concentrations show a strong cytocidal effect (10 µM) and a cytostatic effect (3 µM) without 
cell recovery. Therefore, non-irradiated ZnTMNP diplays no cytotoxicity even at high 
concentrations up to 10 µM and could potentially be used in therapeutical applications such 
as PDT. Possible cytotoxicity of P2 photooxidation products should be tested. 
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5.4. OUTLOOK: P1 AND P2 COMPLEXES’ POSSIBLE MEDICAL 
APPLICATIONS 
 
To sum up, the novel P2 complex acts as a sensitizer, similar to the standard sensitizer 
ZnTPP, yielding 
1
O2 after short irradiation times and after longer irradiation with long-
wavelength light (in the Q-band region) it reacts with singlet oxygen to form endoperoxides 
which could potentially act as an internal source of 
1
O2 in photodynamic therapy. Possible 
1
O2-release from formed endoperoxide substituents in complex P2E should be further 
researched. Such a multichromophore system would then have a much broader time interval 
of singlet oxygen production than typical sensitizers, which generate 
1
O2 only during the light 
irradiation itself. Hence it could possibly be used in a broad application range, such as 
chemotherapeutical applications with delayed triggering of singlet oxygen release inducing 
cellular damage in malignant tissue [12], or potential utilization of biomimetic endoperoxide-
bond cleavage processes for the controlled deactivation of bacteria, viruses [149] and 
parasites such as Plasmodium falciparum, which is known to be responsible for the majority 
of fatal malaria infections [150]. 
 
5.5. CONCLUSION 
 
Synthesis and characterization of two novel functionalized multichromophore 
molecules such as 5,10,15,20-tetrakis-(4-methylnaphthyl)porphyrin) (P1) and (5,10,15,20-
tetrakis-(4-methyl-naphthyl)porphyrinato-zinc(II) (P2), is reported. These complexes were 
designed to act as sensitizers and moreover to enable singlet oxygen “storage” in 
endoperoxide bridges on their peripheral naphthyl substituents after self-sensitized 
peroxidation. Their photophysics and photochemical behaviour in the presence of dioxygen 
was investigated. Singlet oxygen yield of P2 as a sensitizer was determined. Photooxidation 
reaction products of P2 after irradiation in dioxygen presence were investigated. It could be 
shown by several spectroscopic methods (NMR, MS) that upon exposure to long-wavelength 
visible light, these multichromophore systems are forming 
1
O2-derived adducts with up to 
four endoperoxide subunits attached to their peripheric aromatic substituents. 
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6. DISCUSSION AND OUTLOOK 
In this chapter the adjustability of the endoperoxide (of various 1,4-
dimethylnaphthalene derivatives) decay kinetics in various matrices, for the concept of 
controlled 
1
O2 release as stated in Chapter 2 is discussed. It will be shown that such an 
adjustment of decay kinetics is a general principle. On the example of anti-cancer treatment 
possible applications of this concept are demonstrated.  
One of the main goals of this work was to search for an endoperoxide-carrier matrix 
combination and a preparation procedure providing a much longer 
1
O2-release time, t1/2, than 
the time period required for the cellular uptake (tu) of the carrier. Another goal was to analyse 
the decay kinetics on the basis of the knowledge of the endoperoxide decay process, in 
particular concerning structural changes of the endoperoxide molecule during the decay 
process. 
 
6.1. COMBINED DISCUSSION OF THE ENDOPEROXIDE DECAY 
KINETICS IN VARIOUS CARRIER MATRICES  
6.1.1. Mechanistic Properties of Aromatic Endoperoxides Decay 
A three dimensional schematic drawing for the illustration of the molecule geometry 
change occuring during the decay process is here introduced and used as the basis for the 
microscopic model (see Chapter 6.1.2.) explaining the decay kinetics.  
 
Figure 6.1. Mechanism of the endoperoxide decay: 1,4-cyclohexadiene moiety in endoperoxide 
molecule is bent for the angle φ and has to revert to the planar benzene ring releasing singlet oxygen 
during the decay process. 
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Unlike the planar aromatic “parent molecule”, the 1,4-cyclohexadiene moiety of the 
tricyclic endoperoxides (used in this work) is bent for an angle φ  between plane (C9C1C4C10) 
and plane (C1C2C3C4), as shown on Fig. 6.1. During the decay process, the endoperoxide 
molecule has to release O2 from the endoperoxide bridge and the bent 1,4-cyclohexadiene 
moiety has to revert (restructure) back to the planar aromatic “parent molecule”, see Fig. 6.1.  
Interaction of substituents in various positions on naphthalene ring are described in 
literature [31˙, 137]. Moreover, during the decay process orbital rehybridization (sp
3
 orbitals 
of the endoperoxide to sp
2
 orbitals of the “parent molecule”) at C1 and C4 atoms occurs, 
which is important for consideration of side-group interaction on peri substituted 
naphthalenes. In the naphthalene molecule the 1- and 8-positions are typically named to be 
peri to each other [137]. In view of the naphthalene geometry, substituents located at peri 
positions are in much closer proximity with stronger repulsion, than similar substituents 
located ortho to each other. The distance between peri-carbon atoms (C1 and C8, or C4 and 
C5 on Fig. 6.1.) is only about 2.4-2.5 Ǻ [137]. In aromatic molecules, the normal nonbonded 
H…H distance is 2.4-2.5 Ǻ, and the nonbonded C...C distance is 2.8-3.0 Ǻ [137]. Thus 
substituents other than two hydrogens at the peri positions in naphthalene cause considerable 
steric interaction (strain), in the naphthalene ring (or peri stress, as classified by Schiemenz 
and co-workers [151]) due to repulsion, which is responsible for several unique properties of 
peri substituted naphthalenes, including ring distortion, with the larger 1- and 8- substituents 
bending away from each other both in the plane of the ring and perpendicular to it [152]. A 
major effect of peri “proximity effects” is a strong preference for sp
3
- at the expense of sp
2
-
hybridised centres [153], because the strain (caused by interaction of peri substituents) is the 
driving force for reactions of peri substituted naphthalenes [152]. This peri interaction aspect 
is important for stabilization of N2E endoperoxide used in this work, which N2 “parent 
molecule” is peri substituted.  
In this work the endoperoxide decay kinetics was adjusted with various parameters 
influencing the mentioned restructuring process, e. g. by the variation of the matrix, which 
will be further discussed in some detail. 
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6.1.2. Functional Structure Consisiting of Endoperoxide Molecule and its Immediate 
Neighbourhood of the Surrounding Matrix: a Microscopic Model 
The interaction between the embedded endoperoxide molecule and the surrounding 
carrier matrix has to be observed in more detail while having sp
3
 to sp
2 
rehybridization and 
endoperoxide reverting for the angle φ in mind. A scheme of a microscopic model of an 
endoperoxide molecule embedded in a polymer carrier matrix is given in Fig. 6.2. The 
endoperoxide molecule and the immediate neighbourhood of the surrounding carrier matrix 
form a functional structure.  
 
a) 
         
 b)           c) 
Figure 6.2. A microscopic model of an endoperoxide molecule embedded in a polymer carrier matrix 
forming functional structures. a) The 1,4-cyclohexadiene moiety of the endoperoxide molecule is bent 
for an angle φ. In order to revert the bent endoperoxide molecule, NE, to a planar, aromatic parent 
molecule, N, local free volume in the carrier matrix is needed. b) large local free volume and high 
endoperoxide (three dimensionally represented with its electron density distribution) mobility in the 
matrix, yielding FDE; c) small local free volume and reduced endoperoxide mobility in the matrix, 
yielding SDE.  
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The bent endoperoxide has two “wings”: a shorter one, which is bent and a longer one 
with one intact aromatic ring. Obviously, if there is any steric hindrance in the functional 
structure, which restricts the reverting of the endoperoxide molecule for the angle φ to the 
planar aromatic “parent molecule” during the decay process (see Fig. 6.2. a), it will decay 
much slower. Thereby, the carrier matrix could cause the hindrance by disabling the decisive 
movement of either endoperoxide molecule “wing” (reverting for angle φ, as shown on 
Figure 6.2. b) and c), which is necessary for the decay process. 
On Figures 6.2. b) and c), a N1E molecule (represented with an electron density 
distribution) embedded in a polymer matrix (e.g. PVB polymer matrix) and the matrix 
hindrance of the N1E decay are shown. The gray area around the N1E molecule on the 
Figures 6.2. b) and c) represents the local free volume present in the carrier matrix. This 
presence of free volume originates from the common features in the production of both 
polymer materials matrices: in the case of PVB film matrix the ethanol solvent molecules at 
first form a solvation shell [154] around 1,4-dimethylnaphthalene derivatives and the rigid 
polymer matrix cage is not in the immediate vicinity of the dissolved N1 derivative. Thus, N1 
is still mobile in the liquid solvent cage [155]. Later, as the polymer film slowly dries on the 
glass substrate in the ethanol-saturated atmosphere, the solvent molecules slowly diffuse out 
of the polymer matrix leaving some free volume cavities around 1,4-dimethylnaphthalene 
derivatives in the soft matter polymer matrix. However, such cavities caused by the solvation 
shell do not remain infinitely, but disappear slowly through diffusion processes after some 
period of time [156], leaving the more rigid polymer matrix cage around N1 derivative 
molecule. The same reasoning applies to polymer nanoparticle matrix: there is a solvation 
shell around N1 derivative molecules prior to nanoparticles precipitation by non-solvent 
addition. During the particles precipitation, N1 derivative molecule with its solvation shell is 
embedded in the polymer matrix. Subsequently, solvent molecules can slowly diffuse (e. g. 
during dialysis, see PVB nanoparticle preparation) through the polymer matrix, leaving local 
free volume cavities, because the polymer chains are already fixated. 
In order to enable the endoperoxide decay and 
1
O2 release, there has to be enough of 
local free volume not only in a region necessary to remove generated 
1
O2 and at the same 
time for reverting of the bent form of the N1E to the planar aromatic N1 molecule. When 
there is enough local free volume around the endoperoxide molecule present in the carrier 
matrix and/or endoperoxide is mobile to come to a position in which a fast endoperoxide 
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decay process occurs, i.e. FDE part of formed endoperoxides (Figure 6.2. b). This is valid for 
all other combinations of various endoperoxide-forming derivatives and polymer matrices. 
For FDE part of N2E and N4E in PVB film matrix t1/2 values (see Table 4.6.) are even 
shorter than in liposome matrix, or even in organic solvents, probably due to the large 
localized free volume in PVB film. When the local free volume in the carrier matrix is small, 
the mobility of endoperoxides in the matrix is low (Figure 6.2. c), and the endoperoxide 
molecule has to diffuse to the area with larger local free volume in the polymer matrix to 
enable the endoperoxide decay, i.e. only SDE part of endoperoxide decay occurs. In polymer 
matrices there are 2 types of functional structures corresponding to FDE and SDE decay 
occurrence. Principally it is a statistical distribution of functional structures which can be 
characterized with the free volume presence. 
 
6.1.3. Influence of Various Substituents of the N1 Derivative on the Endoperoxide 
Decay Kinetics: Chemical Change of the Functional Structure 
 
By introducing various substituents on the main N1 derivative, interaction of the 
endoperoxides with the matrix was influenced (the functional structures were modified 
chemically) and the decay times changed accordingly. 
The half-life of examined 1,4-dimethylnaphthalene derivatives in organic solvents, for 
the particular endoperoxide decay, see Table 4.4. will be now compared. An explanation for a 
strong difference of N1E and N2E t1/2 values is given by Wasserman et al. [31, 137]. A large 
steric strain caused by the nonbonded peri interaction (see Chapter 6.1.1.) between adjacent 
methyl groups at the 4- and 5- positions (i.e. methyl-methyl repulsion) is present in the N2 
derivative and not present in N1 derivative.  
Orbital rehybridization (sp
2
 to sp
3
) of C1 and C4 atoms (Fig. 6.1.) resulting from the 
endoperoxide formation significantly reduces the steric interaction between adjacent peri 
methyl groups (at C4- and C5-positions on Fig. 6.1.) in the bent N2E compared to the planar 
parent N2 molecule [31, 137]. The aforementioned steric methyl-methyl interaction does not 
exist in the N1 molecule, where the C5- substituent is a hydrogen atom, and therefore causes 
no stabilization of the N1E (compare Scheme 3). For a better overview of used naphthalene 
derivatives structure, Schemes 3 and 4 are here repeated. 
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N1:  R1 = R2 = H 
N2:  R1 = H, R2 = CH3 
N3:  R1 = COCH3, R2 = H 
N4:  R1 = CHOHCH3, R2 = H 
N6:  R1 = CH=CH2, R2 = H 
N7 = poly (N6) 
Scheme 3. Endoperoxide formation and thermally induced decay on various naphthalene derivatives 
used in this work. 
 
Scheme 4. Endoperoxide formation on the N5 derivative, witch possesses double endoperoxide-
forming (and 1O2-releasing) function in comparison to derivatives in Scheme 3. 
Furthermore, N5E with a t1/2 value of 2.26 h at 37 ºC is closer to the N1E value t1/2 of 
1.19 h than to the N2E value t1/2 of 16.2 h, which is also in agreement with the literature: 
energy levels calculation of the endoperoxide stability performed by Wasserman et al. using 
the Density Functional Theory (DFT) with the B3LYP functional and employing the 6-
311G* basis set [31]. Repulsive steric interaction of ortho substituents in C1- and C2- 
position (Fig. 6.1.) of the N5 derivative is much smaller than peri interaction in N2 derivative 
(for details see Chapter 6.1.1.) Therefore, comparatively N5E formation (ortho interaction) 
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causes much smaller intramolecular strain reduction than N2E formation (peri interaction). 
Hence, the endoperoxide stabilization of the N5E is smaller than of N2E derivative. In this 
regard, when N5E with 2 endoperoxide bridges is formed (see Scheme 4.), apparently the 
effective side-group in C2-position on naphthyl ring for each of these 2 endoperoxides is only 
a 1-methoxy-ethyl group without naphthyl rest (for detail perspective see structure on Fig. 
4.2., page 61). Thus, there is no significant additional strain by the other naphthyl group in 
N5 which would stabilise the endoperoxide molecule and prolong its decay. There is an 
additional weak dipole-dipole interaction between ethanol solvent molecules and polar 1-
methoxy-ethyl substituent of N5 (C12-C11-O1 group on Fig. 4.2.) and/or endoperoxide 
bridge, which reduces the N5E mobility.  
With that in mind, the difference in decay kinetics of N4E and N5E and their half-life 
times in ethanol (Table 4.4.) is probably caused by a dipole-dipole interaction of N4E and 
surrounding solvent molecules as well as by a weak H-bonding between ethanol molecules 
and N4E over polar hydroxylethyl substituent of N4 (C2-C1-O1-H1o group on Fig. 4.1., page 
60), which reduces the mobility of N4E molecules and thus slows down its decay kinetics. 
 
6.1.4. Influence of Physical Changes of Functional Structure on the Endoperoxide 
Decay Kinetics 
 
Decay times of N1E and N2E in liposomes (Table 4.5) are comparable to their decay 
time values in organic solvents, with SF values close to 1. N5E (1.5 h at 37 °C) has again a 
t1/2 value similar to N1E (1.1 h at 37 °C) in liposome carrier, but a shorter t1/2 than in ethanol, 
SF = 0.66. Probably this is caused by an increased mobility of endoperoxides in the liposome 
matrix due to the large hydrophobic aromatic part of the N5 molecule embedded between the 
hydrophobic alkyl chains, what would prevent endoperoxide stabilisation by the dipole-
dipole interaction with the polar lipid „heads“.Since the decay was measured at 37 °C, above 
the temperature of liposome phase transition from gel to liquid-crystalline phase, Tc, (24 °C 
for DMPC lipid used in this work) [157], liposome membranes were in the liquid-crystalline 
phase with higher membrane permeability and high translational lipid mobility in the lipid 
bilayer [127], and thus the mobility of embedded endoperoxides was increased. 
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However, t1/2 of N4E in liposomes is longer (11.5 h at 37 °C, SF = 2.63) probably 
because of a much stronger dipole-dipole interaction between the hydroxylethyl substituent 
of the N4 molecule (over O1-H1o atoms in Fig. 4.1. page 60) and the polar “heads” of 
liposomal membrane. The dipole-dipole interaction over the hydroxylethyl side – group 
attracts N4 molecules close to the stacked lipid “heads” and is hindering the reverting of the 
bent endoperoxide molecule to the planar aromatic ring of the parent N4 molecule, which is 
necessary for the decay process (Figure 6.1.)  
Polymer matrices were explored in order to try to increase the t1/2 and SF values in 
comparison to the values in liposome matrix. Two main polymer matrices used were 
polyvinyl butyral and ethyl cellulose. Whereas the endoperoxide decay of all 1,4-
dimethylnaphthalene derivatives in liposome matrix and organic solvents was 
monoexponential and with similar t1/2 values to literature [22, 31] (the only exception was 
N4E in liposome matrix), the decay in PVB and EC matrices was in a good approximation 
biexponential. There is a fast-decaying endoperoxide part and a slow-decaying endoperoxide 
part due to embedding in different functional structures, see Figure 6.2.  
A summary of all 1,4-dimethylnaphthalene derivatives endoperoxide t1/2 values, 
endoperoxide half-life times and corresponding endoperoxide percentages are given in Table 
6.1. In these data the endoperoxide decay kinetics without any further stabilization due to the 
physical changes by endoperoxide formation and decay repetition (for detailed explanation 
see e.g. Chapter 4.3.3.), is presented. N7 nanoparticles are here treated as a N1 variation: a 
polymer with each side-group on the polymer back-bone being a N1 group. The largest 
endoperoxide stabilization was in N7 matrix, with t1/2 (1) = 6.8 h, SF (1) = 5.7 and t1/2 (2) = 
39.7 h, SF (2) = 33.1 values. SF factors were in this case calculated in regard to the N1E half-
life time in organic solvent. However, the endoperoxide formation yield in N7 nanoparticles 
was the lowest: about 45 % after 7h laser irradiation was the highest achieved yield, see 
Figure 4.34. 
Discussion and Outlook 
150 
 
Table 6.1. Endoperoxide t1/2 values for different 1,4-dimethylnaphthalene derivatives 
depending on the carrier matrix. Further stabilisation due to the physical changes of the 
functional structure is not presented. The percentage of formed endoperoxides decaying as 
FDE and SDE, when applicable, is given in parenthesis.  
 N1 N5 N4 N2 
organic solvents 1.2 h 2.3 h 4.4 h 16.2 h 
lipsomes 1.1 h 1.5 h 11.5 h 17.1 h 
PVB film 1.7 h (30%);  
7.3 h (12%) 
6.0 h 4.4 h (8%);  
26.6h (16%) 
6.4 h (8%);  
19.4h (18%) 
PVB nanobeads 0.8 h (75%);  
1.6h (13%);  
5.8h (5%)  
2.0 h (45 %); 
2.65 h (20%) 
7.5 h (30%);  
13 h (25%)  
18.7 h (20%) 
EC nanoparticles / / 0.7 h (20%);  
9.6 h (14%) 
/ 
N7 nanoparticles 6.8h (10%);  
39.7 h (12%) 
   
 
A possible explanation of shorter endoperoxide half-life times in certain matrices (e.g. 
N2 in PVB film, N4 in EC particles) than in organic solvents would be the reduction of strain 
caused by peri interaction in functional structures with large local free volume regions. 
In case of N4E in PVB and EC nanoparticles the interaction between the 
endoperoxide molecule and its immediate surrounding of the matrix is significantly changed 
chemically: a polar hydroxylethyl side-group on N4 molecule causes weak H-bonding to the 
polar groups of the PVB and EC matrices, as discussed above. Thus, N4E mobility is reduced 
and t1/2 of the FDE in PVB nanoparticles is significantly longer than t1/2 of N1E in the same 
matrix. The same weak H-bonding interaction with EC matrix causes longer t1/2 of N4E than 
of N5E in EC nanoparticles under the same nanoparticle and endoperoxide formation 
conditions (compare Figure 4.28. and Figure 4.29.)  
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FDE and SDE half-life times of all examined naphthalene derivatives in PVB film are 
given in the Table 4.6. Existence of functional structures with small free volume in the PVB 
film caused SDE decay and thus endoperoxide stabilization with SF values of about 6 for 
N1E and N4E derivatives. N2E decay in PVB film at 37 °C was actually too slow to reach 
SDE region during the experiment period: in total only 26 % of formed N2E actually decayed 
during the measurement. Probably SDE population of N2E in the PVB film decays with even 
longer t1/2 values. However, such phenomena were only investigated at higher decay 
temperatures of 46 °C (see Figure 4.16.) and 56 °C. On the other hand, N5E derivative in 
PVB film matrix decays monoexponentially, with only the SDE component. FDE component 
is not present due to the low mobility of the larger N5 molecule in PVB matrix. 
Unfortunately, the loading efficiency of PVB nanobeads with 1,4-dimethylnaphthalene 
derivatives was rather low. Probably most of the loaded endoperoxide-forming molecules 
remained on, or close to the nanobead surface. The high FDE percentage of all N1 derivatives 
with SF values around 1 (see Table 4.14.) can be explained by large regions of local free 
volume in the matrix. However, it was possible to repeatedly use the PVB nanobead 
formulations in endoperoxide decay examinations: with the method of successive repetition 
of light-induced endoperoxide formation and subsequent thermal decay a regular 
prolongation of both FDE and SDE t1/2 values and an increase of SDE relative amount in the 
PVB matrix, both in PVB film and in PVB nanobeads (see Figs. 4.17. and 4.22. and Tables 
4.7. and 4.15., respectively), was achieved. This can be explained by the physical changes of 
the functional structures consisting of endoperoxide molecules and immediate neighborhood 
of the polymer matrix forming the cage wall. During the decay process complete 
rearrangement of the electronic and geometrical structures of the involved endoperoxide 
molecule occurs (see Fig. 6.1.) Geometrical rearrangement concerns e.g. the endoperoxide 
reverting to the planar parent molecule. The mentioned electronic and geometrical 
rearrangements create localized vibrational excitations. The relaxation of these excitations 
corresponds to an ultra short local heating, which can provide a physical change of the 
functional structure. Such changes include modification of the cage wall, and therefore, 
changes of the regions of localized free volume in the matrix. According to the common 
features of the polymer preparation procedures of the polymer film and the polymer 
nanoparticles in both cases there is a large local free volume in the functional structures (see 
above) corresponding to a localized non-equilibrium state. The changes of the polymer 
matrix cage wall result in a reduction of localized free volume, and, thus in a decay time 
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prolongation of both FDE and SDE population. Moreover, a variation in the statistical 
distribution of the functional structures (see above) occurs, i. e. the whole decay kinetics is 
influenced, adjusted. The large local free volume was reduced by letting a decay process 
occur as a part of the sample preparation procedure. The physical changes of the functional 
structures were accomplished either 
1. by stepwise separate processes of endoperoxide formation and subsequent (thermally 
induced) decay during the preparation (as described above), or 
2. by a continuous process of the formation and superimposed decay during a very long 
time (e.g. in experiments with 16h irradiation time in the EC matrix, Figure 4.28.) 
Furthermore, a decay time increase of N1E by more than a factor of 30, compared to the t1/2 
value in organic solvents could be achieved by physical changes of the functional structure in 
polymers. 
EC nanoparticles loaded with N1 or N2 could not be produced. N5E and N4E decay 
in EC nanoparticles was also biexponential. The FDE relative amount was significantly 
smaller and SDE amount significantly larger in comparison to the PVB carrier matrix. When 
N4E was formed in EC nanoparticles with a short (t = 1.5 h) light irradiation of MB 
sensitizer (see Figure 4.27.), the small FDE part had t1/2 = 0.7 h, probably due to large free 
volume effect, and larger SDE part had t1/2 = 9.6 h. A long irradiation time enabled 
significant stabilisation of both FDE (t1/2 value increase from 0.7 h to 8.5 h) and SDE (t1/2 
value increase from 9.6 h to 24.6 h) of N4E derivative in the EC matrix (compare Fig. 4.27. 
with irradiation time of 1.5 h and Fig. 4.28. with irradiation time of 16 h). The same principle 
was applied on N5 in EC matrix: after 16 h laser irradiation endoperoxide yield was very high 
(92 %) with stabilized both FDE and SDE (Fig. 4.29.) Thus, the goal of t1/2 endoperoxide 
values adjustment to > 15 h for the in vitro application against cancer cells was reached. 
Such longer t1/2 of N4E in PVB and EC nanoparticles can be even more prolonged 
with additional (physical) changes of the functional structure in PVB matrix (Fig. 4.22.) and 
EC matrix (Figs. 4.28. and 4.29.) 
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6.1.5. Summary of Endoperoxide Decay Kinetics Adjustment 
 
To sum up, varying of the endoperoxide decay-time and thus 
1
O2-release time at 37 
°C in a broad range was achieved chemically, by synthesis of N4 and N5 endoperoxide-
forming molecules, as well as with polymer N7 synthesis, in which each monomer on the 
polymer back-bone has an endoperoxide-forming group. In case of N7 the highest t1/2  value 
was reached. Moreover, by choosing matrices with various interactions with endoperoxides 
(e. g. steric hindrance, hydrogen bonding with N4 compound), variations of t1/2 values of 
synthesized and comercially available endoperoxide-forming molecules were achieved. The 
decisive adjustment of t1/2 values and relative amounts of FDE and SDE population in these 
matrices was made with physical changes by endoperoxide formation and decay cycles or by 
the continuous procedure as described above for EC matrix. The highlight of such 
1
O2-release 
time adjustment in a broad range is the example of N1E derivative in PVB film matrix: with 
t1/2 values from 1.5 h to 38.2 h and SF = 31.8 in 2
nd
 cycle (see Table 4.7.) Even an additional 
enhancement of the endoperoxide stabilization is reachable by performing further cycles of 
sample irradiation and thermolysis, as shown for N1E decay in PVB film matrix at 56 °C 
(Figure 4.17.) The SDE N1E t1/2 values at 37 °C after 3
rd
 cycle can then be roughly estimated 
to be in 50-60 hours range. Thus, by such a prolongation of 
1
O2-release, the potential 
pharmaceutical applications of the N1 biocompatible parent molecule, as described in 
Chapter 2 [107, 108] are more numerous. 
Discussion and Outlook 
154 
 
6.2. DISCUSSION OF THE CYTOTOXICITY ASSAY RESULTS OF 
ENDOPEROXIDE-LOADED NANOPARTICLES ON HUMAN BREAST 
CANCER CELLS 
 
In this work the concept of a novel 
1
O2-release procedure for potential pharmaceutical 
applications, based on the photodynamic therapy is presented. The main difference is the 
introduction of an intermediate step of 
1
O2-„storage“ in the endoperoxide form and then 
delayed adjustable release. Hence, the patient would not be directly irradiated with light, as in 
the classical photodynamic therapy, but the irradiation of the sensitizer and endoperoxide 
formation would be performed externally, and thus, would not be dependent on the oxygen 
concentration at the target (in tissue, cells). Such an endoperoxide would then be delivered in 
a biocompatible carrier to the body region of interest and then the effective 
1
O2 would be 
released. Thus, the application range of such a therapy would be much broader than of 
classical PDT, which is restricted to diseases within the light penetration depth, see Chapter 
1.3.5. Furthermore, within this concept it would be possible to extract the sensitizer (e.g. 
methylene blue) after the light irradiation and prior to the drug delivery to the patient. This 
would also remove the problem of patient sunlight sensitivity after the PDT procedure when 
the sensitizer is not quickly cleared from the body.  
Obviously, the adjustment of 
1
O2-release periods to the particular therapeutic demands 
is here of a crucial interest. Appropriate biocompatible carries for drug-delivery and selective 
delivery restricted to diseased tissue are two additional aspects which must be adressed. The 
latter two challenges are also a hot topic in the PDT field, trying to increase the PDT 
therapeutic options range through development of delivery systems for hydrophobic 
sensitizers [82]. 
In order to exploit the cytotoxicity of 
1
O2-release by the aromatic endoperoxides, 
several factors (requirements) have to be taken into account: 
1
O2-lifetime and diffusion radius 
in water/cell medium, 
1
O2-release time which equals the endoperoxide decay time, 
endoperoxide‘s 
1
O2 yield, endoperoxide‘s carrier material drug-delivery potential, including 
cell-uptake time, carrier loading with a high-concentration of endoperoxide-forming “parent 
molecule”, endoperoxide-formation yield in the carrier matrix. 
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1
O2-lifetime data in water, blood plasma and leukemia cells are known [3], see Table 
1.1. Skovsen et al. calculated a 
1
O2-diffusion radius of 268 nm with a τ (
1
O2) = 3 µs [6] in a 
single D2O-incubated nerve cell, which is a rather controversial topic, as stated in Chapter 
1.1.2., see references [6, 7] On the other hand, other reports point to 0.3 µm diffusion length 
of singlet oxygen in cellular membranes [158], with a possibility of τ (1O2), and thus, 
diffusion radius, increase up to 7 times in case of high Staphylococcus aureus bacteria 
concentration [159]. Therefore, at the time-point of 
1
O2-release, the carrier loaded with 
endoperoxides should be either in cells, or in cell membrane, with the carrier diameter at least 
≤ 200 nm in order to 
1
O2 be able to diffuse out of carrier and be effective.  
1
O2 yield of N1E and N2E is in the 69-76 % range [22], and the rest is than lost as 
pharmaceutically inactive 
3
O2. Presumably, endoperoxides of N4 and N5 derivatives have 
similar 
1
O2 yield values, which should be experimentally confirmed in the future work. 
Obviously, it is crucial that the endoperoxide half-life t1/2, in a particular carrier, is 
much longer than the carrier cell-uptake time, tu, so that as few as possible endoperoxide 
molecules release 
1
O2 prior to the cell-uptake. How long should t1/2 precisely be depends on 
the particular pharmaceutical application: cancer therapy, antimicrobial treatment etc. On the 
other hand, the 
1
O2-release time should not be too long: there have to be a high enough local 
concentrations of 
1
O2 in an interval of a few hours in order to induce a strong enough cell-
damage which would cause cell death by apoptosis or necrosis. 
1
O2-release in mitochondria 
or nucleus is likely to induce apoptosis and release in the plasma membrane is likely to cause 
necrosis [46]. A too low 
1
O2 concentration would cause only moderate cell damage and 
trigger cellular repair mechanisms. Additionally, after some time (estimated 1-2 days) the 
carrier materials land in lysosomes, as shown for liposome carrier with CLSM images [160] 
where 
1
O2 can no longer be effective. The threshold value of necessary intracellular 
1
O2 
concentration for a photodynamic therapy modification, as done in this work, is rather 
difficult to estimate, because of all the factors mentioned above. Thus, the appropriate 
1
O2-
releasing endoperoxide/carrier concentration combination is rather empirical and can not be 
precisely stated as in the classical drug pharmacology. 
What can be measured is the endoperoxide-forming molecule concentration, its carrier 
concentration and, if applied, coating material concentration. The concentration of formed 
endoperoxide is than determined (spectroscopically: with absorption or fluorescence intensity 
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change of “parent molecule”) immediately after the light irradiation of the sensitizer. If the 
endoperoxide yield is low, the following options should be considered: longer irradiation 
and/or stronger light intensity and/or higher photosensitizer concentration.  
With this in mind, the kinetic chemosensitivity assay results are shortly reviewed:  
 
6.2.1. Limitations of Carrier Loading and Cytotoxicity  
 
When liposomes or PVB nanobeads or poly(1,4-dimethyl-2-vinyl-1,4-
dimethylnaphthalene) (N7) nanoparticles were used as endoperoxide carriers, several 
problems regarding carrier loading ability and/or carrier in vitro cytotoxicity occurred. 
 
6.2.1.1. Cytotoxicity of Endoperoxide-Loaded Liposomes 
 
N1E t1/2 value was too short, but N4E and N2E both had a t1/2 value longer than tu 
(estimated at 0.5-1.0 h) of the liposome carrier. Conventional non-coated liposomes, a 
familiar biocompatible carrier used for cancer targeting, because of the enhanced 
permeability and retention (EPR) effect [136], and for intracellular drug delivery [132, 161] 
were the first-choice carrier. The highest reached N2E doping concentration of 6.3 µM in 
unmodified liposomes, c (lipid) = 20 µM made a cytotoxic effect on MDA-MB-231 human 
breast cancer cells growth. For a desired cytostatic effect, an endoperoxide concentration of 
10 µM or higher is probably necessary. This was not reachable without increasing the 
liposome concentration in such a manner that even the unloaded liposomes inhibited the cell 
growth. With such a tightly packed naphthalene derivatives in liposomes, possibly 
naphthalene dimers are formed which would have an unknown effect on the endoperoxide-
formation and 
1
O2-release dynamic. N4E in liposome concentration increase in comparison to 
the loaded N2E concentration was probably negated by a shorter t1/2 value and therefore 
faster endoperoxide decay and 
1
O2 loss prior to the liposomes’ cellular uptake. 
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6.2.1.2. PVB Nanobeads Low Endoperoxide Loading Ability 
 
Spherical nanoparticles of PVB polymer were formed. PVB nanobeads were 
developed as a potential biocompatible carrier: non-coated PVB nanobeads with diameter 
smaller than 300 nm were capable of cell penetration and reached the perinuclear region 
within a few hours, as determined with CLSM. As shown on Figure 4.21. PVB nanobeads 
may be employed at concentrations at least one order of magnitude higher than liposomes’ 
cytotoxic concentration for intracellular drug-delivery purposes. It is also conceivable, that 
PVB nanobeads could enable passive cancer targeting through the EPR effect, which is 
applicable for any biocompatible macromolecular compounds above 40 kDa [162], but this 
needs to be tested. Dopants, such as PTC may also be included into PVB nanospheres at 
concentrations of at least one percent with respect to the polymer, which enables PVB 
nanobeads use as an excellent imaging agent, and not only as a biocompatible carrier.  
Decay times of both N2E and N4E in PVB nanobeads were significantly longer (see 
Table 4.14.) than the PVB nanoparticles tu range. Thus, N2E and N4E in PVB nanobeads 
were conceivably usable for the cancer cell therapy, as imagined in this project. However, 
PVB nanospheres could not be loaded, at least not with the precipitation method and 
subsequent post-concentration by centrifugation as employed in this work, with a high 
enough 1,4-dimethylnaphthalene derivative concentration in order to cause a significant 
cytotoxic effect due to 
1
O2-release during the endoperoxide decay. Possibly loading with a 
high enough concentration could be reached with some high-pressure preparation procedure 
[163]. 
 
6.2.1.3. Cytotoxicity of N7 Particles 
 
Synthesized N7 nanoparticles had the highest endoperoxide-forming groups 
concentration of all derivatives used in this work. However, above a certain treshohld 
concentration (depending on the particle size, see Figure 4.36.) N7 particles without any 
endoperoxide formation had an antiproliferative effect on MDA-MB-231 cells growth. This 
rendered a use of N7E in too low of a concentration (also due to the low endoperoxide 
formation yield, ≤ 40 %) in cytotoxicity assays to have any inhibitory effect on the breast 
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cancer cells growth. Thus, our results are to the contrary of Käsermann and Kempf work in 
which they used endoperoxides of poly(1,4-dimethyl-6-vinyl-1,4-dimethylnaphthalene) for 
inactivation of two viruses, Semliki Forest virus and vesicular stomatitis virus [149]. 
Furthermore, their endoperoxide formation yield was ≥ 90 % using the methylene blue 
sensitizer and the endoperoxide half-life time was short, in the 40 min range at 37 °C [149]. 
The mechanism of the N7 particles interaction with cancer cells causing cell growth 
inhibition remains unknown. Further investigations should be performed, to determine 
whether N7 nanoparticles, with or without polysorbate 80™-coating, indeed penetrate into 
cells or not. A stable fluorescent labeling of the N7 nanoparticles would provide a major 
advantage for monitoring a potential cellular uptake in vitro, and consequently elucidate the 
mechanism of possible nanoparticle drug delivery. 
 
6.2.2. Problem Solution: Cytotostatic Effect of Endoperoxide-Loaded EC 
Nanoparticles and General Demands of the Endoperoxide Concentration 
 
In contrast to the PVB nanobeads, non-coated EC nanoparticles were excluded from 
MDA-MB-231 cancer cells. Only polysorbate80-coated EC nanoparticles were a suitable 
potential drug delivery carrier, with tu < 2 h, as determined with CLSM. However, the 
loading capacity of the EC nanoparticles was for about 2 orders of magnitude higher than of 
PVB nanobeads. Moreover, by means of a long irradiation it was possible to stabilize the 
endoperoxides of N4 and N5 (see Figs. 4.28. and 4.29., respectively) and reduce the FDE 
percentage, in order to keep the percentage of extracellularly released 
1
O2 (due to the 
endoperoxide decay prior to the intracellular delivery of EC nanoparticles) low. It can be 
roughly estimated that only 10-15 % of N4E and 20-30 % of N5E in EC particles are not 
delivered, but decay extracellularly. On top of that, from cytostatic concentrations of N4E 
and N5E (Figs. 4.32. and 4.33.), it can be fairly estimated that on N5 derivative a 2 times 
higher number of singlet oxygen binding sites is present. These sites may not release 
1
O2 
simultaneously, but rather depending on the free volume in carrier matrix present in the 
immediate vicinity of 2 endoperoxide bridges. Nevertheless, a concentration of 
intramolecular 
1
O2-releasing sites is in case of N5 twice larger than for other 1,4-
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dimethylnaphthalene derivatives, which lowers the necessary N5E concentration for a 
positive therapeutic effect.  
Thus, it can be stated that generally, a ca. 15 µM concentration of endoperoxide 
groups in the system will generate a cytostatic drug effect on the growth of MDA-MB-231 
cells with conditions used in this work (average carrier diameter 50-100 nm, tu = 2-3 h, t1/2 > 
10 h). 
However, tests regarding the reproducibility of loading the EC particles with N4 and 
N5 showed inconsistencies regarding the doping efficiency. Hence, it seems to be difficult to 
keep the ratio dopant/EC particle constant. Practically, this causes a need to vary the EC w/w 
concentration to keep the N4 or N5 concentration constant for cytotoxicity assays. During the 
EC nanoparticles formation crystalline (up to 48 %) and amorphous regions of ethyl cellulose 
on the nanometer scale are formed [164, 165]. 1,4-dimethylnaphthalene derivatives are 
loaded only in amorphous regions of EC nanoparticles. Additionally, the nanocrystalline 
regions cause EC aggregation, nanocluster formation (in 200-400 nm range as determined 
with DLS and TEM) and after a week a strong aging effect of EC nanoparticles with an 
inclination towards precipitation, crystallization out of the aqueous suspension is present. 
Therefore, it is difficult to estimate the optimal polysorbate 80™ coating concentration for 
adsorption on EC particles carrier. It was found that free, not adsorbed on the EC surface, 
polysorbate80™ and non-coated EC nanoparticles both cause inhibitory effects on MDA-
MB-231 cells proliferation. Therefore, extensive and careful preparation optimization 
regarding the EC particles loading and coating parameters is necessary. The goals would be 
to reach as high a dopant/EC particle ratio as possible, as low EC cluster building and optimal 
coating (monolayer, if possible) on the EC carrier surface. 
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6.3. OUTLOOK 
 
The procedure as designed here could be used for tumour therapy, as done in this 
work in vitro, and furthermore 
1
O2-release from thin polymer films (e.g. PVB) could be tried 
out as an anti-infectional protection layer after medical implants surgeries, where until now, 
amongst others, polymer films with antibiotics are used [166], e. g. for knee, hip and dental 
implants. Beside antibiotics, in literature also the PDT use for the bacteria inactivation is 
mentioned [167], including the multiresistant bacteria, such as Staphylococcus aureus, as 
reported for classical PDT procedure [168]. A possible anti-bacterial use of the 
1
O2-releasing 
polymer film would be two-fold: FDE population could be applied against bacteria during the 
implantation procedure and SDE population could be used against bacteria colonies settling 
on the implants after surgery. 
A possible solution for problems regarding carrier cytotoxicity and loading ability for 
the tumour therapy application (as stated in Chapter 6.2.1.) would be to covalently bind a  
1,4-dimethylnaphthalene derivative to PVB polymer (see Scheme 7. in Appendix) and then 
form nanoparticles of such a polymer. This covalent binding would resolve the problem of 
loading the PVB nanoparticles with a high enough 1,4-dimethylnaphthalene derivative 
concentration because each alcohol group in PVB structure would have a covalently bound 
endoperoxide-forming 1,4-dimethylnaphthalene side-group. Hence, the concentration of 
1
O2-
releasing group would be large enough for a possible cytostatic effect (necessary 
concentration estimated > 15 µM, see previous page) and such nanoparticles would 
conceivably employ all the advantageous properties of PVB nanobeads: amorphous structure, 
non-cytotoxicity, cellular permeability without coating, formation reproducibility, neglegible 
aging effect. 
In addition, PVB polymer films could be perceivably used for surface coating of 
magnetic nanoparticles, which are also used in local hyperthermia (up to 45 °C) treatment 
[138] and are now also considered as promising agents for drug delivery into regional lymph 
nodes and for diagnostic imaging purposes [132]. It would be possible to load a 100 nm thin 
PVB film with a very high concentration (up to mM range) of 1,4-dimethylnaphthalene 
derivatives, with an endoperoxide-formation yield in 80-90 % range after 45 min LED 
irradiation and to adjust the 
1
O2-release time in a broad range by means of endoperoxide 
Discussion and Outlook 
161 
 
formation and decay cycle repetition, see Figure 4.17. Thus, t1/2 could be adjusted in such a 
manner that a large portion of endoperoxides would be stable enough at the human body 
temperature of 37 °C (during magnetic nanoparticles transfer to tumour region) and then 
would preferentially release 
1
O2 in the tumour region when magnetic nanoparticles reach 
higher temperatures in the alternating magnetic field.  
Another advantageous possibility for the cancer therapy application would be to grow 
N1- or N2-doped polymer onto the mesoporous silica particles by hyperbranching surface 
polymerization procedure [169]. Such a hybrid poly(ethylene imine)-silica nanoparticles are 
taken up to HeLa cervical cancer cells by the receptor-mediated endocytosis followed by 
accumulation in endosomes and cargo-release into the cytoplasm [169]. In general, the 
surface adsorption of N1 derivatives on inorganic nanoparticles used in pharmaceutical 
applications, such as γ-Al2O3, could be tried out. 
Conceivably, other carrier materials (already under development for PDT drug 
delivery purposes) could be tested for loading with, and drug delivery of endoperoxides used 
in this work. For example, PEGylated gelatin nanoparticles [170] with long blood circulation 
and preferential tumour distribution properties could be tested. Another possibilities worth 
exploring would be biodegradable nanoparticle carriers such as FDA approved [171], 
biocompatible, amorphous stereoisomer of poly(D,L-lactide) (PLA) [172] or biodegradable 
poly(D,L-lactide-co-glycolide) nanoparticles [173, 174, 175] with various copolymer ratios, 
which are both used for in vitro delivery of various sensitizers. For the purpose of drug 
encapsulation, the use of amorphous PLA is preferred over the semi-crystalline PLLA and 
PDLA isomers [176] as it enables more homogeneous dispersion of the drug in the polymer 
matrix.  
The use of other established drug-delivery polymer nanoparticles such as 
poly(butylcyanoacrylate) (PBCA) nanoparticles could be also tried out. Moreover, non-
biodegradable ceramic-based nanoparticles with great stability, easily functionalized surface 
and size, shape, and porosity control [177] are worth exploring for non-covalent doping, as 
well. 
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7. SUMMARY 
The decay kinetics of aromatic endoperoxide molecules embedded in carrier matrices 
(liposomes, polymer films and nanoparticles) was studied to provide a method for the 
adjustment of the thermally induced release time of singlet oxygen (
1
O2) to the requirements 
of possible pharmaceutical applications.  
Excitation of a sensitizer with a laser or LED generated 
1
O2, which reacted with 
aromatic molecules (1,4-dimethylnaphthalene and its derivatives) forming endoperoxides. 
The decay of these photoproducts enabled the delayed release of 
1
O2. Some of the 
endoperoxide-forming molecules, such as 1-(1,4-dimethyl-naphthalen-2-yl)-ethanol (N4), di-
1-(1,4-dimethylnaphthene-2-yl)-ethylether (N5), and poly(1,4-dimethyl-2-vinylnaphthalene 
(N7), were synthesized and characterized, while others were commercially available: 1,4-
dimethylnaphthalene (N1) and 1,4,5-trimethylnaphthalene (N2). In addition, 
multichromophore molecules such as 5,10,15,20-tetrakis-(4-methylnaphthyl)porphyrin) (P1) 
and (5,10,15,20-tetrakis-(4-methyl-naphthyl)porphyrinato-zinc(II) (P2), acting as sensitizers 
and forming endoperoxides in their peripheral naphthyl subunits (N1 derivatives) by 
autoperoxidation, were synthesized and characterized. 
1
O2 generation and endoperoxide 
decay by the compounds P1 and P2 were also studied. 
The N1 derivatives were embedded in several different carrier systems: biocompatible 
liposomes or polymer materials such as nanoparticles of ethyl cellulose (EC) and polyvinyl 
butyrale (PVB) and PVB films. The sensitizer (porphyrin derivatives) was embedded in the 
carrier, as well. Only one sensitizer (methylene blue) was separately dissolved in aqueous 
carrier suspension, thus composing in both cases multichromophore systems. The average 
diameter of nanoparticles, as determined by dynamic light scattering and/or transmission 
electron microscopy, was in the 50-150 nm range. 
Endoperoxide formation in the selected matrix could be determined by the time-
dependent decrease of fluorescence intensity in the course of the irradiation, because the 
endoperoxides are non-absorbing at the excitation wavelength of the original aromatic 
molecule. Moreover, the reappearance of the fluorescence signal (of the “parent molecule”) 
enabled the measurement of the decay of the endoperoxides. The decay kinetics of the 
endoperoxides (N1E, N2E, N4E, N5E, N7E) was examined at different temperatures (with 
emphasis on the human body temperature of 37°C) in the various carrier materials. 
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 For the experiments with cancer therapy application the decay time had to be 
adjusted to be significantly longer than the average time period of cellular uptake tu, 
(determined with confocal microscopy) for the particular carrier. The basis for the adjustment 
of the decay kinetics is the structural change by reverting of the bent 1,4-cyclohexadiene 
moiety of the endoperoxide to the planar, “parent molecule”. The decay kinetics is generally 
determined by the distribution of the (supramolecular) functional structures consisting of the 
endoperoxide molecule and the immediate neighbourhood of the surrounding carrier matrix. 
The endoperoxide decay time, t1/2, was adjusted by chemical and/or physical modifications of 
the functional structure. Chemical changes were the introduction of various substituents (e.g. 
1-hydroxyethyl), whereby the endoperoxide mobility was reduced (e.g. by H-bonding to the 
matrix). Physical changes, in particular a reduction of the large local free volume regions in 
the functional structures, were obtained for both types of sample preparation (i. e. polymer 
films and nanoparticles). These large local free volume regions occur in both types due to a 
common feature in the sample preparation procedures. This reduction was obtained by letting 
an endoperoxide decay process occur as a part of the sample preparation procedure. The 
reduction of the local free volume was performed either 
• by stepwise separate processes of endoperoxide formation and subsequent (thermally 
induced) decay during the preparation, or 
• by a continuous process of the formation and superimposed decay during a very long 
irradiation time.  
A prolongation of the decay time up to a factor of 30 (in comparison to t1/2 in organic 
solvents) could be achieved in both cases. 
The kinetic crystal violet assay was used to determine the in vitro cytotoxicity of the 
endoperoxides in above mentioned carriers against human breast cancer cells (MDA-MB-
231) at 37 °C. On the basis of the results obtained with N4E and N5E it can be concluded 
that a ca. 15 µM concentration of endoperoxide groups results in a cytostatic effect on MDA-
MB-231 cells growth. 
The role of the decay adjustment for various possible applications such as cancer 
therapy or anti-microbial treatment is discussed. 
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A. APPENDIX: COVALENT BINDING OF N4 DERIVATIVE TO THE PVB 
POLYMER BACKBONE 
A.1. Motivation 
 
Due to the problems regarding carrier cytotoxicity (liposomes, EC nanoparticles, N7 
nanoparticles) and loading ability (not high enough concentration of 1,4-dimethylnaphthalene 
derivatives in liposomes, PVB nanobeads), a possibility to covalently bind a 1,4-
dimethylnaphthalene derivative to a nanoparticle-forming polymer was searched for. This 
would also enable to reach a very high concentration of endoperoxide-forming groups in the 
polymer carrier. Practically it would be possible to use a high polymer (and endoperoxide 
group) concentration up to the cytotoxic threshold value of the particular polymer carrier. 
Furthermore, the endoperoxide decay and 
1
O2-release time would thus be prolonged 
according to the demands of in vitro application on the cancer cells. 
The PVB polymer was aimed at because of high PVB nanobeads formation 
reproducibility, low aging effect, non-cytotoxicity, and cellular uptake of non-coated PVB 
nanobeads in a relatively short time-frame (about 2-3 h, see Fig. 4.20.) Thus, binding of 1-
(1,4-dimethyl-naphthalen-2-yl)-ethanol (N4) to hydroxyl groups of the PVB polymer using 
the dicyclohexylcarbodiimide (DCC)-method [178, 179] was performed. 
 
A.2. Experimental 
 
Materials: 
LP B 16H polyvinyl butyral (PVB) powder was from Kuraray Specialities Europe GmbH, 
Frankfurt, Germany. Solvents ethyl acetate, hexane, dichloromethane were purchased from 
Sigma-Aldrich, Munich, Germany. Succinic anhydride (SAH), dicyclohexylcarbodiimide 
(DCC), and N,N-dimethylaminopyridine (DMAP) were also from Sigma-Aldrich, Munich, 
Germany. 
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UV-Vis absorption spectra were recorded with a Varian Cary 300 Bio UV/Vis 
Spectrometer with a 1-cm quartz cell (Hellma GmbH & Co. KG, Müllheim, Germany) and 
Uvasol® quality solvents from Sigma-Aldrich (Munich, Germany). 
1
H-NMR measurements were carried out by the Centre for Chemical Analysis of the 
Faculty of Chemistry and Pharmacy of the University of Regensburg. 
FTIR spectra were recorded with a Jasco (Tokyo, Japan) FTIR-610 using a ZnSe-
ATR device of Pike Technologies (Madison, USA). 
 
Synthesis: 
Step 1: 1.5 g of LP B 16H PVB powder (6.14 mmol of PVB OH-groups) was 
dissolved in 120 ml of ethyl acetate at b.p. (with reflux) and stirred for 1 hour. 6.14 mmol 
(0.614 g) of succinic anhydride was dissolved in 70 ml of ethyl acetate using an ultrasonic 
bath for 5 minutes, and added to the PVB solution. This mixture was stirred over night at 
ethyl acetate b.p. of 77 °C (with reflux) and later cooled slowly to room temperature (RT). 
Hexane was added to the mixture until a white suspension appeared. The suspension was 
filtrated leaving a white product (PVB-SAH). Product characterization was done with 
1
H 
NMR, FTIR and UV absorption. 
Step 2: 187 mg of PVB-SAH was dissolved in 5 ml of dichloromethane, to which 
DCC (158 mg, 0.767 mmol), DMAP (6.25 mg, 0.0511 mmol), and finally, N4 derivative 
(104.5 mg, 0.767 mmol) were added. The mixture was vigorously stirred at RT for 72 h. 
Hexane was added until white DCC-urea precipitated. The solution was filtrated and hexane 
evaporated until a white oily product (PVB-N4) remained. Product characterization was done 
with 
1
H NMR, FTIR and UV absorption. 
 
A.3. Results 
 
The binding of N4 derivative to the hydroxyl group of the PVB polymer was done 
according to Scheme 7 by transforming the hydroxyl group of PVB to a carboxylic acid 
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(PVB-SAH) using succinic anhydride and then acid esterification with N4 alcohol with the 
DCC-activation method [178, 179]. 
D
C
C
/D
M
A
P
 
Scheme 7. Binding N4 to the PVB backbone using the DCC-method. 
On following Figs. the comparative characterization of PVB-N4 product, PVB-SAH 
intermediate product and PVB polymer educt with 
1
H-NMR (Fig. A.1), UV-Vis (Fig. A.2), 
and FTIR (Fig. A.3) is shown. 
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Figure A.1. 
1
H NMR spectra in CDCl3 demonstrating the PVB (black line) reaction with succinic anhydride to 
give PVB-SAH (red line) intermediate and esterification with N4 to give PVB-N4 product (green line). 
After the step 1 reaction from the PVB polymer (Fig. A.1. black line) PVB-SAH 
intermediate product was formed with a strong peak at 2.6 ppm corresponding to CH2 protons 
between the ester and carboxylic acid group (Fig. A.1. red line). Upon step 2 reaction PVB-
N4 product with characteristic aromatic 
1
H NMR peaks in 7.2-8.1 ppm region (Fig. A.1. 
green line) in CDCl3 appeared.  
The UV-absorption spectra of the same polymers: PVB (dashed line), PVB-SAH 
(dotted line) and PVB-N4 (solid line) are shown on Fig. A.2. Clearly, in case of PVB-N4 
absorption peaks typical for 1,4-dimethylnaphthalene derivatives (compare Fig. 4.5.) appear, 
hinting at successful binding of N4 to the PVB backbone. 
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Figure A.2. UV-absorption spectra of PVB educt, PVB-SAH intermediate and PVB-N4 product in methanol, 
with appearance of typical naphthalene derivative’s peaks at about 230, 290nm. 
Furthermore, the FTIR spectra of PVB (dashed line, Fig. A.3.) PVB-SAH (dotted line, 
Fig. A.3.) and PVB-N4 (solid line, Fig. A.3.) similarly demonstrate the reaction on Scheme 7. 
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Figure A.3. FTIR absorption spectra of PVB educt, PVB-SAH intermediate and PVB-N4 product in ethanol. 
Ethanol solvent spectrum was used as a reference. 
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The characteristic carbonyl stretching band at 1778 cm
-1
 [180] appears in the PVB-SAH and 
PVB-N4 FTIR spectra and is not present in the PVB spectrum on Fig. A.3. The negative 
peaks appearing in the PVB-SAH and PVB-N4 FTIR spectra on Fig. A.3. most probably 
appear due to lower ethanol solvent concentration: the peak at 3388 cm
-1
 corresponds to  
–O-H stretching of the ethanol solvent, the peak at 2975 cm
-1
 corresponds to –CH2- stretching 
of the ethanol solvent, and 1072 cm
-1
 and 1028 cm
-1
 peaks correspond to –C-O- stretching of 
the ethanol. 
 
A.4. Outlook 
 
The synthesized polymer PVB-N4 with endoperoxide-forming 1,4-
dimethylnaphthalene each covalently bound to alcohol groups in PVB structure could 
potentially be used for in vitro chemosensitivity assay on human cancer cells, as done in this 
work. In any case, the concentration of endoperoxide group in PVB-N4 is high enough for a 
possible cytostatic effect (estimated necessary concentration > 15 µM).  
The future steps would be: nanoparticles of this polymer should be made. 
Endoperoxides on the mentioned side-groups of such nanoparticles should be 
photochemically formed and their decay kinetics should be investigated. Appropriate coating, 
which would prevent the polymer hydrolysis reaction in aqueous media, for these 
nanoparticles should be searched for. Finally, the cytotoxycity of such high-endoperoxide 
concentration carrying nanoparticles should be tested.   
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